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ABSTRACT 
The overall aim of the present study was to investigate the effects of obesity on oxidant 
stress and platelet responsiveness and examine the modulating effects of both short- 
term dietary interventions and acute exercise on oxidant stress levels and also the 
effects of acute exercise on platelet responsiveness. The role of oxidant stress in 
mediating platelet responsiveness was also studied and selenium supplementation was 
investigated as a potential antioxidant therapy to decrease oxidant stress levels and 
improve platelet responsiveness. 
This work has shown that LH levels is enhanced in obese individuals compared to 
normal-weight individuals (P<0.01) but no other significant differences were identified 
between normal-weight, overweight and obese individuals for TAS, SOD and GSH. A 
multiple regression analysis found the following variables to be predictors of LH levels: 
positive association with weight, vitamin A and fasting triglycerides and a negative 
association with fasting glucose. Although overweight individuals were not prone to 
increased oxidant stress at rest compared to normal-weight individuals, adherence to a 
short-term low carbohydrate diet or completion of a high-intensity aerobic exercise 
session, enhanced oxidant stress. For example on the low-carbohydrate diet, LH 
levels significantly increased at week 2, which decreased by week 4. After four weeks 
on the low-carbohydrate diet, TAS levels significantly increased and SOD and GSH 
showed a non-significant increased trend. Following 30-minutes high intensity aerobic 
exercise LH levels significantly increased which returned to resting levels thirty minutes 
post-exercise. No other changes in TAS, SOD and GSH was identified. Interestingly 
this exacerbated exercise induced response in overweight subjects was ameliorated by 
selenium supplementation. In a double-blind cross-over study, compared to placebo, 
short-term selenium supplementation (3-weeks) significantly increased plasma 
selenium levels in both the normal-weight and overweight groups. Consequently, 
compared to placebo, the overweight group showed a non-significant trend for reduced 
LH levels at rest, significant reduction following high-intensity exercise and a non- 
significant trend for reduced LH thirty-minutes post-exercise following selenium 
supplementation. The normal-weight group did not show any benefit from selenium 
supplementation on LH levels at rest, following high-intensity exercise and thirty- 
minutes post-exercise. No significant changes were found in TAS, SOD and GSH pre 
and post exercise following selenium supplementation in both the normal-weight and 
overweight groups. 
Platelet responsiveness was also studied in several of the above studies to examine 
the role of oxidant stress in mediating platelet responsiveness. Despite showing a 
possible association between oxidant stress and platelet responsiveness pre- and post- high-intensity exercise in both normal-weight and overweight subjects, the nature of the 
association between oxidant stress and platelet aggregation still remains unresolved as 
no association was found between LH levels and percentage ADP-induced platelet 
aggregation at rest across normal-weight, overweight and obese groups. In addition 
although selenium supplementation ameliorated oxidant stress in the overweight group, 
this did not improve platelet responsiveness. Therefore oxidant stress does not appear 
to mediate platelet responsiveness (enhance in vivo platelet reactivity). 
Abbreviations 
LH, lipid hydroperoxide; TAS, total antioxidant status; SOD, superoxide dismutase; 
GSH, reduced glutathione; ADP, adenosine triphosphate. 
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Chapter ONE 
Introduction 
1.0 Introduction 
Oxidant stress is an imbalance between the formation of reactive oxygen/nitrogen 
species and antioxidants (Powers et al., 2004) which is capable of damaging tissues 
i. e. DNA, lipids and protein (Nicki, 1991) which consequently has implications in 
biological phenomena such as cellular aging, mutagenesis, inflammation, and other 
pathologies (Alessio, 1994). Oxidant stress is elevated in conditions such as 
hypertension, hyperinsuliemia and hyperlipidaemia (Vincent and Taylor, 2006). 
Obese patients (Yesilbursa et al., 2005; Mohn et al., 2005; Keaney et al., 2003; Ozata 
et aL, 2002; Davi et al., 2002; Dandona et al., 2001; Präzny et al., 1999) have also 
been shown to have elevated oxidant stress levels but it is unknown if this enhanced 
stress is also evident in overweight individuals. Effective strategies are being sought to 
combat oxidant stress, and in overweight/obese patients an obvious solution would be 
to lose weight. Since overweight/obese individuals often undergo repeated episodes of 
weight loss via short term changes to dietary intake and/or acute bouts of exercise, 
both these strategies will be examined independently in terms of their impact on 
oxidant stress levels. High fat (Slim et aL, 1996) and high sugar diets (Faure et al., 
1997) and moderate unaccustomed exercise have all been shown to pose an acute 
oxidant stress (Alessio et al., 2000), but the independent effects of a short-term low 
carbohydrate diet and acute high intensity exercise on oxidant stress levels in 
overweight individuals is unknown. Antioxidant therapy (Ashton et al., 1999; Skrha et 
a/., 1999; Manning et al., 2004) has been shown to improve oxidant stress levels but 
there appears to be no published data to ascertain the effects of selenium 
supplementation on oxidant stress levels at rest or following acute exercise. Selenium 
is an essential component of the GSH-Px system (Ladenstein et al., 1979), which 
functions as part of an antioxidant system and since Olusi et al (2002) demonstrated 
reduced GSH-Px levels in obesity, Se supplementation in overweight/obese individuals 
1 
may increase GSH-Px activity (Bortoli et al., 1991; Wilke et al., 1992) and hence 
reduce oxidant stress levels. 
In this thesis, the role of oxidant stress in mediating platelet responsiveness is also 
investigated. This potential link was examined as a mechanism contributing to an 
increased risk of cardiovascular disease which is observed in obese individuals. 
Diabetes mellitus, hypertension and hypercholesterolemia have all been associated 
with ROS-mediated platelet aggregation (Davi et al., 2003; Minuz et al., 2002; Davi et 
at., 1997). 
1.1 Aims and Objectives 
The principle aim of this work is to investigate the effects of BMI on oxidant stress and 
examine the modulating effects of both short-term dietary interventions and acute 
exercise and selenium supplementation on oxidant stress levels. In addition the work 
set out to examine the link between oxidant stress and platelet responsiveness. 
The primary objectives may be outlined as follows: 
Pilot Studies: 
(a) To develop and evaluate PlateletWorks®, a platelet aggregation whole-blood 
assay 
(b) To determine the reliability of the Bioelectrical Impedance Analyser. Bodystat 
QuadScan 4000. 
Study 1 
(a) To investigate the effect of BMI (normal-weight, overweight and obese) on 
lipid hydroperoxide, total antioxidant status, superoxide dismutase and 
reduced glutathione levels. 
2 
(b) To identify physiological and lifestyle factors that may contribute to the 
normal variability of the overall oxidant stress status. 
Study 2 
(a) To investigate the effect of BMI (normal-weight, overweight and obese) on 
ADP-induced platelet aggregation. 
(b) To investigate the association between lipid hydroperoxide, total antioxidant 
status and ADP-induced platelet aggregation in normal-weight, overweight 
and obese subjects. 
Study 3 
(a) To investigate the effects of two commercially available diet plans for weight 
loss i. e. low carbohydrate and conventional diet (Slimming World) versus a 
control diet on lipid hydroperoxide, total antioxidant status, superoxide 
dismutase and reduced glutathione. 
Study 4 
Part 1 
(a) To investigate the effects of an acute exercise session of low- and high- 
intensity on lipid hydroperoxide and total antioxidant status in healthy 
subjects. 
Part 2 
(a) To investigate the effect of acute high-intensity exercise on lipid 
hydroperoxide, total antioxidant status, superoxide dismutase and reduced 
glutathione and percentage ADP-induced platelet aggregation in normal- 
weight and overweight subjects. 
(b) To investigate the association between lipid hydroperoxide and total 
antioxidant status and percentage ADP-induced platelet aggregation pre 
and post acute high-intensity exercise. 
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Study 5 
(a) To investigate the effect of selenium supplementation on lipid 
hydroperoxide, total antioxidant status, superoxide dismutase, reduced 
glutathione and percentage ADP-induced platelet aggregation at rest and 
post high-intensity exercise in normal-weight and overweight subjects. 
(b) To investigate the association between lipid hydroperoxide and percentage 
ADP-induced platelet aggregation pre and post Se supplementation at rest 
and post high-intensity exercise. 
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Chapter TWO 
Review of Literature 
This chapter discusses the main issues relating to this research project, which include 
obesity, weight management treatment (mainly dietary and exercise interventions) and 
their corresponding effects on oxidant stress markers, antioxidant status and platelet 
responsiveness. In addition, nutritional therapy is discussed to identify possible 
antioxidant-therapy treatments to reduce oxidant stress and improve platelet 
responsiveness. This literature review also highlights the association between oxidant 
stress and platelet responsiveness, a known marker for increased cardiovascular risk. 
1.0 Obesity 
Obesity is defined as a body mass index (BMI) of 30 kg/m2 or more, where a person's 
BMI is defined as their weight in kg divided by the square of their height in metres 
(Health Survey for England, 1999). Overweight is defined as a BMI between 25 and 
29.9 kg/m2 (Health Survey for England, 1999). In 1980 just 6% of men and 8% of 
women were classified as obese, whereas by 2002 the proportion of the population 
obese had trebled to 23% of men and 25% of women (16 years to 75+ years). 
Approximately 55% of the adult population in the UK is overweight or obese (Health 
Survey for England, 2000). 
Obesity has been rated as the sixth most important risk factor contributing to the overall 
burden of disease worldwide (Ezzati et at, 2002). Obesity causes or exacerbates a 
large number of health problems, both independently and in association with other 
diseases (Kopelman, 2000). In particular it is associated with the development of type 
2 diabetes mellitus, coronary heart disease, obstructive sleep apnoea, osteoarthritis of 
large and small joints and increased risk of certain forms of cancer (Kopelman, 2000). 
Obesity has also been associated with a decrease in life expectancy (Department of 
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Health, 2004a). The UK Government estimates that a BMI of 25.0 kg/m2 decreases the 
life expectancy of English men by 2 years and given the progressive epidemic of 
obesity, the eff ect will increase to 5 years by 2050 (Department of Health, 2004a). 
Obesity is accompanied by a range of physiological changes, which is largely 
dependent on the regional distribution of adipose tissue. Generalised obesity causes 
deterioration to respiratory and cardiac function whilst upper body obesity or intra- 
abdominal visceral deposition is a major contributor to 'syndrome X' (Lapidus et al., 
1994). Syndrome X refers to the clustering of abdominal obesity, 
hypertriglyceridaemia, reduced high-density lipoprotein (HDL) cholesterol levels, 
hyperinsulinemia, glucose intolerance and hypertension (Reaven, 1997). In addition to 
these clustering risk factors, further abnormalities have been added to the metabolic 
alterations namely, elevated apoprotein (apo) B concentrations and raised 
plasminogen activator inhibitor-1 (PAI-1) (Kopelman and Grace, 2004). The addition of 
these biochemical abnormalities rephrased the syndrome as the metabolic syndrome 
or insulin-resistance syndrome (Kopelman and Grace, 2004). 
1.1 Aetiology of obesity 
By definition, obesity is caused by an imbalance between energy intake and energy 
expenditure (Kopelman and Grace, 2004). Excessive caloric intake, or low energy 
expenditure, or both may explain the development of obesity if the net positive balance 
is prolonged (Kopelman and Grace, 2004). Although it is assumed that obesity results 
simply from overeating or a sedentary lifestyle, obesity is regarded as a 'complex 
disease' because it arises from multifaceted interactions between genetic, 
physiological, 'behavioural and environmental factors (Lindpaintner, 1995). 
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The genetic hypothesis underlying obesity in both animal and human models has 
allowed immense progress in the understanding of body weight regulation. Monogenic 
forms of obesity in humans have been characterized by mutations in genes affecting 
the central pathways of food intake regulation e. g. mutations in the leptin-hypothalamic 
feedback loop; for example the 'ob' gene may lead to improper coding of leptin 
resulting in obesity (Andersson, 1996). However, monogenic forms of obesity are rare, 
so human obesity is commonly considered as a complex polygenic disease involving 
interactions between multiple genes and the environment (Weinsier et al., 1998). So 
far more than 600 genes, gene markers and chromosomal regions have been identified 
(Perusse et al., 2005), which highlights obesity as a `complex trait' (Nammi et al., 
2004). Candidate genes such as adrenergic beta-3 receptor (Arner, 1995), regions 
regulating the leptin gene (Andersson, 1996), neuromedin B (Bouchard at al., 2004) 
and glutamic acid decarboxylase enzyme (GAD2) (Boutin and Froguel, 2005), may 
play a minor role in the development of obesity. Several susceptibility genes may 
affect energy expenditure, fuel utilization, muscle fibre characteristics and even taste 
preferences, which could impact on our behavioural responses to the environment. 
Therefore unprecedented environmental influences together with genetic susceptibility 
may underpin the obesity prevalence. Weinsier et a/ (1998) highlighted that genetic 
predisposition may permit obesity but the environment determines if individuals do 
become obese. 
Environment is a major determinant of overweight and obesity, which is primarily 
related to food intake and physical activity behaviour (James, 1995). Calorie-dense 
and aggressive food marketing in mass media, supermarket and restaurants and the 
large portions of food served outside the home, promote high calorie consumption 
(James, 1995). The high prevalence of a sedentary lifestyle resulting from the 
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proliferation of labour-saving machinery is also a major environmental factor 
contributing to the development and maintenance of obesity (James, 1995). 
From a behavioural perspective, a number of individual characteristics may place 
individuals at increased risk of obesity (Rennie et al., 2005). Specific behavioural risk 
factors may promote or protect against excess weight gain in adults. A number of 
behavioural factors have been postulated, including diets with a high energy density, 
large portion sizes, eating patterns, high levels of sedentary behaviour and low levels 
of physical activity (Rennie et al., 2005). 
1.2 Complications of obesity 
Obesity is associated with increased morbidity and mortality (Manson et al., 1995). 
Clear associations have been found between obesity and the risk factors for coronary 
heart disease, type 2 diabetes mellitus, certain forms of cancer, gallstones, some 
respiratory disorders and osteo-arthritis (Kopelman, 2000). In addition to the amount of 
excess weight, upper body obesity (as opposed to lower body obesity) contributes 
significantly to the risk for metabolic and cardiovascular disease (CVD) (Pi-Sunyer, 
2002). Physiologically, upper body obesity is a major contributor to the development of 
hypertension, elevated plasma insulin concentrations and insulin resistance, 
hyperglycaemia, hyperlipidaemia, and metabolic alterations (increased LDL particles, 
elevated apo B concentrations and raised PAI-1 (Pi-Sunyer, 2002). This condition is 
known as the metabolic syndrome. 
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1.3 Treatment of obesity 
Clinical guidelines have been published in the UK on the management of obesity 
(National Institute for Clinical Excellence, 2006; Scottish Intercollegiate Guidelines 
Network, 1996; The Royal College of Physicians of London, 1998,2003; National 
Institute of Health, 1998). Several treatment strategies have been identified for weight 
loss: dietary therapy, physical activity, behavioural therapy, combined therapy, 
pharmacotherapy and weight loss surgery. 
General goals of treatment: are prevention of further weight gain (at the very least), 
weight loss and long-term maintenance of a lower weight. An initial weight loss of 10% 
over 6 months is generally recommended (National Institute for Clinical Excellence, 
2006; Scottish Intercollegiate Guidelines Network, 1996; The Royal College of 
Physicians of London, 1998,2003; National Institute of Health, 1998). After 
achievement of 10% weight loss, individuals can then move into a maintenance phase 
programme or attempt additional weight loss, through alterations to the initial weight 
loss plan. Treatment plans such as dietary intake and physical activity for obesity 
management will be discussed individually in the next section but generally the 
scientific evidence suggests that a combination of dietary modification and exercise is 
the most effective behavioural approach for weight loss (National Institute for Clinical 
Excellence, 2006; National Institute of Health, 1998). 
2.3.1 Dietary intervention 
It is common for weight loss programmes to reduce energy intake to 1000-1500 
kcal/day to induce weight loss in overweight adults, which has shown to be safe and 
effective in individuals averaging 90kg before weight loss (American College of Sports 
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Medicine, 2001). Absolute energy intake is generally adjusted based on body weight to 
elicit an energy deficit of 500-1000 kcal/day. With this level of deficit a minimum weight 
loss of 0.5-0.9 kg (1-2 pounds) a week would be realistic. Alternatively, in the severely 
obese patient, very low calorie diets (VLCD) may be useful under medical supervision 
(National Institute of Clinical Excellence, 2006; Scottish Intercollegiate Guidelines 
Network, 1996,1996; The Royal College of Physicians of London, 1998; National 
Institute of Health, 1998). VLCDs are defined as energy intake <800 kcal/day and can 
greatly increase the magnitude and rate of weight loss compared with more 
conservative reductions in energy intake (Wadden et al., 1997). However due to the 
low energy value of these diets, they are generally used for relatively short periods of 
time (12-16 weeks) alongside dietary supplements (American College of Sports 
Medicine, 2001). Evidence suggests that VLCDs produce a 13kg weight loss over six 
months (Nammi of al., 2004), but long-term weight loss by VLCDs is not superior to 
moderate dietary strategies (National Institute of Health, 1998). 
Commercial programmes recommend various combinations of macronutrient 
compositions for weight loss including high-fat, high-protein, and high- and low- 
carbohydrate diets (American College of Sports Medicine, 2001). However the ideal 
macronutrient composition for weight management and risk reduction is still debatable, 
as macronutrient composition dietary treatments are often varied to meet patients' 
requirements and preferences (Kopleman and Grace, 2004). Furthermore scientific 
evidence suggests that the level of energy intake has the greatest impact on weight 
loss short term and that changes in the composition of the diet affects weight loss by 
ultimately affecting energy intake (Astrup et aL, 2000). 
The impact of dietary fat restriction on weight loss has received much attention and has 
been shown to be an effective method in lowering energy density with spontaneous 
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weight loss (Astrup et aL, 2000). A 10% reduction in dietary fat may lead to 
approximately a 5-6 kg weight loss in the obese (Astrup et al., 2000). However these 
diets are still often associated with poor compliance (Westerterp et al., 1996) and 
weight regain in the long term (Toubro and Astrup, 1997). As a result, public interest in 
alternative diets to encourage weight loss have escalated, sparking particular interest 
in short term bouts of 'crash' dieting and carbohydrate restriction (Consumer reports, 
2002) e. g. Atkins Diet (Atkins, 1992). The low-carbohydrate diet (LowCD) promotes 
rapid weight loss within a few days or weeks (Atkins, 1992). The LowCD diet contains 
a high proportion of protein foods, unrestricted use of fat particularly saturated fats and 
a severe restriction of carbohydrates (Atkins, 1992). But despite the renewed interest, 
there is little scientific evidence to determine the safety and efficacy of LowCDs on 
health (Freedman et al., 2001; Blackburn et al., 2001). As most energy in a LowCD is 
derived from protein and fat, there is considerable concern that such diets will raise 
lipid levels and increase risk of coronary disease (Blackburn et al., 2001). Furthermore 
the long-term safety of the LowCD on kidney function and bone health is unknown 
(Astrup et al., 2004). In addition to possible detrimental effects on health, Foster et al., 
(2003) highlighted that weight loss initially achieved on the LowCD was not maintained 
after one year. Such findings, alongside health complications, question the efficacy of 
long-term LowCDs for weight loss and health improvements. 
2.3.2 Physical activity 
Physical activity is an important variable component of energy expenditure, 
representing approximately 20-50% of total energy expenditure (Saris, 1989), and is a 
way to induce an energy deficit (American College of Sports Medicine, 2001). When 
physical activity is used in the treatment of obesity, little evidence suggests that 
exercise produces magnitudes of weight losses that are similar to that achieved with 
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dietary modification (National Institute of Health, 1998). However in a review by Ross 
et al (2000a), it was shown that when energy deficit is held constant and other factors 
that affect energy balance are controlled, exercise can induce significant weight loss. 
For example Ross et al (2000b), found that a 700 kcal/day energy deficit produced 
solely through exercise with energy intake remaining constant resulted in a weight loss 
of 7.6kg over a 3-month period. Exercise is also important for preserving fat-free mass 
in exercising obese subjects, which is important because fat-free mass is the best 
predictor of resting metabolic rate (RMR) and that is the largest contributor to daily 
energy expenditure (Ravussin and Bogardus, 1992). Independent of weight loss, 
regular physical activity has several other physiological benefits including reduced 
blood pressure (BP), improved lipid profile and improved glucose tolerance (Kopelman 
and Grace, 2004) and improved mental and emotional status (Nammi et al., 2004). 
Physical activity guidelines recommend 30 minutes of moderate activity on at least five 
days a week (Department of Health, 2004b), which is associated with improved fitness 
and protection from CVD (Pate et a/., 1995). However Saris et al (2003) highlighted 
that a longer duration of daily activity (45-60 minutes/daily) is required to maintain 
lowered weight and prevent weight regain. There is also evidence that the benefits of 
physical activity can be obtained through brief exercise periods that do not necessarily 
need to be continuous. For example, three 10-minute periods of moderate intensity 
aerobic exercise (intensity eliciting a heart rate of 65-75% of peak heart rate attained 
on a treadmill) is equivalent to a single 30-minute period of exercise (DeBusk et al., 
1990). 
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2.4 Basic concepts of Free-radicals 
Oberley (1988) defined free-radicals as harmful by-products of oxidative metabolism, 
causing molecular damage in living systems. This concept has implications in 
numerous biological phenomena such as cellular aging, mutagenesis, inflammation, 
and other pathologies (Alessio, 1994). 
The term `free-radical' can be defined as any atom or molecule that contains an 
unpaired electron in its outer orbit that can exist independently (Halliwell, 1994; 
Halliwell and Gutteridge, 1999). As a result, free-radicals can be highly reactive 
towards cellular targets, although this varies from radical to radical. To achieve 
stability, free-radicals accept or donate electrons to other molecules. The collective 
term for a variety of free-radicals and non-radical intermediates is reactive oxygen 
species (ROS) (Halliwell, 1994). Examples of oxygen (02) free-radicals are superoxide 
(02 '"), hydroxyl (OH"), and peroxyl (ROO") radicals. The nitrogen free-radicals include 
nitric oxide (NO*) and nitrogen dioxide (N02 ). Both oxygen and nitrogen free-radicals 
can be converted to other non-radical reactive species such as hydrogen peroxide 
(H202) and peroxynitrite (OONO"). 
2.5 Biochemistry of Free-radicals 
Free-radicals are formed in vivo at rest and exercise as by-products of normal energy 
metabolism (Jackson, 1995) which represents the most powerful obligatory source of 
free-radicals in the body (Locatelli et al., 2003). It has been estimated that for every 
twenty-five 02 molecules reduced by normal respiration, one free-radical is formed 
(McCord, 1979). Therefore a rise in metabolism may increase free-radical production, 
which may inevitably damage surrounding tissues and organs. For example, the rate 
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of 02 uptake by the body during exercise may increase by up to approximately 35-fold 
(Aw et al., 1986) and that 02 flux through active-whole-muscle tissue may reach 200- 
fold above resting values (Keul et al., 1972). This paradoxical `02 relationship between 
an apparently healthy act (exercise) and the occurrence of harmful biological reactions 
(Kanter, 1998) prompted Jenkins (1993) to state that: 
`Elemental and gaseous oxygen presents a conudrum in that it is simultaneously 
essential for and potentially destructive to human life 
In addition to the mitochondrial respiratory chain, free-radicals are also formed via 
activation of neutrophils (Halliwell, 1994), generated in the body in response to 
electromagnetic radiation from the environment and are acquired directly as oxidizing 
pollutants such as ozone and NO2 (Halliwell, 1994). However the majority of free- 
radicals in biological systems are oxygen-derived free-radicals. The complete 
reduction of 02 to water (H2O) requires four steps and generates further free-radical 
intermediates and other toxic products during the process (Figure 2.0) 
+CI- 
Chlorine 
Hypochlorus acid 
Myeloperoxidase (MPO) 
e 
-k.. ^º 
02 Hydrgogen 
peroxide 
Singlet oxygen 
-: o ýý H2O Hydroxyl H20 
ý: NOz'; .:.: 
Nitrogen dioxide 
NO' º OONO' pp. HOONO Nitric oxide Peroxynitrite Peroxynitrous acid 
Figure 2.0. Generation of ROS 
Fe2+ re- ý 
Ferrous ion: Ferric state 
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The first one-electron reduction of 02 generates the 02- anion. Addition of a second 
electron and two protons to 02. will form H202. Both 02 and H202 are precursors for 
the production of more powerful oxidants. 02" interacts with NO* to form highly reactive 
nitrogen species, while H202 reacts with intracellular iron to form OR, that are heavily 
implicated in cell membrane lipid degradation, protein aggregation and DNA damage. 
Furthermore H202 is the substrate for myeloperoxidase (MPO) to produce the 
chlorinated oxidants. In the presence of chlorine (Cl), "MPO converts H202 into 
hypochlorous acid (HOCI), a powerful compound capable of oxidizing a number of 
molecules such as lipids and other membranous or intracellular constituents, 
particularly the thiol groups of membrane proteins. 02', H202 and OR, the first three 
intermediary molecules in the 02 reduction pathway will be examined in more detail in 
the following sections. 
2.5.1 Oxygen and its derivatives 
All oxygen-derived intermediates are potentially reactive, but they vary in their 
biological importance. The 02' radical is the most important oxygen-derived free- 
radical because it can lead to the formation of additional ROS (Harris, 1992). 
Molecular 02 is actually a di-radical, having two unpaired electrons, located in a 
different antibonding orbital with the same directional spin. The subsequent effect of 
this arrangement is that 02 can only react with non-radicals by accepting a pair of 
electrons that spin in an anti-parallel manner (McCord, 1979; Young, 1994). 
Free-radicals in living organisms include 02--, hydroperoxyl (H02'), OH', ROO*, alkoxyl 
(RO-) and NO. H202 and HOCI have no unpaired electrons and by definition are not 
free-radicals but are powerful oxidants that are involved in the free-radical reactions 
(Halliwell, 1989, Karlsson, 1997). H202 is predominately produced via the dismutation 
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of 02" and is able to generate high reactive OR through interactions with transition 
metals (Clarkson and Thompson, 2000). OH is potentially one of the most reactive 
oxidants in biological systems (Clarkson and Thompson, 2000). Furthermore the 
OH 
readily attack polyunsaturated fatty acids (PUFAs) to initiate lipid peroxidation 
(Gutteridge, 1995). 
2.5.2 Superoxide anion (021 
02" is a commonly known oxygen-centred free-radical species. 02. is formed when a 
single electron enters an 02 molecule (Pryor, 1986). 02" is relatively unreactive with 
non-radical species in comparison to other radical types, but if it is generated near the 
site of any biochemical molecule it can be extremely destructive. The chemistry of 02: 
differs greatly depending on its solution environment (aqueous solutions or organic 
solvents), but in general aqueous-phase reactions are more likely to occur in vivo 
(Halliwell and Gutteridge, 1999). In aqueous solutions 02' can act as a base, 
accepting a proton to form HO2. 
Some of the 02' production that occurs in vivo appears to be a chemical accident, due 
to autooxidation reactions and the 'leakage' of electrons from electron-transport chains 
to 02 (Fridovich, 1989; Imlay and Fridovich, 1991). Other 02' productions appear to be 
made deliberately e. g. by activated phagocytes (Babior and Woodman, 1990) and to a 
lesser extent, by different cell types such as fibroblasts and lymphocytes (Murrell et al., 
1990, Maly, 1990). 02' is also continuously produced by vascular endothelium to 
neutralise NO' (Young and Woodside, 2001). Under normal conditions, removal of 
excess 02' by the enzyme superoxide dismutase (SOD) is an important physiological 
antioxidant defence mechanism in aerobic organisms (Fridovich, 1989). However too 
much SOD (in relation to the activities of H2O2 - removing enzymes such as catalase 
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(CAT) and glutathione peroxidase (GSH-Px) may sometimes be deleterious (Scott of 
a/., 1989). This is because SOD enzymes convert 02' into 02 and H202 as shown in 
the following equation; 
02- + 02- + 2H+ f 
H2O2 + 02 
SOD has no other purpose than to dismute 02'" to H202 and 02. 
2.5.3 Hydrogen peroxide (H202) 
Any biological system producing 02", will produce H202, as a result of the dismutation 
reaction. Although SOD is the main method for production of H202 many enzymes 
such as irate oxidase, glucose oxidase and D-amino acid oxidase produce H202 
directly by the transfer of two electrons to 02 (Gutteridge, 1995). H202 has an 
uncharged covalent structure (Gutteridge, 1995), a relatively long-lived half-life (Matsuo 
and Kaneko, 2000), and is treated as a water molecule, which allows it to pass freely 
through biological membranes (Young and Woodside, 2001). H202 can therefore act 
as a passage to transmit free-radical induced damage across cellular compartments 
(Young and Woodside, 2001). H202 is a weak oxidant and a weak reducing agent that 
is relatively stable in the absence of transition metal ions (Gutteridge, 1995). In the 
presence of transition metal ions (e. g. copper and iron, fenton chemistry), H202 can 
lead to the production of OR, which is an extremely highly reactive free-radical (Slater, 
1984; Bast et al., 1991). The redox properties of H2O2 and its ability to form highly 
reactive free-radicals necessitated the evolution of body defence mechanisms. For 
example H2O2 is removed from cells by the action of CAT and GSH-Px (selenium 
containing) (Gutteridge, 1995). 
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2.5.4 Hydroxyl radical (OH-) 
The OH is probably the final intermediary product to be formed before tissue damage 
occurs (Lloyd et al., 1997). All ROS also exert most of their pathological effects 
through OR formation (Young and Woodside, 2001). This most powerful oxidant when 
formed has the ability to react immediately and abstract a hydrogen atom from many 
biological molecules, including carbohydrates, DNA, lipids and thiols at an extremely 
high rate (Halliwell, 1991; Young and Woodside, 2001). The degradation of these 
compounds may produce damaged products and a range of secondary organic 
radicals of variable reactivity (peroxyl, alkoyl and alkyl radicals) (Halliwell and 
Gutteridge, 1999). Because the OH is extremely highly reactive and has a short half- 
life, the radical is unable to react with any molecule beyond 5 molecular diameters from 
its site of formation (Pryor, 1986; Matsuo and Kaneko, 2000), and therefore OH- 
induced damage is site specific. The best-characterized biological damage caused by 
OH is its ability to stimulate the free-radical chain reaction known as lipid peroxidation 
(Halliwell, 1991). This occurs when the OH is generated close to membranes and 
attacks the fatty-acid side-chains of the membrane phospholipids e. g. PUFA side- 
chains such as arachidonic acid. In biological systems OH derives from the less toxic 
02' and H2O2 via the Haber-Weiss and Fenton reactions (Gutteridge, 1995). 
02'+ H202 0 OH, + OH' + 02 (Haber-Weiss Reaction) 
Fe2+ H202 N. - OH- + OH" + Fe 
3+ (Fenton Reaction) 
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2.5.5 Reactive Nitrogen Species (RNS) 
Reactive Nitrogen Species (RNS) is a term to explain the process of an unpaired 
electron residing on a nitrogen molecule (Halliwell and Gutteridge, 1999). RNS 
includes N02, nitroxyl anion (NO"), NO and ON00'. The most discussed RNS is NO. 
NO- is a free-radical due to the presence of a single unpaired electron (Sen et al., 
2000). NO, is produced in some mammalian cells and can influence blood flow, 
thrombosis and neural activity (Beckman and Koppenol, 1996). NO- has the ability to 
diffuse between cells and bind to 02" to produce the ONOO' which is not itself a free- 
radical but has the potential to attack and damage cellular membranes (Sen et aL, 
2000). This RNS has been reported to have OR characteristics in that it can damage 
most molecules in its surrounding location (Beckman and Koppenol, 1996). One- 
electron reduction of NO- yields the NO', which is relatively unreactive and short-lived 
(Halliwell and Gutteridge, 1999). Given the lack of literature on RNS in health and 
disease, ROS will be the major species referred to in this thesis. 
2.6 Antioxidant and defence system 
To prevent the harmful effects of ROS, antioxidant systems, both enzymatic and non- 
enzymatic, are naturally present in the body to counteract free-radicals (see Table 2.0). 
Halliwell and Gutteridge (1999) defined antioxidants as; 
'any substance which, when present at much lower concentrations than an oxidisable 
substrate, significantly delays or prevents oxidation of that substrate' 
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Antioxidants can act at several different stages in an oxidative sequence; 
a) Removing 02 or decreasing local 02 concentrations 
b) Removing catalytic metal ions 
c) Removing key ROS such as 02 " and H202. 
d) Scavenging initiating free-radicals such as OH', RO* 
e) Quenching or scavenging singlet 02('02). 
(Gutteridge, 1995; Halliwell and Gutteridge, 1999) 
Enzymatic Non-enzymatic 
Superoxide dismutase (SOD) Glutathione 
Catalase (CAT) Vitamin E&C 
Glutathione peroxidase (GSH-Px) Selenium and Ferritin 
Transferrin and Albumin 
Carotenoids 
Table 2.0 Examples of Antioxidants 
Specifically, enzymatic and non-enzymatic antioxidants exist in both the intracellular 
and extracellular environment and work as complex units to remove different ROS. To 
provide maximum intracellular protection, these scavengers 
compartmentalized throughout the cell. 
2.7 Antioxidant enzymes 
are strategically 
The antioxidant enzymes involved in removing ROS include SOD, CAT and GSH-Px 
and other peroxidases. These free-radical-scavenging enzymes are the first line of 
cellular defence against oxidative injury. 
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It consists of four protein subunits (each processing a haem group) and is found in high 
concentrations in the peroxisomes of liver and erythrocytes (Halliwell and Gutteridge, 
1999). CAT becomes an important antioxidant enzyme when H202 levels are high 
(Halliwell and Gutteridge, 1999; Brown, 1993). 
2.7.3 Glutathione peroxidase (GSH-Px) 
GSH-Px catalyses the decomposition of H202 and organic peroxides, consuming 
reduced glutathione (GSH) to form oxidized glutathione, glutathione disulphide (GSSG) 
(step 1). GSSG is then converted back to GSH by glutathione reductase (step 2). 
2GSH + H202 -10 GSSG + 2H20 (step 1) 
GSSG + NADPH + H+ -0' NADP+ 2GSH (step 2) 
GSH-Px is a low-molecular mass thiol compound found intracellularly in most 
mammalian cells, particularly erythrocytes (Halliwell and Gutteridge, 1999). GSH-Px is 
thought to be more important than CAT in H202 detoxification, particularly when it is low 
in concentration (Halliwell and Gutteridge, 1999; Brown, 1993). This may be because 
GSH-Px is located near SOD (Halliwell and Gutteridge, 1999; Brown, 1993). 
2.8 Non-enzymatic antioxidants 
Non-enzymatic antioxidants include, but are not limited to uric acid, albumin, GSH, 
vitamin E, vitamin C, carotenoids, bilrubin and ubiquinone (Powers et al., 2004). These 
endogenous nutrients are all important sources of antioxidants obtained from the diet. 
The most prominent dietary antioxidants are tocopherols, the fat-soluble vitamins 
(Vitamin E), ascorbate, water-soluble vitamins (vitamin C) and carotenoids (Jackson, 
22 
1994). Minerals such as selenium (Se), iron, copper and zinc also possibly interact 
with every nutrient that affects the pro-oxidant/antioxidant balance of the cell (Jackson, 
1994) These trace minerals contribute to the body's antioxidant defence system by 
acting as co-factors for antioxidant enzymes (Powers et al., 2004). Se is an integral 
part of GSH-Px (Rotruck et al., 1973) and also appears to support the activity of vitamin 
E limiting the oxidation of lipids (Burk and Levander, 1999). Copper and iron are also 
critical components of SOD and CAT, respectively (Jackson, 1994). Other antioxidants 
such as albumin and other proteins including ceruloplasmin and transferrin, also 
protect against oxidative injury by binding the transition metal Fe 2+ (ferrous ion) and 
Cu2+ (copper ion) thereby preventing generation of OR via the Fenton reaction 
(Gutteridge, 1995). 
2.8.1 Ascorbic acid (Vitamin C) 
Vitamin C is a water- soluble vitamin that is widely distributed in mammalian tissues, 
but is present in relatively high amounts in the adrenal and pituitary glands (Yu, 1994). 
Vitamin C is a dibasic acid with an enediol group embedded in a five-membered 
lactone ring. The molecular structure contains two ionising hydrogen atoms that give 
the compound its acidic character (pKa, 4.25). In aqueous environments, vitamin C is 
readily oxidised to the ascorbyl radical and further to dehydroascorbic acid, oxalic acid 
and L-theonic acid as shown in Figure 2.1 (Elmadfa and Koenig, 1996; Tsao, 1997). 
The ascorbate anion is the predominant form that exists at physiological pH (Yu, 1994). 
Vitamin C H--º Ascorbyl 4 -º Dehydroascorbic acid 
Oxalic acid 
L-Threonic acid 
Figure 2.1. Vitamin C degradation properties 
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The role of vitamin C as an antioxidant is two-fold. Vitamin C can directly scavenge 
02 OH' and lipid hydroperoxides (LH) (Powers et al., 2004). Additionally vitamin C 
plays an important role in recycling vitamin E back to its reduced and active state 
(Packer et al., 1979). In the process of recycling vitamin E, reduced vitamin C is 
converted to a vitamin C radical which can be regenerated back to its original form by 
GSH or a-lipoic acid (LA) (Sen and Packer, 2000). 
In association with vitamin E, increased cellular concentrations of vitamin C should 
provide protection against radical-mediated injury (Yu, 1994). However in high 
concentrations, vitamin C can exert pro-oxidant effects in the presence of transition 
metals ions. Ascorbic acid has the ability to reduce Fe3+ (ferric state) to Fe 2+ (Sen, 
1995). Fe 2+ is known to be a potent catalyst in the production of free-radicals (Powers 
et al., 2004) which is important because the majority of hydroxyl radical generation 
comes from Fenton chemistry. Therefore mega-dose vitamin C supplementation has 
been questioned by some investigators due to its pro-oxidant potential (Yu, 1994). 
2.8.2 a- tocopherol (Vitamin E) 
Vitamin E refers to at least eight structural isomers of tocopherols, but among these 
vitamin E is the best known and possesses the most potent antioxidant activity (Burton 
and Ingold, 1989; Janero, 1991). From an antioxidant perspective, vitamin E is the 
primary chain-breaking antioxidant in cell membranes (Burton and Ingold, 1989; 
Janero, 1991). 
Because of its high lipid solubility, vitamin E is associated with lipid-rich structures such 
as the mitochondrial, sarcoplasmic reticulum and the plasma membranes. Under most 
dietary conditions, the concentration of vitamin E in tissues is relatively low (e. g. ratio of 
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vitamin E to lipids in the membrane may range from 1: 1000 in red blood cells to 
1: 3000 
in other tissues and organelles, Janero, 1991; Packer, 1991) but continues to have the 
ability to react directly with most free-radicals (converts 02' and OR to less reactive 
forms) before they interact with fatty acids (Janero, 1991). If oxidation occurs, vitamin 
E inhibits propagation by free-radical stabilisation. 
Despite vitamin E being an efficient radical scavenger, the interaction of vitamin E with 
a radical results in a decrease in functional vitamin E and the formation of a vitamin E 
radical. However, the vitamin E radical can be `recycled' back to its native state by a 
variety of other antioxidants (Packer et al., 1979; Burton and Traber, 1990). The ability 
of vitamin E to serve as an antioxidant is synergistically connected to other 
antioxidants, such as glutathione, vitamin C and LA, which are capable of recycling 
vitamin E during periods of oxidant stress (Packer et al., 1979). 
2.8.3 Carotenoids 
Carotenoids (e. g. a- and ß-carotene) are lipid-soluble antioxidants located primarily in 
biological membranes (Strain and Benzie, 1998). They serve as precursors of vitamin 
A (Halliwell and Gutteridge, 1999) and it is believed that ß-carotene in particular is 
protected by vitamin E (Strain and Benzie, 1998). Their antioxidant properties come 
from their structural arrangement consisting of long chains of conjugated double bonds, 
which permit the scavenging of several ROS, including 102,02'-, and OH' and can also 
trap ROO' at low P02, with a potency as great as vitamin E (Burton and Ingold, 1984; 
Yu, 1994). Carotenoids display an efficient biological antioxidant activity as evidenced 
by their ability to reduce the rate of lipid peroxidation induced by radical generating 
systems (Krinsky and Deneke, 1982). In contrast, carotenoids can function also as a 
pro-oxidant. Under nonphysiological circumstances, high 02 tensions have shown 
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caroteniods to lose its antioxidant capacity (Burton and Ingold, 1989; Palozza et al., 
1997). 
2.8.4 Selenium (Se) 
Se plays a critical role in antioxidant defence as a co-factor for the antioxidant enzyme 
GSH-Px (Rotruck et al., 1973). GSH-Px is located in both the cytosol and mitochondria 
of cells and is responsible for removing H202 and other organic hydroperoxides from 
the cell (Halliwell and Gutteridge, 1999). Its antioxidant mechanism is outlined in more 
detail in the antioxidant enzyme section under GSH-Px (see Section 2.8.3). Se also 
appears to support the activity of vitamin E in limiting the oxidation of lipids (Burk and 
Levander, 1999). Animal studies indicate that Se and vitamin E tend to spare one 
another and that Se can prevent some of the damage resulting from vitamin E 
deficiency in a model of oxidant stress (Burk and Levander, 1999). 
2.8.5 Reduced glutathione (GSH) 
GSH is the most abundant non-protein thiol source in muscle cells (Meister and 
Anderson, 1983). GSH is primarily synthesized in the liver and transported to 
peripheral tissues via the circulation. 
GSH concentration in the cell is variable across organs in the body with the two highest 
concentrations being in the lens of the eye(10mmol"mol-1) and the liver (5-7mmol"mol"1) 
(Halliwell and Gutteridge, 1999). Other key organs include lung, kidney and heart 
containing around 2-3 mmol"mol-1 of GSH (Ji, 1995a). Skeletal muscle GSH 
concentration varies depending on muscle fibre types, for example in rats slow fibres 
(type 1) contain 600% more GSH than fast fibres (type Ilb). 
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GSH as a cellular antioxidant may directly scavenge a variety of free-radicals by 
donating a hydrogen atom (Yu, 1994) or may act as a co-substrate with GSH-Px in the 
elimination of both H202 and other organic peroxides (Ji et aL, 1992). GSH has also 
been shown to be involved in reducing a variety of cellular antioxidants. For example 
GSH has been reported to reduce vitamin E radicals that are formed in the chain- 
breaking reactions with alkoxyl or lipid peroxyl radicals (Packer, 1991). In addition 
GSH is used to reduce the semidehydroascorbate radical generated during the vitamin 
C-mediated recycling of vitamin E (Powers and Lennon, 1999). Finally GSH has been 
reported to reduce LA to dihydrolipolate, which is a powerful antioxidant acting against 
several radical species (Packer, 1994) and is important in recycling vitamin C (Packer, 
1994). 
2.9 Oxidant stress 
When free-radical formation is greatly increased, or protective antioxidant mechanisms 
compromised, a state of oxidant stress will result (Powers et al., 2004, figure 2.2). If 
oxidant stress persists, it will eventually lead to molecular damage and tissue injury 
(Symons and Gutteridge, 1998). Consequently, oxidant stress has been defined as a 
disturbance in the balance between production of free-radicals and antioxidant 
defences, which may lead to tissue injury (Halliwell, 1994). Oxidant stress has the 
potential to cause damage to critical cellular targets, such as DNA, proteins and lipids 
(Niki, 1991). The extent of the damage caused to cells depends on the duration, 
degree of stress and the nature of the system stressed (Halliwell and Chirico, 1993). 
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Redox Balance and Oxidative Stress 
Oxidants 
Antioxidants 
Oxidants 
Antioxidants 
Adapted from Powers et al., (2004) 
Figure 2.2. Relationship between oxidants and antioxidants in the determination of 
cellular redox balance. An increase in oxidants or antioxidants results in a disturbance 
in cellular redox balance. Oxidant stress occurs when oxidants outnumber the available 
antioxidants. In contrast, reductive stress occurs when antioxidants out-number the 
oxidants present in the cell (Powers et al., 2004) 
2.10 Lipid peroxidation 
Lipid peroxidation is probably the most extensively investigated free-radical-induced 
process (Halliwell and Gutteridge, 1999). The potential consequences of peroxidation 
of membrane lipids include: loss of PUFAs, loss of lipid fluidity, altered membrane 
permeability, effects on membrane-associated enzymes, altered iron transport, release 
of material from subcellular compartments and the generation of cytotoxic metabolites 
of LHs (Rice-Evans and Miller, 1994). PUFAs are particularly susceptible to 
peroxidation and once the process is initiated, it proceeds as a free-radical-mediated 
chain reaction involving initiation, propagation and termination (see figure 2.3) 
(Gutteridge, 1995). 
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Lipid peroxidation is initiated by the attack on a fatty acid or fatty acyl side-chain by any 
primary free-radical that has sufficient reactivity to abstract a hydrogen atom from a 
methylene group upon PUFAs (step 1). Since a hydrogen atom in principle is a free- 
radical with a single paired electron, its removal leaves behind an unpaired electron on 
the carbon atom to which it was originally attached (step 2). The carbon-centred 
radical is stabilised by a molecular rearrangement to form a conjugated diene (step 3) 
followed by reaction with 02 to give a ROO' (step 4). The ROO' is capable of 
abstracting a hydrogen atom from another fatty acid side-chain to form a LH (step 5), 
but can combine with each other or attach membrane proteins. When the ROO' 
abstracts a hydrogen atom from a fatty acid, the new carbon-centred radical can react 
with 02 to form another ROO', and so the propagation of the chain reaction of lipid 
peroxidation can continue. This propagation step, can be amplified with the availability 
of 02 and PUFA side-chains (Rice-Evans and Miller, 1994). Hence a single substrate 
radical may result in conversion of multiple fatty acid side-chains into LHs, leading to 
oxidative damage in cells, membranes and lipoproteins (Rice-Evans, 1994). The 
length of the propagation chain before termination depends on several factors, e. g. 02 
concentration and the amount of chain-breaking antioxidants present (Young and 
McEneny, 2001). LHs are fairly stable molecules, but their decomposition can be 
stimulated by high temperatures or by exposure to transition metal ions (iron and Cue+). 
Decomposition of LHs generate a complex mixture of secondary lipid peroxidation 
products such as hydrocarbon gases (e. g. ethane and penthane) and aldehydes (e. g. 
malondialdehyde (MDA) and 4-hydroxynonenal). The fatty acid structure determines 
the product. Another complexity of the lipid peroxidation process is that the initial 
abstraction of a hydrogen atom can occur at different points on the carbon chain of the 
fatty acid. Thus, peroxidation of arachidonic acid for example gives six different LHs as 
well as cyclic peroxides and other products such as isoprostanes (Halliwell and 
Gutteridge, 1999). Furthermore, the number of double bonds determines the 
29 
susceptibility of a fatty acid to peroxidation (Wagner et aL, 1994; Porter et al., 1995). 
PUFAs are readily attacked by free-radicals and become oxidised into LHs (Symons 
and Gutteridge, 1998), whereas saturated fatty acids (SFAs) with no double bonds and 
monounsaturated fatty acids (MUFAs) with one double bond are more resistant to 
peroxidation (Reaven et al., 1991). An adjacent double bond weakens the energy of 
attachment of the hydrogen atoms present on the next carbon atom. Therefore, the 
greater the number of double bonds in a fatty acid chain the easier the removal of a 
hydrogen atom, which is why PUFAs are more susceptible to peroxidation. 
PUFA 
9 
R« 
GarUcn- 
cenued 
radical 
F; 
Conjugated 
diene 
1 
+02 
Step 1 
Loss of H' to a free radical 
Molecular reairanggemeu" 
Uptake of oxygen 
Step 2 
P, oo- Pemý)i 
radical 
ROOH 
W-41- 
o- 1 -m- Ir 
aayýuv- ý 
perc-ade 
ý 
H 
Step 3 
Step 4 
Abstraction of a H' from an 
adjacent fatty acid 
Step 5 
Figure 2.3. Mechanism of lipid peroxidation (modified from Gutteridge, 1995). 
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2.11 Oxidant Stress in obesity 
There is emerging evidence suggesting that obese individuals have concomitant 
increased free-radical production and depletion of cellular antioxidant defence systems. 
It has been shown that the balance between pro-oxidant/antioxidant is shifted towards 
an increased oxidant stress in obese rats (Dobrian et aL, 2001; Beltowski et aL, 2000; 
Vincent et al., 1999; Vincent et aL, 2001) and obese humans (Yesilbursa et aL, 2005; 
Mohn et al., 2005; Keaney et ah, 2003; Ozata et aL, 2002; Davi et aL, 2002; Dandona 
et aL, 2001; Präzny et a/., 1999). Yesilbursa et al (2005) found significantly higher 
MDA levels in non-diabetic obese adults compared to healthy normal-weight controls 
(2.0±0.77 vs 0.63±0.14nmol/mL). Mohn et al (2005) studied the effects of childhood 
obesity on oxidant stress. In prepubertal children, obese subjects had significantly 
increased MDA levels compared to normal-weight controls (0.90±0.31 vs 
0.45±0.24nmol/mg). Keaney et al (2003) found that in more than 2800 men and 
women, BMI was independently associated with increased levels of urinary 
concentrations of the F2 isoprostrane 8-iso prostaglandin Fla (8-iso PGF2a), a bioactive 
product of lipid peroxidation. For example following multivariable regression models, 
each 5 kg/m2 was associated with a 9.9% increase in 8-iso PGF2a. Overall the 
multivariate model obtained was able to explain 15.8% of the variability in 8-iso PGF2a. 
The most important contributors to the model were smoking, BMI, gender, glucose, 
total cholesterol and HDL cholesterol ratio and prevalent CVD that contributed 7.7%, 
2.4%, 2%, 2%, 0.5%, 0.6% and 0.3% respectively. Davi et al (2002) found that obese 
women had significantly higher levels of urinary 8-iso PGF2a compared to their non- 
obese counterparts. In addition, android obese women had significantly higher levels 
of urinary 8-iso PGF2a (523 (393-685) pg/mg of creatine) than gynoid obese women 
(275 (220-349) pg/mg of creatine). Both android and gynoid obese women had 
significantly higher levels of urinary 8-iso PGF2a when compared to non-obese women 
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(187 (140-225) pg/mg of creatine). Dandona et al (2001) found significantly increased 
plasma of thiobarbituric acid-reactive species (TBARS) (an assessment of 
lipid 
peroxidation) in obese adults compared to age-matched controls (1.68±0.17 vs 
1.29±0.12pmol/L). Präznjr et a/ (1999) concluded that plasma MDA concentration was 
significantly correlated with BMI in both Type 1 and Type 2 diabetic patients (r=0.68). 
Ozata et al (2002) presented significant evidence that BMI was associated with 
significantly increased levels of TBARS (obese vs non-obese; 7.77±3.41 vs 
3.92±0.93mmol/mL). In animals, Vincent et al (1999) demonstrated that in the 
myocardium of obese Zucker rats markers of oxidant stress were enhanced by obesity. 
In Wistar rats, Beltowski et al (2000) demonstrated increased levels of TBARS by 43% 
and 52% after following an 8-week high calorie high fat (HCHF) diet and a high calorie 
normal fat (HCNF) diet, respectively. Body weight gains were 9.3% and 15.2% higher 
than the control group for HCHF and HCNF diets, respectively. Following a study by 
Vincent et al (2001) it appears that obesity may be associated with enhanced oxidant 
stress, irrespective of underlying cause. Vincent et al (2001) found that obesity 
induced by either a leptin receptor defect or high-fat feeding was associated with 
similar oxidative injury levels e. g. the high-fat fed and fatty animals had similar 
significant elevations in myocardial TBARS in comparison to those of lean controls, 
23% and 25% respectively. 
Inducing weight loss has been shown to reduce oxidant stress levels providing 
additional evidence for a cause and effect relationship between obesity and oxidant 
stress (Yesilbursa et al., 2005; Mohn et aL, 2005; Uzan et aL, 2004; Kisakol et aL, 
2002; Davi et al., 2002). Yesilbursa et al (2005) found that plasma MDA 
concentrations reduced significantly following 6-months of Orlistat treatment (anti- 
obesity drug) in obese patients. After 6-months treatment, the mean weight of the 
obese patients decreased by 6.8kg and plasma MDA levels were significantly reduced 
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by weight loss from 2.0±0.77 to 0.89±0.41 nmol/mL. Mohn et al (2005) studied the 
effect of a6 month dietary restriction weight loss programme on prepubertal severely 
obese children. During the intervention period, children showed a significant reduction 
in BMI (28.99±2.40 vs 27.34±1.87kg/m2) which was associated with a significant 
reduction in MDA levels (0.86±0.43 vs 0.47±0.09nmol/mg). The 6-month change then 
reversed to baseline levels together with fatness indexes when children followed a 
further 6-month control diet. 
Kisakol et al (2002) and Uzan et al (2004) both investigated the impact of bariatric 
surgery on oxidant stress and both concluded a positive effect. Kisakol et al (2004) 
found that a vertical banded gastropasty significantly decreased MDA levels in 22 
morbidly obese patients with significant weight loss [pre-op vs 24 weeks post-op; MDA 
levels: 1.505±0.11 vs 0.712±0.05pmol/L and weight: 123.8±3.65 vs 88.78±2.45kg]. 
Uzan et al (2004) studied the impact of open vs laparoscopic surgery for a gastric band 
in obese patients. Following 6 months, both surgery types produced similar reductions 
in both MDA and weight which were all significant. Lastly Davi et al (2002) studied the 
effects of a 12-week calorie restriction diet on urinary 8-iso PGF2a levels in 20 women. 
Of 20 women with android obesity, 11 achieved successful weight loss (mean weight 
loss averaged 15.3±10.5kg), which was associated with significant reductions in 8-iso 
PGF2ai levels by 32%. However, despite highlighting evidence for a cause and effect 
relationship between the obese state and oxidant stress, there is still confusion that the 
association between oxidant stress and obesity may be related to variables such as 
obesity-related diseases i. e. hypertension, hyperlipidaemia and hyperinsulinemia. 
Irrespective of this, several mechanisms have been suggested which may explain the 
obesity-related oxidant stress: 
a) Increased 02 consumption (i. e. mechanical overload) and subsequent radical 
production via mitochondrial respiration 
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b) Diminished antioxidant capacity 
c) Increased fat deposition 
d) Cell injury causing increased rates of radical formation such as 02 and OH'. 
(Vincent et al., 2001) 
2.11.1 Mechanical overload 
Increased muscle activity can activate metabolic pathways that form free-radicals, 
including increased electron transport chain activity (Ji, 1995a; Ji, 1996) and 
conversion of hypoxanthine to urate (Saiki et al., 2001). Increased respiration rates 
and rapid electron transfer can cause some electrons to leak from the electron 
transport chain to form 02 and H202 P. 1995a; Ji, 1996) and the conversion of 
hypoxanthine (during high muscle activity) to urate forms 02 (Saiki et al., 2001). 
Among obese persons, high cell respiration rates and 02 consumption may be 
exacerbated in muscle tissue during physical activity due to the additive mechanical 
load of carrying excessive body weight (Vincent et al., 2004) and mechanical 
inefficiency (Vincent and Taylor, 2006). For example during the same absolute load- 
bearing walking activity, obese persons have 38% higher V02 (oxygen consumption) 
values than non-obese persons and these values are correlated with post-exercise LH 
values (Vincent et al., 2004). Higher resting and post-exercise hypoxanthine and uric 
acid levels in obese compared to non-obese persons have been identified (Saiki et al., 
2001), suggesting that hypoxanthine may be a cause for increased oxidant stress in 
obese persons (Saiki et al., 2001). 
2.11.2 Compromised antioxidant defence 
Adequate tissue, dietary, enzymatic and non-enzymatic antioxidant defences are 
critical to maintain the pro-oxidant/antioxidant balance in tissues (Halliwell and 
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Gutteridge, 1999). However in obesity, perturbations to antioxidant defences may 
occur (Vincent and Taylor, 2006). For example several studies suggest that obesity is 
associated with lower plasma antioxidant concentration (Reitman et al., 2002; Strauss 
et aL, 1999; Decsi et al., 1997; Kuno et aL, 1998; Moor De Burgos et al., 1992) and 
decreased activities of erythrocyte cytoprotective enzymes (Olusi, 2002; Ozata et aL, 
2002; Beltowski et al 2000). Reitman et al (2002) demonstrated that levels of fat- 
soluble antioxidants, plasma carotenoids and vitamin E were significantly lower in 
patients with severe obesity as compared to normal-weight subjects (0.69±0.32 vs 
1.25±0.72micrograms/mL and 24±10 vs 33±14micrograms/mL, respectively). Strauss 
et al (1999) concluded that vitamin E and ß-carotene were significantly lower in obese 
children compared to their normal-weight counterparts (2.68±0.59 vs 3.17±±0.60pmol/L 
and 0.22±0.14 vs 0.29±0.17pmoVL, respectively). Strauss et al (1999) highlighted that 
the lower serum antioxidants in obese children remained despite similar self-reported 
intakes of fruit and vegetable servings between the normal-weight and obese children. 
Kuno et al (1998) and Decsi et al (1997) also found significantly lower levels of lipo- 
proteins and plasma concentrations of vitamin E and ß-carotene in obese children 
compared to their normal-weight counterparts [Kuno et al (1998); 8.77±1.93 vs 
13.14±2.73nmol/mg protein and 0.30±0.23 vs 0.61±0.25nmoVmg protein, respectively, 
and Decsi et al (1997); 0.34 (0.13-0.70) vs 0.75 (0.32-1.48) mg/dL and 3.8 (1.4-21.4) 
vs 7.8 (1.5-38.6) pg/dL, respectively]. Furthermore Kuno et al (1998) found that the 
obese girls also had a higher 'peroxidizability index' (lipid peroxidation per amount LDL) 
and concluded that the inadequate antioxidants available within the large LDL lipid pool 
caused the oxidant stress. Similarly, in adults, Moor De Burgos et al (1992) found that 
blood retinol, vitamin E, vitamin C and carotene concentrations were 18-37% lower in 
obese women than in lean women respectively. Overall they speculated that the 
altered antioxidant vitamin levels in obesity were due to the redistribution of fat-soluble 
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vitamins into fatty tissues, leaving fewer antioxidants available for plasma and other 
essential sites (Reitman et al., 2002). 
Activities of the major antioxidant enzymes may also be inadequate in obesity. Olusi 
(2002) found that erythrocyte Cu/ZnSOD activity and GSH-Px were significantly lower 
in obesity than in the non-obese state (Cu/ZnSOD: 1005±26 vs 1464±23U/g Hb and 
GSH-Px: 84.3±6.7 vs 98.4±3.3U/g Hb). Similarly, Ozata et al (2002) also reported 75% 
and 42% lower erythrocyte GSH-Px and Cu/ZnSOD activities in obese men than in 
non-obese men. In rat models of diet-induced obesity, erythrocyte SOD and GSH-Px 
activities were reduced by 29-42% in the HFHC group compared with the control 
animals after the 8-week diet-induced obesity period (Beltowski et A, 2000). Other 
research have shown that individual antioxidant enzymes were enhanced in obesity 
(Vincent et aL, 2001, Dobrian et al., 2000). Vincent et al (2001) found that Cu/ZnSOD 
activity in the left ventricles of rats was significantly greater in the obese animals 
compared to lean controls (135 vs 1171U/mg protein). Dobrian et al (2000) also 
reported increased activities of erythrocyte Cu/ZnSOD and GSH-Px after 10 weeks of 
diet-induced obesity. They attributed the increases in these erythrocyte cytoprotective 
enzymes to their stimulation by oxidant stress. Olusi (2002) believed the discrepancies 
in antioxidant enzymes in obesity could be due to the duration of the obesity. For 
example, in the early days of the development of obesity, antioxidant enzymes may be 
stimulated whereas chronic obesity continually depletes antioxidant enzymes. 
Other measures of antioxidant activity have been used such as total antioxidant status 
(TAS) and ferric reducing antioxidant power (FRAP). Several studies have shown 
significantly lower TAS and FRAP values in obese persons than in non-obese 
individuals (Lopes et al., 2003, Fenkci et al., 2003). For example, FRAP values were 
22% lower in obese than in non-obese matched controls (271±15 vs 333±29pmol/L) 
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(Lopes et al., 2003) and TAS values were moderately lower in obese persons 
compared to non-obese persons (1.15±0.01 vs 1.30±0.02mmol/L) (Fenkci et al., 2003). 
More recently, obese children with the metabolic syndrome had significantly lower 
plasma TAS levels than their non-obese counterparts (1.2±0.4 vs 1.57±0.21 mmoVL) 
(Molnar et al., 2004). Furthermore, lower TAS values were directly related to lower 
levels of various forms of plasma carotenoids such as vitamin E, vitamin C and 13- 
carotene (Molnar et al., 2004). 
2.11.3 Increased fat deposition 
Obesity is characterized by increased dietary fat intake, increased fat storage, 
excessive free fatty acids (FFA), excessive intracellular triglycerides and dyslipidaemia 
(Davi et al., 2002; Vincent et al., 2004), which may all contribute to the production of 
oxidant stress (Vincent and Taylor, 2006). 
Dietary lipids influence oxidant stress by providing double bonds in fatty acid chains 
(Reaven et al., 1991). For example, diets high in PUFAs are readily attacked by free- 
radicals as a result of their high number of double bonds in a fatty acid chain which 
makes it easier to remove the hydrogen atom (Symons and Gutteridge, 1998). 
However fatty diets high in SFAs (no double bonds) and MUFAs (one double bond) are 
more resistant to peroxidation (Reaven et aL, 1991). Basu et al (2000) studied the 
effect of consuming PUFAs in the diet on oxidant stress. In a randomized controlled 
trial obese middle-aged men were supplemented with 4.2 g day of conjugated linolenic 
acid (CLA) for one month. Compared to the control group significant increases in 8-iso 
PGF2a were observed in the supplemented group. The lipid peroxidation parameters 
(8-iso PGF2a) returned to their basal levels at 2 weeks after the cessation of CLA (Basu 
et aL, 2000). Riserus et al (2004) studied the effects of consuming a diet added with 
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CLA (an 18 carbon unsaturated fatty acid with two conjugated double bonds derived 
from dairy products and consumption of meat from ruminant animals) for four-weeks in 
obese men. Compared to those who consumed the normal diet, urinary 8-iso PGF2a 
significantly increased by 50% in the treatment group. 
Alternatively, the increased number of lipid molecules present in obesity may simply be 
an enlarged target for oxidative modification of ROS (Vincent et al., 2001). A 
comparative, experimental study investigated myocardial tissue in 16-week old lean 
controls (fa/?, normal diet), obese high-fat fed (Fa/?, 45% dietary fat) and obese fatty 
(fa/fa, normal diet) Zucker rats. Compared to lean controls, the high-fat fed and fatty 
animals had similar significant elevations in myocardial TBARS and PEROX (23%, 
25% and 29% 45%, respectively), and elevated susceptibilities to oxidant stress in vitro 
following exposure to oxidizing agents. Resting heart work was slightly higher in both 
the high-fat fed and fatty animals compared to controls. Myocardial lipid content, SOD 
activities and non-protein thiol (glutathione) levels were significantly elevated in high-fat 
fed and fatty animals compared to controls. The rate of superoxide formation by 
isolated papillary muscles in vitro did not differ among groups. Regression analysis 
revealed that the myocardial lipid content contributed most to myocardial lipid 
peroxidation (R2=0.76). This observation can be explained by increased PUFAs, 
promoting lipid peroxidation (Symons and Gutteridge, 1998) since myocardial oxidative 
injury was not closely associated with heart work, insufficient antioxidant defences or a 
greater rate of superoxide production (Vincent et al., 2001). Furukawa et al (2004) 
reported that increased oxidant stress in accumulated fat is an important pathogenic 
mechanism in obesity-associated metabolic syndrome. Furukawa et al (2004) 
demonstrated that, in non-diabetic subjects, fat accumulation closely correlated with 
the markers of systemic oxidant stress (TBARS and hydrogen peroxide concentration). 
The findings were reproduced in several mouse models of obesity and production of 
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ROS increased selectively in adipose tissue, accompanied by augmented expression 
of NADPH oxidase and decreased expression of antioxidative enzymes (SOD, GSH-Px 
and CAT) (Furukawa et al., 2004). 
Abdominal or visceral adiposity is also linked with increased levels of plasma FFA 
(Vincent and Taylor, 2006) which elevates blood glucose and produces NO' in smooth 
vascular and endothelial cells via a protein kinase C mechanism (Inoguchi et al., 2000). 
FFA can also induce the oxidative respiratory burst in white cells and acutely increase 
ROS formation in culture (Inoguchi et al., 2000). 
Excessive triglycerides may also increase ROS formation via their impact as a 
mitochondrial adenine nucleotide transporter suppressor. This results in an increase in 
02' production within the mitochondrial electron transport chain, which in turn 
decreases intramitochondrial adenine diphosphate. Electrons then accumulate within 
the electron transport chain and react with adjacent 02 to form 02' (Bakker et al., 
2000). 
Hype rcholesteraemia is associated with enhanced oxidizability of LDL molecules 
(Vincent and Taylor, 2006). The lag phase of lipid oxidation is shorter in LDL particles 
from obese individuals and rapid lipid peroxidation occurs in the PUFA of LDL particles 
(Van Gaal of al., 1998; Ozata et al., 2002). 
2.11.4 Cell Injury / low grade inflammation 
Obesity is associated with a state of chronic inflammation (Saito et al., 2003) and 
serum adipokines increase with fat mass, especially visceral fat (Vincent and Taylor, 
2006). Inflammation is characterized by inflammatory cytokine expression (interleukin- 
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6 (IL-6) and tumor necrosis factor alpa (TNF-a), C-reactive protein (CRP) production 
and increased white blood cell concentration and white cell activity (Vincent and 
Taylor, 2006). Expansion of the adipose tissue depot in obesity may increase IL-6 and 
TNF-a which both activate CRP production (indication of vascular inflammation) (Kopp 
et al., 2003). Elevations of inflammatory molecules (specifically TNF-a) promote 
oxidant stress by stimulating the expression of atherogenic endothelial adhesion 
molecules and promoting the attachment and migration of monocytes to macrophages 
in vessel walls (Lyon et al., 2003). Macrophages themselves also produce interleukins 
and TNF-a (Vincent and Taylor, 2006). Furthermore increased adhesion molecules 
may impair the insulin signalling cascade which leads indirectly to glucose 
dysregulation and hyperglycaemia (Hotamisligil et al., 1994), contributing further to 
ROS formation (Cosentino et al., 1997). In summary, TNF-a, IL-6 and CRP all cause a 
shift towards a pro-oxidant environment in obesity (Taylor and Vincent, 2006). 
However weight loss in humans have shown to attenuate CRP, TNF-a and IL-6 (Kopp 
et al., 2003). 
2.11.5 Other potential sources of increased oxidant stress in obesity 
Vincent and Taylor (2006) highlighted several other additional potential sources of 
increased oxidant stress in obesity. These include hyperglycaemia, hypertension and 
hyperleptinemia. 
2.11.6 Hyperglycaemia 
Several oxidative pathways are activated in hyperglycaemia by advanced glycosylation 
end products (AGE), polyol pathway and glucose autooxidation (Jiang et al., 1990). 
AGE formed from proteins, lipid and nucleic acids are diabetic precursors which bind to 
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specific cell surface receptors (RAGE) and lead to postreceptor signalling and further 
generation of ROS. AGE also activate intracellular transcription factors such as factor- 
kB which initiates a cascade of intracellular pathways (vascular cell adhesion molecule 
(VCAM-1) and intracellular adhesion molecule-1 (ICAM-1). Activation of these 
molecules can produce ROS as shown in rodent vessel tissues (Rodriguez-Manas et 
al., 2003). In addition this accelerates monocytes homing into the endothelium (Evans 
et al., 2002). Intracellular glucose elevations also stimulate the polyol pathway in which 
aldose reductase mediates conversion of glucose to sorbitol. Excess sorbitol causes 
oxidative damage and activates stress genes (Evans et al., 2002). When glucose auto- 
oxidises itself, oxidants are produced which are similar to OH. and 02" (Aronson and 
Rayfield, 2002). Hyperglycaemia also increases nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase activity and NADPH produces 02 especially in the 
endothelium (Zhang et al., 1999). Finally diet-induced elevations of glucose uptake 
into adipocytes of obese mice increase ROS formation (Talior at al., 2003). 
2.11.7 Hypertension 
Hypertension in obesity is a major co-morbidity (Vincent and Taylor, 2006). In the 
endothelium, there are several enzymatic sources of oxidant generation including 
NADPH oxidase, xanthine oxidoreductase, NO synthase and intraluminal pressure 
from hypertension. NADPH oxidase provides the major source of endothelial 02 
which can be enhanced by the presence of other cytokines and hormones of the renin- 
angiotensin system (Rajagopalan et aL, 1996). In particular concentrations of 
hormones in the renin-angiotensin system are higher in obese persons (Egan et ah, 
2001) Under ischaemic conditions, the enzyme xanthine oxidase reacts with 02 to 
form 02 and H2O2 (Kaminski et al., 2002) and increased 02' may react with NO to 
produce ONOO', which in turn reduces NO bioavailability (Wheatcroft et aL, 2003). 
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Hence these alterations are implicated in endothelial dysfunction and vascular 
insensitivity. Elevated intra-luminal pressure from hypertension may also stimulate the 
production of 02ý and ONOO- in the vasculature (Frisbee et al., 2002). ROS inhibits 
calcium-activated K+ channels and reduces vascular sensitivity as has been found in 
the arterial tissues of obese Zucker rats (Frisbee et al., 2002). In addition, 
hypertension itself may increase oxidant formation and excessive renin-angiotensin 
system hormones may exacerbate this process. Therefore both mechanisms can 
enhance endothelial dysfunction in obesity. 
2.11.8 Hyperleptinemia 
Leptin, a polypeptide mediator produced by white adipose tissue acts on hypothalamic 
centres to regulate food intake and energy expenditure (Vincent and Taylor, 2006). 
However excessive amounts of leptin have been associated with increased CVD risk in 
obese persons (Maingrette and Renier, 2003). Leptin may play several roles in 
obesity-induced oxidant stress by increasing direct production of OR and H202, by 
being a proinflammatory substance and by reducing cellular antioxidant paranoxase-1 
(PON-1) (Vincent and Taylor, 2006). 
Leptin can directly stimulate production of ROS in cultured endothelial cells (Bouloumie 
et al., 1999). Following injection with leptin, higher plasma and urine LH, MDA, 
isoprostane and protein carbonyl content (27-33% higher) were noted in Wistar rats 
compared to non-treated controls (Beltowski et al., 2003). This was attributed to lower 
antioxidant defences such as PON-1 (Beltowski et al., 2003). Leptin is a 
proinflammatory substance and indirectly stimulates production of inflammatory 
cytokines such as IL-6 and TNF-a, which may then increase NADPH oxidase which 
generates 02--. Finally leptin reduces the activity of PON-1 and this is directly related to 
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increased plasma MDA and LH (Beltowski et al., 2003). Ferretti et al (2005) recently 
reported that PON-1 activity in HDL was lower in obese compared with non-obese 
individuals (120 vs 4751U/mg protein). In the obese group, low PON-1 activity was 
accompanied by elevations in LH content in HDL and LDL and was inversely correlated 
with plasma leptin concentrations (Ferretti et al., 2005). 
2.12 Oxidant stress in obesity complications 
Vincent and Taylor (2006) and Furukawa et al (2004) believe that obesity creates the 
oxidant conditions of a `breeding ground' for diseases such as diabetes, hypertension 
and CVD. For example, oxidant stress in accumulated fat underlies the dysregulation 
of adipocytokines or adipokines, including PAI-1, TNF-a, resistin, leptin and 
adiponectin. Increased production of PAI-1 and TNF-a from accumulated fat 
contributes to the development of thrombosis (Shimomura et al., 1996) and insulin 
resistance (Hotamisligil et al., 1994; Uysal et al., 1997) respectively, in obesity. In 
contrast, adiponectin exerts insulin-sensitizing (Yamauchi et aL, 2001) and anti- 
atherogenic effects (Yamauchi et aL, 2003) and hence a decrease in plasma 
adiponectin causes insulin resistance and atherosclerosis in obesity. Furukawa et al 
(2004) demonstrated that ROS increased selectively in white adipose tissue which was 
accompanied by augmented expression of NADPH oxidase, which is a major source of 
oxidant stress (Rajagopalan et al., 1996). 
Oxidant stress in obesity can be corrected either by improving antioxidant defences, 
decreasing fat volume, exercise and dietary modification, or a combination of the three. 
Alternatively the redox state in adipose tissue may be a potentially useful target in new 
therapies targeted against obesity-associated metabolic syndrome. 
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2.13 Lifestyle factors affecting oxidant stress 
Various lifestyle, nutritional, environmental and genetic factors can induce an abnormal 
increase in free-radical production and/or a decrease in antioxidant defences causing a 
negative effect on the oxidant stress balance (Moller et al., 1996). Non-smoking, 
vitamin and/or trace element supplementation, regular physical activity and limited UV 
light exposure all contribute to an enhanced antioxidant defence potential, whilst 
tobacco smoking, high psychologic stress, heavy alcohol drinking and low/moderate 
vegetable intake, low fruit and little fish consumption contribute to a decreased 
antioxidant potential (Lesgards et al., 2002). 
The following chapters consider the effect of two primary weight management 
strategies on oxidant stress, namely dietary composition and physical exercise. 
2.13.1 Diet composition 
Endogenous antioxidant defences are inadequate to scavenge ROS in the body 
completely so ongoing oxidative damage to DNA, lipids and proteins and other 
molecules may ultimately contribute to the development of disease (Halliwell, 1996). 
Diet-derived antioxidants may be particularly important in protecting against these 
diseases. However the optimal intake of the most commonly diet-derived antioxidants 
is uncertain, but numerous studies have examined the effects of dietary composition on 
oxidant stress. 
Hyperlipidaemia (Aliev et al., 1998), high sugar (Faure et al., 1997) high protein 
(Mohanty et al., 2002) and high-fat diets (Slim et al., 1996) have all been shown to 
induce oxidant stress. Furthermore, the high sucrose content of a high-fat, refined 
carbohydrate diet may cause postprandial hyperglycaemia (Roberts et al., 2000), which 
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has been demonstrated recently to increase the generation of 02-' in human endothelial 
cells (Cosentino of al., 1997). In support of this, Roberts et al (2002) observed that a 
reduced consumption of fat and refined sugar consumption decreased oxidant stress. 
Velthuis-te Wierik of al (1996) suggested that the quantity and composition of dietary 
fat may affect fat-soluble anti-oxidative vitamin intake and/or anti-oxidative capacity and 
lipid peroxidation status. Fats in food serve as a carrier for fat-soluble vitamins. 
Therefore, reduced-fat foods may adversely affect the availability of fat-soluble vitamins 
and subsequently, anti-oxidative capacity (Velthuis-te Wierik et aL, 1996). In addition, 
increased consumption of PUFAs may enhance lipid peroxidation due to the existence 
of two or more double bonds within their structure (Symons and Gutteridge, 1998). 
However both Velthuis-te Wierik et al (1996) and Swinburn of al (1999) found that the 
consumption of reduced-fat products did not affect the integrity of the anti-oxidative 
scavenging capacity, assessed by measuring plasma MDA and anti-oxidative vitamins 
(B-carotene and a-tocopherol) and erythrocyte free-radical scavenging enzymes (SOD, 
GSH and CAT). SFAs have been shown to adversely affect plasma lipids, lipoproteins 
and haemostatic factors (Mitropoulos et al., 1994) as well as susceptibility to oxidation 
(Mata of aL, 1996). However replacing SFAs with either MUFAs or PUFAs in diets that 
provide less total fat did not appreciably affect LDL oxidative susceptibility (Schwab et 
al., 1998) but Berry of al (1991) and Reaven of al (1991) support the notion that 
subjects who consumed diets rich in MUFAs demonstrated lower LDL oxidation than 
subjects who consumed diets rich in PUFAs. However, unfortunately Wolff and 
Nourooz-Zadeh (1996) noted that the above research findings relating to lipid content 
and oxidant stress are not entirely straightforward. Although it has been shown that 
diets high in PUFAs and MUFAs and low in SFAs decrease atherosclerosis risk (Watts 
of aL, 1992), lipoproteins isolated from individuals consuming diets rich in PUFA and 
MUFA also demonstrated greater pre-disposition to peroxidation than lipoproteins from 
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individuals given SFAs (Kleinveld et aL, 1993). Individual hydroperoxide intake is 
expected to vary widely but will be largely dependent upon the intake of food containing 
hydroperoxides generated by pyrolysis such as fatty fried foods (Wolff and Nourooz- 
Zadeh, 1996). Hydroperoxide intake will also be influenced by the consumption of lard 
and compound cooking fat (such as baking and frying margarines) which contain high 
levels of pre-formed hydroperoxides (Wolff and Nourooz-Zadeh, 1996). Margarine has 
substantially lower levels of hydroperoxide but contains more hydroperoxide than 
butter, which may be due to the greater amount of processing required in its 
manufacturing (Wolff and Nourooz-Zadeh, 1996). 
Both a reduced or increased protein intake may also affect the oxidant stress balance. 
For example, dietary deficiency of protein not only impairs the synthesis of antioxidant 
enzymes but also reduces tissue concentrations of antioxidants, thereby compromising 
antioxidant status (Sies, 1999; Machilin and Bandito, 1987). According to Fang at al 
(2002) high protein diets lead to increased oxidant stress on the basis of the following 
considerations. First homocysteine, an independent risk factor for cardiovascular 
disease, (Boushey et aL, 1995) increases endothelial 02 production and induces 
oxidant stress in the vasculature (Wu and Meininger, 2002). Secondly, increasing 
protein intake has been shown to stimulate generation of ROS and lipid peroxidation in 
human polymorphonuclear leukocytes and mononuclear cells (Mohanty et aL, 2002). 
Finally, increasing dietary protein intake increases whole-body NO production by 
constitutive and inducible NOS in rats (Wu et al., 1999). 
In addition to studying the effects of short term and long term effects of dietary 
composition of oxidant stress parameters, it has been shown that immediately following 
consumption of a high fat meal or glucose load, free-radical production is enhanced 
(Vogel et al., 1997; Dandona et al., 2001). This suggests that increased ROS in 
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obesity maybe due to over-eating rather than dietary macro-nutrient consumption or 
the pathologies associated with obesity. 
2.13.2 Calorie restriction 
If over-eating increases ROS, under-eating may have the opposite effect. Velthuis-te 
Wierik et al (1996) demonstrated that reduced energy intake and fat intake over 6- 
months compared to controls contributed to a reduction in MDA levels. Ramsey et al 
(2002) observed that energy restriction, without malnutrition could retard the 
development of atherosclerosis, due to a reduction in 02 molecules within the 
mitochondria, thereby lowering the production of ROS. This is also supported by the 
studies of Guo et al (2002) who demonstrated that calorie restriction retarded the 
development of atherosclerosis, reduced the levels of lipid peroxidation and decreased 
the production of ROS in the arterial wall of ApoE''mice (mice homozygous knockout 
for the APoE gene). As calorie restriction did not alter the level of plasma cholesterol, 
the results suggested that reduction of oxidant stress in the arterial wall is a possible 
mechanism, by which dietary restriction inhibits atherogenesis in ApoE''mice. In 
humans, Dandona et al (2001) found significant reductions in concentration of TBARS 
following four weeks' of energy restriction and weight loss in humans independent of 
changes in anti-oxidant levels. Mean weight loss was 4.5±2.8kg at week 4 and there 
was a reduction in plasma TBARS from 1.68±0.17pmol/L at week 0 to 1.47±0.13pmol/L 
at 4 weeks. It remains unclear whether energy restriction without weight loss or weight 
loss without energy restriction could reduce oxidant stress. This would identify the 
independent contributions energy restriction and weight loss has on influencing oxidant 
stress levels (Fenster et al., 2002). 
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2.13.3 Acute aerobic exercise session 
Acute-exercise-generated oxidant stress has been well documented (Alessio et al., 
2000). Whole body 02 consumption during exercise may increase 15 fold and 02 flux 
in skeletal muscle may increase 100-fold (Sen, 1995). Therefore it is conceivable that 
an increase in metabolism can overwhelm endogenous antioxidant defences to form 
free-radical species (Ashton et al., 1998). Even moderate exercise may increase ROS 
production exceeding the capacity of antioxidant defences (Alessio, 1993; Ji, 1993). 
However Toshinai et a/ (1998) demonstrated that high-intensity exercise (80% VO2max 
for 22.5 minutes) induced a larger increase in lipid peroxidation compared to moderate 
exercise (40% VO2max for 45 minutes and 60% VO2max for 30 minutes). Tozzi- 
Ciancarelli et a/ (2002) demonstrated that strenuous exercise (maximal exercise test on 
a cycle ergometer), but not moderate exercise (30 minutes at 60% VO2max on a cycle 
ergometer), resulted in significant increased levels of TBARS and significant decreased 
levels of TAS [rest vs post-exercise (TBARS: 1.5±0.2 vs 1.4±0.1 pmol/L and 1.6±0.2 vs 
3.9±0.3pmol/L, respectively; TAS: 1.35±0.04 vs 1.47±0.05U/mL and 1.45±0.03 vs 
1.05±0.03U/mL)]. Lovlin et a/ (1987) also demonstrated that higher aerobic exercise 
intensities caused an increase in oxidant stress. For example exercise eliciting 100% 
VO2max resulted in a 26% significant increase in plasma MDA, exercise eliciting 70% 
VO2max resulted in a non-significant reduction in plasma MDA and exercising at 40% 
VO2max resulted in a 10.3% significant decrease in plasma MDA. A vast majority of 
exercise-induced oxidant stress has been studied in healthy individuals whilst the effect 
of certain pathologies on exercise-induced oxidant stress remains unclear. 
To date, four studies have investigated the effect of obesity on exercise-induced 
oxidant stress (Saiki et aL, 2001; Vincent et al., 2004; Vincent et al., 2005a; Vincent et 
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al., 2005b). Saiki et al (2001) studied 7 obese and 16 normal-weight individuals and 
observed changes in serum hypoxanthine (marker of free radical production) following 
aerobic exercise on a treadmill (15 minutes at 70% heart rate reserve). Baseline 
serum hypoxanthine levels were significantly higher in the obese group than in the 
normal-weight group (3.46±3.70 vs 1.23±1.16pmol/L). Exercise also induced a 
pronounced increase in serum hypoxanthine level in the obese group compared with 
the normal-weight group (43.86±4.56 vs 10.65±6.81 pmol/L) despite the obese group 
achieving a significantly lower peak V02 than in the control group (28.16±4.0 vs 
37.16±4.7mUkg/min). Vincent of al (2004) assessed LH levels in normal-weight and 
obese individuals, pre and post aerobic exercise. At rest LH levels were not 
significantly different between the normal-weight and obese group, but post-exercise 
LH levels increased by 70% and 62% in the obese and normal-weight, respectively, 
which was significantly different to pre-exercise LH levels and significantly different 
between the normal-weight and obese group. Vincent of al (2005a) also found 
significantly increased post-exercise LH levels in obese women compared to normal- 
weight women following a maximal aerobic exercise session (0.13 vs 0.02 (nmol/mL) 
(02/kg/min). This occurred despite 20% shorter exercise times for the obese than for 
the normal-weight women. After controlling for body fat percentage and baseline LH, 
the major contributors to the change in LH levels during exercise were age, peak heart 
rate and exercise duration. However when exercise loads were matched by relative 
intensity, LH responses still remained higher in obese than normal-weight persons 
(0.289 vs 0.054 (nmol/mL) (02/kg/min) (Vincent et al., 2005b). 
Several mechanisms that may contribute to increased free-radical generation during 
exercise include 02 metabolism, anoxia-reoxygenation, mechanical damage to tissues 
and enhanced inhalation of environmental pollutants (NO2, ozone etc) (Vincent et aL, 
2004). The redirection of blood flow during exercise to exercising muscle (reduced 
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blood supply to other organs: liver, kidney and intestine) then the return of the 
blood 
flow to liver, kidney and intestine mimics ischaemia-reperfusion phenomenon. 
Evidence highlights that ischaemia-reperfusion causes excessive production of free- 
radicals, leading eventually to extensive tissue damage (McCord, 1988). Physical 
stress and shearing forces can also cause significant damage to the skeletal muscle. 
The tissue damage may attract neutrophils, leading to further generation of free- 
radicals (Weiss and LoBuglio, 1982). Air pollutants can also be a direct source of free- 
radicals such as NO or an indirect source of free-radicals, such as ozone. Strenuous 
exercise which leads to hyperventilation can cause increased exposure to 
environmental pollutant related free-radicals (Singh, 1992). Strenuous exercise is 
known to stimulate catecholamine secretion and the circulation, which could potentially 
generate free-radicals in the body through autooxidation, and/or through metal-ion or 
02' catalyzed oxidation (Jewett et al., 1989) and neutrophil activation (Steensberg et 
al., 2001). 
2.13.4 Exercise training 
Although an acute bout of exercise induces oxidant stress (Alessio et al., 2000) regular 
physical activity can favourably effect the pro-oxidant/antioxidant balance (Fukai et aL, 
2000). Repeated exposures to the mild oxidant stress, which occurs with exercise 
training can initiate adaptations to reduce oxidative insult, such as reducing 02' 
production or up-regulating antioxidant enzyme cells (Fukai et aL, 2000). Miyazaki et al 
(2001) found that 12 weeks of strenuous aerobic exercise training (running at 80% 
maximal exercise heart rate for 60 minutes a day, 5 days a week) in untrained normal- 
weight individuals increased basal activity of erythrocyte antioxidant enzymes and 
decreased the production of neutrophil 02" production following an acute period of 
exhaustive exercise on a cycle ergometer. Regardless of exercise training, exhaustive 
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exercise caused a significant increase in the ability of the neutrophils to produce 02' 
and increased levels of TBARS. However, the magnitude of the increase of both 
neutrophil 02" production and TBARS was significantly reduced after training. The 
activities of SOD and GSH-Px increased by 17.1 % and 11.5% at rest, respectively after 
12 weeks of intense exercise training but were unaffected by the period of acute 
maximal exercise. No change in CAT activity was observed with either maximal 
exercise or endurance training. In summary many of the cardio-protective effects 
(decreased blood pressure, reduced platelet aggregation and adhesiveness, and 
increased coronary blood flow (Gielen et a!., 2001) of regular exercise can be attributed 
to adaptations that minimize oxidant stress (Powers et a!., 1999) and/or those that 
increase bioavailable NO (Gielen eta!., 2001). 
In addition to weight management therapy (dietary composition, calorie restriction and 
exercise training) reducing oxidant stress levels in obesity, the improvements in oxidant 
stress levels may be enhanced with antioxidant therapy. The use of antioxidant 
therapy to reduce oxidant stress is discussed in the following chapters. 
2.14 Antioxidant therapy 
Many research studies have studied the effect of antioxidant therapy on reducing 
oxidant stress, following the assumption that the solution to oxidant stress was to 
increase antioxidant status by administering antioxidants. This hypothesis was 
supported by studies undertaken by Armstrong and Doll (1975) and Rimm et al (1996), 
who demonstrated that people in higher socioeconomic classes suffered lower rates of 
CVD compared to lower socioeconomic groups because they ate more fresh fruit and 
vegetables and they smoked less with the net effect of improving their antioxidant 
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status. The studies considered below highlight the potential antioxidant therapy can 
have on reducing oxidant stress in obesity. 
2.14.1 Effect of antioxidant therapy on oxidant stress in obesity 
Various studies have been undertaken to study the therapeutic use of antioxidants on 
the primary and secondary prevention of CVD and in summary they revealed an overall 
lack of benefit (Morris and Carson, 2003). This lack of effect may be explained by 
several facts such as trial populations which were generally older and/or had advanced 
stages of disease or had major confounding variables that negated any potential 
positive supplementation effect. The timing, type and dosage of antioxidant 
supplementation may not have been optimal for the specific population studied (Morris 
and Carson, 2003). Furthermore many CVD antioxidant interventions have used 
endpoints of clinical symptoms of disease i. e. myocardial infarction to assess the 
effectiveness of antioxidant therapy in reducing disease. This is not suitable for early 
detection of disease processes and therefore prevention. Heinecke (2001) stressed 
that future antioxidant supplementation studies should always include biomarkers of 
oxidant stress. 
Although the studies are few in number, they demonstrate the potential antioxidant 
therapy may have for decreasing oxidant stress levels, which may in turn prevent or 
delay disease onset. Skrha et al (1999) found that vitamin E (600mg daily) 
administration in obese diabetic patients for 3 months decreased plasma MDA from 
3.13±0.68 to 2.87±0.97pmol/L. A similar finding was also observed by Manning et al 
(2004) who found reduced LH levels in obese subjects following 6-months of vitamin E 
supplementation (3 months 8001U vitamin E/day, 3 months 1200lU vitamin E/day). LH 
was decreased by 27% at 3-months and by 29% at 6-months following vitamin E 
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supplementation and the decrease in LH was positively correlated with plasma vitamin 
E concentrations at the 6-month time point (r = 0.40). Another study also indicated 
protection against formation of oxidative biomarkers with antioxidant treatment, for 
example in overweight type II diabetic versus non diabetic contols (Anderson et al., 
1999). Twenty diabetics completed an 8-week control period, 8 week treatment period 
(p-carotene (24mg), vitamin C (1000mg) and vitamin E (8001U) followed by an 8-week 
control period (subjects were on a weight maintaining diet). Following the treatment 
period in the diabetic group, lag time for LDL oxidation (measured using copper 
oxidation at 37°) significantly increased (pre vs post: 27.9±6.81 vs 58.9±8.68minutes) 
and TBARS formation significantly decreased (pre vs post: 101.5±10.70 vs 
70.6±9.75nmol/mg). 
Although antioxidant therapy may be suitable therapy to reduce the obesity-associated 
oxidant stress, there still remains few data on the effects of other antioxidants not 
mentioned above on oxidant stress, such as Se. 
2.15 Selenium (Se) 
The essential trace mineral, Se is of fundamental importance to human health 
(Rayman et al., 2000). As a constituent of selenoproteins it plays both structural and 
enzymatic roles, in the latter context it is best known as an antioxidant and catalyst for 
the production of active thyroid hormone (Rayman et al., 2002). Se is the essential 
metal cofactor for the activity of the antioxidant enzyme, GSH-Px (Rotruck et a/., 1973). 
GSH-Px removes H202, lipid and phospholipid hydroperoxides and other 02 derived 
species (Alissa at ah, 2003). If not removed, LH impairs membrane structure and 
function (Gutteridge and Halliwell, 1990) and causes blood clotting disturbances by 
decreasing the production of prostacyclin while increasing the production of 
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thromboxane (Rayman et aL, 1996). Furthermore, in the presence of transition metal 
ions, LH can decompose to give further reactive free-radicals and cytotoxic aldehydes 
(Diplock, 1994). Such secondary products may initiate more lipid peroxidation, promote 
atherosclerosis, damage DNA, and metabolically activate carcinogens (Diplock, 1994). 
The activity of these selenoproteins depends on adequate dietary content of Se. Se 
enters the food chain through plants but its bioavailability is variable on a geographical 
level. For example, Se bioavailability is low in most parts of Europe and in areas of 
China, soils being a poorer source of Se (MacPherson of aL, 1997). Low concentration 
of Se is associated with Se deficiency diseases such as Keshan disease 
(cardiomyopathy) and Kashin-Beck disease (deforming arthritis) (Rayman, 2000). In 
the UK, Se intake is a cause for concern (Rayman, 2002). For example, 22 years ago 
Se intake in Britain was 60pg/day (Thorn et al., 1978) compared to 34pg/day in 1994 
as found in a survey undertaken for Britain's Ministry of Agriculture, Fisheries, and Food 
(Barclay et al., 1995). The UK reference Se intake for males and females is 75 and 
60ug/d respectively (Department of Health, 1991) which current intakes clearly do not 
meet. 
The fall in Se intake may be explained by the drop in imports of Se rich, high protein 
wheat for breadmaking flour from North America (Rayman, 2002), coupled with 
changes in breadmaking technology (Rayman, 1997). Parallel reductions in intake 
have occurred in other European Union countries for similar reasons; added to which, 
bioavailability of Se may have fallen in areas subjected to acid rain or excessive 
artificial fertilisation of soils, both of which reduce plant absorption of the mineral 
(Rayman, 1997). 
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The current Se intake does not allow for maximal expression of plasma GSH-Px 
(Duffield et al., 1999). It has been shown that maximum GSH-Px activity plateaus at 
serum Se levels between 90 and 100ug/I (Pearson et al., 1990). Excessive doses of 
Se are not required to enhance GSH-Px activity, because there appears to be a level of 
Se, above which further increases in its availability cause no elevation in enzyme 
activity i. e. GSH-Px (Pearson et ah, 1990). 
Increasing Se intake from dietary foods may be achieved by consuming meat, poultry 
and fish, which make the biggest contribution to Se intake (about 36% in the UK). 
Breads and cereal are also commonly consumed and make a substantial contribution 
to Se intake in northern Europe (around 22% in the UK) (UK Ministry of Agriculture 
Fisheries and Food, 1997). Brazil nuts, kidneys and crab are also sources of Se 
(Barclay et al., 1995). Other solutions to increase Se intake would be to add Se to the 
food supply by treating crops with fertiliser containing sodium selenate (Na2Se04) via 
the process fortification of foods or via Se supplementation (Aro et al., 1998). Se 
consumed in foods and supplements exists in a number of organic and inorganic forms 
including selenomethionine (plant and animal sources and supplements), 
selenocysteine (mainly animal sources), selenate and selenite (mainly supplements) 
(Young at al., 1982). Bioavailability and tissue distribution depends on the form 
ingested. For example, selenomethionine is more effective in increasing apparent Se 
status because it is non-specifically incorporated into proteins (e. g. haemoglobin and 
albumin) in place of methionine (Thomson et al., 1993). However, it has no catalytic 
activity and so must be catabolised to an inorganic precursor before entering the 
available Se pool (Rayman at al., 2000). Selenomethionine is a less-available 
metabolic source of Se than selenite or selenate, since these only need to be reduced 
to selenide to provide selenophosphate, the precursor of selenocysteine, the active 
form of Se in selenoproteins (Allan et al., 1999). Despite this, organic forms of Se (high 
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Se yeast) are often preferred in interventions because they are less acutely toxic 
(Institute of Medicine, 2000) but they may be more toxic during long-term consumption 
owing to non-specific retention of Se as selenomethionine in body proteins, rather than 
its excretion (Rayman et al., 2000). 
2.15.1 Effects of selenium supplementation on oxidant stress 
To date, no study has examined the effects of administering Se supplements on 
oxidant stress in obese individuals, but Olusi of a/ (2002) has shown that obese 
individuals have reduced GSH-Px activity (which may be due to reduced Se intake 
levels) and so may benefit from Se supplementation as a potential to reduce the 
obesity-associated oxidant stress. Several investigators have examined the effect of 
Se supplementation on oxidant stress in other population groups as discussed in the 
next chapter. 
Bortoli et al (1991) studied the effects of 30-days Se supplementation (4 x 16.5pg 
inorganic Se and 5.0mg Vitamin E) in twenty elderly women. Following 30-days Se 
supplementation, plasma Se levels significantly increased from 73.2±15.9 to 
95.7±21.8pg/L which decreased to 78.5±8.9pg/L, 30-days post supplementation. 
GSH-Px increased from 35.9±7.2 to 41.4±3.5U/g Hb, which increased further to 
42.7±9.2UI/g Hb, 30-days post Se supplementation. MDA levels showed insignificant 
changes during the Se supplementation period but 30-days post Se supplementation, 
MDA significantly decreased to a level lower than pre Se supplementation (baseline vs 
30-days post-Se supplementation: 4.3±0.6 vs 3.3±0.3pmol/L). Wilke et al (1992) noted 
improvements in oxidant stress status in phenylketonuric (PKU) children (at risk of Se 
deficiencies) who were given a daily sodium selenite (0.13pmol Se/kg/day) supply for 
6-months. Compared to controls, PKU children had significantly lower plasma and 
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erythrocyte Se, significantly lower plasma and erythrocyte GSH-Px and significantly 
higher plasma MDA. Following Se supplementation, compared to control values 
plasma Se and GSH-Px values normalised after 1-month, erythrocyte Se after 2- 
months, and erythrocyte GSH-Px and plasma MDA after 4-months. The relatively 
slower biochemistry correction in red cells compared to plasma may be due to red cell 
turnover times (Wilke et aL, 1992). Sarada et al (2002) examined the role of Se in 
reducing hypoxia-induced oxidant stress (at high altitudes ROS are continuously 
generated as a consequence of low 02 partial pressure). In a study by Sarada et al 
(2002), twenty four male Sprague-Dawley rats were divided into four groups: control 
(normoxia), group II (hypoxia), group III (normoxia plus Se) and group IV (hypoxia plus 
Se). The rats being exposed to hypoxic stress were placed in a decompression 
chamber for 6-hours daily for one week. Compared to the control group, hypoxia 
(group II) significantly increased plasma MDA production (2.4±0.5 vs 4.0±0.4nmol/mL), 
significantly decreased plasma GSH (21.2±1.1 vs 11.9±1. Onmol/mL), significantly 
decreased blood GSH-Px, significantly decreased plasma protein and significantly 
decreased plasma Se content. However Se supplementation in group IV reversed the 
trend. Compared to group II, group IV demonstrated a significant decrease in MDA 
(4.0±0.4 vs 1.7±0.7nmol/mL) and subsequent significant increase in plasma GSH 
levels (11.9±1.0 vs 25.8±9.7nmol/mL). Similarly blood GSH-Px, plasma protein and 
plasma Se content all significantly increased in the Se supplemented hypoxia group 
(group IV) compared with hypoxia alone (group II). These results indicated that Se 
could decrease lipid peroxidation during hypoxia. 
However, no beneficial effect of Se supplementation was found by Portal et a/ (1995) 
who performed a double-blind cross-over Se supplementation study on lipid 
peroxidation markers in cystic fibrotic children. Similar to obese patients, cystic fibrosis 
patients have been shown to have increased lipid peroxidation markers (Wilke et A, 
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1990), as a result of increased production of ROS mediated by infections or a defect in 
antioxidant defences (Portal et aL, 1995). Portal et al (1995) assessed twenty seven 
cystic fibrosis children who were given 2.8pg of sodium selenite per kg per day for 5- 
months and 5-months with a placebo control and inversion of treatment periods. 
Simultaneously, 17 healthy children were also investigated as control subjects. 
Although Se status was similar in both the control and cystic fibrosis children, cystic 
fibrosis children had significantly higher lipid peroxidation markers (organic 
hydroperoxides) (122.6±23.3 vs 171.5±54.4pmol/L). However organic hydroperoxides 
were normalized at 12-months on either Se or placebo treatment. After the initial 
treatment, Se supplementation significantly increased both plasma Se concentration 
and GSH-Px- activity whilst the placebo group demonstrated a significant reduction in 
plasma Se concentration and no significant changes in GSH-Px activity [baseline vs 
first treatment: Se concentration (Se group, 0.83±0.17 vs 1.11±0.18pmoVL and placebo 
group, 0.78±0.14 vs 0.67±0.13pmol/L), GSH-Px concentration (Se group, 269.8±40 vs 
340.4±77pmol/L and placebo group, 260±45 vs 291.4±67pmol/L)]. However compared 
to month 5, following the second treatment period, Se supplementation significantly 
increased plasma Se concentration but decreased GSH-Px activity whilst in the 
placebo group plasma Se concentration significantly decreased and GSH-Px activity 
decreased. These results indicated that improvement of lipid peroxidation markers in 
cystic fibrosis was not related to the Se supplementation. The decrease in organic 
hydroperoxide levels observed following Se treatment may be linked to the 
improvement of the biological indices of Se status as reported in studies by Bortoli et al 
(1991) and Wilke et al (1990). However this relationship is inconsistent with data 
observed in the placebo group since organic hydroperoxide levels normalized in spite 
of a reduced plasma selenium concentration. It may be possible that the variable 
organic hydroperoxide levels in healthy subjects was a result of seasonal variations or 
the interpretation of the data may have been limited a result of inferences in the organic 
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hydroperoxide marker, despite complying with the criteria of good analytic practice. 
Alternatively, the reduced organic hydroperoxide levels in the placebo group may be a 
placebo effect which may have been influenced by change in patient behaviour due to 
inclusion in the clinical protocol (Portal et al., 1995). 
Overall Se supplementation may have an important role as a potent antioxidant effect 
but its effects on oxidant stress in obesity is unknown. When considering Se 
requirements, the following factors should be borne in mind; the form of selenium 
ingested affects the response of the selenoenzymes (Brown et aL, 2000), the 
concentration of some selenoenzymes is affected more than others by scarce selenium 
supply owing to the hierarchy of selenoprotein expression (Behne et al., 2000), there is 
a significant variation between individuals in the extent of the response of the 
selenoenzymes to Se supplementation so Se requirements between individuals in the 
same population may differ (Institute of Medicine, 2000) and adaptation to low Se 
intake can occur by sparing excretion (Thomson et al., 1993). 
In addition to studying the impact of Se supplementation on oxidant stress it seemed 
appropriate to incorporate other possible potential benefits of Se supplementation on 
preventing disease such as CVD. For example, oxidants may influence the process of 
thrombus formation by interfering at multiple steps within the `cascade of 
thrombogenesis' (Ambrosio of aL, 1997). Of particular interest is the association 
between oxidants and platelet aggregation. In the following chapters the importance of 
haemostasis and platelet aggregation is discussed which is followed by a discussion of 
the possible association between obesity and platelet aggregation and ROS mediated 
platelet aggregation. 
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2.16 Haemostasis and platelets 
Haemostasis protects the integrity and ensures the balance of blood components by 
preventing excessive blood loss through damaged vessel walls (Horne, 2005). The 
normal haemostatic system is extremely complex but exquisitely well regulated. 
Interrelationships exist between responses of the vasculature; circulating platelets, 
coagulation proteins and fibrinolytic mechanisms, which all serve to limit blood loss, 
preserve tissue perfusion and stimulate local repair processes (Troy, 1988). Following 
pathologic stimuli, natural inhibitors of coagulation and fibrinolysis modulate the above 
systems to prevent uncontrolled thrombosis or haemorrhage, although some of the 
constituent proteins involved in the above mechanisms also have additional roles in 
inflammation, angiogenesis and tissue repair (Horne, 2005). Platelets play a central 
role in the process of thrombus formation (Hoak, 1988), as well as playing an important 
role in atherogenesis (Rabbani and Loscalzo, 1994) and the progression of 
atherosclerotic lesions (Kamath et al., 2001). 
2.16.1 The platelet 
Platelets are small anucleate cells derived from human bone marrow megakaryocytes 
(George, 2000). Each megakaryocyte releases about 4000 platelets on maturation. 
The normal platelet count in blood is between 150 x 109 and 400 x 109/1, the average 
life span being around 7-10 days (George, 2000). 
Platelets have a complex internal structure of membranes. Platelets reveal an open 
canalicular system comprising invaginated plasma membrane, thus increasing the 
effective platelet surface many-fold. The membrane of phospholipids promotes the 
60 
cascade of coagulation by converting coagulation factor X to Xa and prothrombin to 
thrombin (George, 2000). 
In the platelet interior are numerous granular bodies including dense granules, alpha- 
granules, Iyosomes and glycogen. Dense granules are packed with 5- 
hydroxytryptamine (5-HT), noradrenaline, adenosine triphosphate (ATP), adenosine 
diphosphate (ADP) and calcium all of which have a profound effect on other platelets 
and vasomotor responses i. e. contraction and relaxation of the blood vessels. 
(George, 2000) The alpha granules contain a range of proteins, including growth 
factors, coagulation proteins and platelet-specific proteins that influence the adhesion 
of the platelets to each other and to the endothelium. These proteins include platelet- 
derived growth factor (PDGF), platelet-derived endothelial growth factor (PDEGF), 
fibrinogen, Von Willebrand factor (vWF), factor F, bironectin, beta-thromboglobulin 
(BTG), thrombospondin-1 (TSP-1) and the platelet factor 4 (PF4) (George, 2000). 
Platelets have a complex cytoskeleton which is involved in the initial changes in platelet 
shape associated with platelet activation and also the movement and release of the 
internal granules and their contents (George, 2000). The platelet plasma membrane 
contains many glycoproteins which serve as receptors for agonists that initiate platelet 
adhesion and platelet aggregation (McEver, 1990). Specific glycoprotein (GP) 
receptors that react with aggregating factors, clotting factors and inhibitors include: 
  GP la - that facilitates adhesion to collagen exposed by trauma 
  GP lib and Illa (integrin) - attach the platelet to subendothelial vWF; GP lib 
- Illa also binds fibrinogen to promote platelet aggregation 
  GP lb-that also binds to vWF. 
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2.16.2 Platelet function 
The main function of platelets is the formation of mechanical plugs during the normal 
haemostatic response to vessel wall injury, following platelet activation. The platelet 
surface has various receptors, which activate platelets following diverse stimuli, with 
equally diverse platelet responses (mediated by the binding of various stimulants to 
specific platelet receptors). For example, the occupation of ADP receptors by ADP 
leads to the transformation of specific proteins (GP Ilb/Illa complexes) into a form that 
binds fibrinogen (Seiss, 1989). Platelet response may be categorized by 'reversible or 
irreversible' platelet responses (Seiss, 1989). Reversible platelet responses include 
adhesion, shape change and reversible aggregation and the irreversible platelet 
response includes release action, and secondary reversible aggregation (Seiss, 1989). 
Platelet adhesion and a change in shape are the initial physiological responses leading 
towards the development of a haemostatic plug or thrombus (Sixma et al., 1991). 
Vascular injury causes brief vasoconstriction, which is then followed by platelet plug 
formation, then coagulation (Horne, 2005). Constriction or narrowing of the lumen of 
the arterioles, minimizes both the flow of blood to the wounded area and the loss of 
blood from the wound. Platelets then quickly adhere to the injury site because they 
come in contact with sub-endothelial collagen and vWF (Horne, 2005). As a result of 
adhesion, platelets become activated and change their characteristics by extending 
many projections that enable them to recruit additional platelets to the primary 
haemostatic plug (Roberts et al., 2001). Thromboxane A2 and ADP release play a 
major role in the activation of nearby platelets. The occupancy of these agonists on 
receptors (the agonists are released from damaged vessel walls) on the platelet 
plasma membrane, initiate a sequence of events, namely shape change, adhesion of 
the platelets to the vessel wall, the release of granule contents, activation of 
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neighbouring plug and a transitory local vasoconstriction (Rand et al., 2003). 
Following 
primary haemostasis, the matrix of platelet and other blood components temporarily 
arrests the bleeding. However the plug is fragile and could be easily dislodged 
from 
the vessel wall at this stage, so platelets form links to become more stable, which is 
induced by a number of agents such as ADP, collagen and thrombin (Kinlough- 
Rathbone, 1977). The linking of platelets via fibrinogen brings about platelet 
aggregation. Simplistically, vWF and fibrinogen bind to receptors on one platelet and 
crosslink to the other platelets by binding onto receptors on the latter (McManama et 
al., 1986). Once platelet aggregates are formed, there is a tendency for the fibrin 
threads to be laid on them to form a clot. The addition of fibrin to the primary 
haemostatic plug creates the secondary haemostatic plug (Roberts et al., 2001). This 
process is facilitated by platelets using several mechanisms such as the platelet 
membrane phospholipids which potentiate the intrinsic pathway of coagulation to form 
thrombin from prothrombin by activated factor X (Hemker et al., 1983). PF4 is a 
platelet release reaction which possesses fibrinogen and P-selectin and which result in 
platelet-leukocyte interaction leading to fibrin deposition by the leukocytes to form a 
thrombus (Palabrica et al., 1992). The entire process is contained at the site of vessel 
injury by anticoagulant proteins (antithrombin and activated protein C) which prevent 
the reactions from spreading (Simmonds et al., 1998). When the vessel injury has 
healed, the secondary haemostatic plug is no longer needed and is broken down and 
removed by additional components of the haemostatic system, known as fibrinolysis 
(Horne, 2005) 
2.17 Haemostatic risk factors for vascular disease 
The importance of the involvement of platelets in the early development of 
atherosclerosis has received differing degrees of support (Miller and Bruckdorfer, 2005) 
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but evidence for the involvement of platelet activity in the terminal stages of CVD is 
compelling (Miller and Bruckdorfer, 2005). 
According to Tsiara et al (2003) and Broadley et al (2003), platelet aggregation and 
platelet activation are central processes in the pathophysiology of CVD. Platelets have 
been found to be engulfed within macrophages (Sevitt, 1986) and there is evidence of 
episodic platelet involvement during plaque development (indicated by fluorescent 
antibodies to platelet antigens which identify platelet emboli). Platelet activity is also 
increased in individuals following myocardial infarction and a low-dose aspirin for the 
suppression of platelet activation has been shown to be effective as a prevention for 
myocardial infarction and stroke (Antiplatelet Trialists' Collaboration, 1994). However 
Elwood et al (2001) found that platelet aggregation did not provide any predictive 
power for myocardial infarction in a cohort of 2000 men. 
2.18 Platelets in obesity 
Obese subjects are predisposed to CVD and furthermore independent of the degree of 
obesity, abdominal obesity strongly correlates with established risk factors for CVD 
(Coleman et al., 1992). In addition to factors such as hypertriglyceridaemia, 
hypercholesterolaemia, low HDL cholesterol and impaired glucose tolerance, 
haemostatic abnormalities in obese individuals have been identified as a cause for 
increased CVD risk (Avellone et al., 1994). For example, obesity has been associated 
with higher fibrinogen levels (Avellone et al., 1994), increased Factor VII (Avellone et 
al., 1994) and higher baseline tissue plasminogen activator and higher PAI-1 levels 
(Landin at al., 1990). In addition, platelet aggregation has been shown to be enhanced 
in obesity (Davi et al., 2002; Haszon at al., 2003). For example, Davi et al (2002) found 
that obesity increased 11-dehydrothromboxane B2 (a marker of in vivo platelet 
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activation), which was further enhanced in individuals with android obesity. It was 
concluded that a potential mechanism between CVD mortality and gross obesity was 
via enhanced thromboxane-dependent platelet activation. However in this particular 
study it should be noted that the authors did not directly measure platelet aggregation. 
Haszon et al (2003) concluded that obese children demonstrated increased platelet 
aggregation (measured using collagen as an agonist with a laser rheoaggregometer) 
which contributed to the development of hypertension and to the promotion of vascular 
damage. However Juhan et al (1980) found that platelet activity was not related to 
body weight and displayed no correlation with excess fat mass. However, platelet 
activity was significantly increased in cases where obesity predominated in the upper 
body (hyperandroid obesity). Alternative measures of platelet activity such as mean 
platelet volume have been shown to be higher in obese individuals (Coban et aL, 
1992), which may also be an indicator of platelet activation (Park et al., 2002). 
Current literature discussed on the association between platelet activity and obesity is 
non-existence despite platelet activity playing an important part in the complex 
`cascade of thrombogenesis'. The lack of literature may be due to the problems 
associated with measuring platelet activity. Provided a robust measure of platelet 
activity can be identified, platelet activity could be assessed in high risk populations to 
ascertain possible risk factors for increased platelet activity i. e. increased oxidant 
stress. This may potentially lead to new founding mechanisms and thus the 
development of future treatments to reduce the risk of CVD in high risk population 
groups. A possible treatment may be antioxidant therapy if a close association 
between oxidants and platelet aggregation is present. 
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2.19 Association between oxidant stress and haemostasis risk factors 
At the vascular endothelial level, oxidant attack disrupts endothelial integrity, which 
disturbs the dynamic interaction between the endothelial cell surface and mechanisms 
aimed at inhibiting or promoting thrombus formation (Ambrosio et al., 1997). Disrupted 
activities include the coagulation cascade, platelet function and fibrinolysis system. In 
normal circumstances the endothelial cells can inhibit thrombus via coagulation by 
synthesizing various substances such as thrombomodulin, tissue-factor pathway 
inhibitor, prostacyclin and PAI-1 or by activating fibrinolysis (Ambrosio et al., 1997). 
Oxidants may also impair anti-thrombotic properties more directly via the breakdown of 
endothelial-derived relaxing factor (EDRF). Endothelial cells release EDRF in the 
vascular lumen, which exerts anti-platelet effects via stimulation of guanylate cyclase 
(Mellion et al., 1981), which counteracts platelet aggregation. 02' have been 
implicated in the breakdown of EDRF (Ambrosio et al., 1997). In vitro, the half-life of 
EDRF is significantly shortened in the presence of 02" and conversely, SOD has been 
demonstrated to prolong EDRF half-life (Rubanyi and Vanhoutte, 1986; Gryglewski et 
al., 1986). 
Unwanted intravascular thrombus formation is usually inhibited by an important 
component of the coagulation pathway, 'tissue factor' (TF) which is suppressed in 
endothelial cells and under tight control because the endothelium is in contact with 
circulating blood (Jaffe, 1991). TF forms a complex with coagulation factors VII and 
Vila, allowing enzymatic activation of factors X and IX, the substrates for factor Vila, 
ultimately leading to the generation of thrombin and the potential to trigger intravascular 
thrombus formation (Pawashe et aL, 1994). Exposure to 02 radicals has been shown 
to significantly increase in TF mRNA levels, which has been indicated in coronary 
artery occlusion and reperfusion in rabbits (Golino et al., 1996). Consequently 
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Ambrosio et al (1997) speculated that 02 radical-mediated TF expression by 
endothelial cells, with its attendant activation of the extrinsic coagulation pathway, may 
have important consequences as it might impact on the pathophysiology of post- 
ischemic reperfusion. In addition to inducing TF expression in endothelial cells, ROS 
could promote intravascular thrombus formation by interfering with mechanisms that 
normally inhibit activation of the coagulation pathway (Ambrosio et al., 1997). Lipid 
peroxides have been shown to increase thrombin production and slow down the rate of 
thrombin decay (Barrowcliffe et al., 1975). Other key anti-thrombotic factors have been 
shown to be susceptible to oxidant-mediated inactivation i. e. plasminogen activator 
(Lawrence et al., 1986), thrombodulin (Glaser et al., 1992) and tissue factor pathway 
inhibitor (TFPI) (Golino et al., 1995). 
Platelets, which play a major role in thrombus formation are a prime target for oxidants 
produced or released in the vascular lumen and at the same time are also capable of 
endogenous generation of oxidants (Finazzi-agro et aL, 1982; Del Principe et aL, 
1991). Previous research investigating the effects of oxidants on platelet aggregation 
is misleading. Some investigators have described an inhibitory effect of oxidants on 
platelets and others have reported that oxidants enhanced platelet aggregation 
(Ambrosio et aL, 1997). These discrepancies may be the result of differences in 
experimental protocols. Relationships between oxidant stress and platelet 
aggregation, to date, have demonstrated that H202 plays an inhibitory role when 
platelets are exposed (Ambrosio et al., 1997). According to Ambrosio et a/ (1997) 02' 
demonstrated a lack of effect on platelet aggregation. Other studies have shown 02' 
as having an pro-aggregatory role, but this finding was found after platelets were 
washed in buffer which lacks the endogenous scavengers usually present in plasma 
(Ambrosio et al., 1997). However this effect has been shown to be lost when platelets 
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are resuspended in plasma which indicates that the effects of 02' on platelets may 
have limited pathophysiological relevance. 
Several mechanisms are associated with the complex effects of oxidants on platelets. 
For example, adenylate cyclase and guanylate cyclase both control platelet 
aggregation. Oxidant exposure to plasma resuspended platelets had no effect on 
basal cAMP (Ambrosio et aL, 1994). However exposure to H202 caused an impaired 
aggregation alongside a 10-fold increase in platelet concentration of cGMP (Ambrosio 
et aL, 1994). Cyclooxygenase, a key enzyme of prostanoid metabolisms, is also 
affected by oxidants, mainly H202. For example arachidonic acid-dependent 
aggregation was almost completely suppressed in the presence of CAT (Ambrosio et 
aL, 1994). Therefore low level production of H202 seems necessary to promote 
thromboxane synthesis, and hence platelet aggregation in response to arachidonic aid 
stimulation (Ambrosio et al., 1997). Another possible mechanism by which oxidants 
may influence platelet aggregation is through potentiation of the effects of platelet- 
activating factor (PAF). PAF is an auta-coid released by platelets and other cell types 
e. g. endothelium and leukocytes, which acts at low concentrations on platelets. 02 
radicals may enhance platelet aggregation through local increases in PAF 
concentrations secondary to reduced breakdown of PAF (Ambrosio et al., 1997). For 
example 02' administration in dogs indicated that PAF-mediated aggregation of 
platelets resuspended in plasma, reduced significantly whilst plasma acetylhydrolase 
activity was preserved (Yao et aL, 1993). Finally, platelet aggregation is influenced by 
NO availability (Chen et aL, 1996). Impaired NO degraded by 02 derived free-radicals 
have been shown to enhance platelet aggregation (Chen et al., 1996). 
In summary, ROS may affect thrombus formation within the vasculature through 
several mechanisms. Oxidants may enhance the activity of the extrinsic coagulation 
68 
cascade, leading to thrombin formation (via effects in stimulation of tissue factor activity 
and inhibition of fibrinolytic pathways) (Ambrosio et aL, 1997). In addition, oxidants 
may have a complex effect on platelets. For example H202 may inhibit aggregation 
(Ambrosio et al., 1994) whilst 02' may inactivate EDRF and PAF-acetylhydrolase and 
enhance thrombin formation via TF (Ambrosio et aL, 1997). However the net effects of 
oxidants on intravascular thrombosis is dependent on the integrity of the endothelium 
as well as on oxidant-mediated alterations of other major players in thrombosis, such 
as endothelial-derived relaxing factor and coagulation factors (Ambrosio et aL, 1997). 
Although there is a complex relationship between oxidant stress and platelet 
aggregation, weight management or antioxidant therapy may have a indirect effect on 
reducing platelet aggregation through reducing oxidant stress, potentially reducing the 
risk of CVD. 
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Chapter THREE 
General Methodology 
3.0 Introduction 
This chapter outlines the full details of equipment used and testing procedures used in 
the studies described in this thesis. 
3.1 Haematological measurements 
3.1.1 Blood sampling 
Blood sampling was carried out by several technicians with previous experience and 
qualifications in the methods employed. To standardise blood handling and minimise 
inter-subject analytical variation, the same technicians were used for each subject. All 
venous blood sampling was completed after a 12 h fast because it has been shown 
that diet may adversely affect several blood borne metabolites, in particular plasma 
lipids and lipoproteins (Pronk et al., 1993). Blood was obtained from a forearm ante- 
cubital vein (venous vein) and from finger-tip (arterialised capillary blood). The 
equations of Dill and Costill (1974) were used to correct and control for exercise 
induced plasma volume shifts. 
3.1.2 Collection of venous blood 
Each subject assumed a supine position and a tourniquet was fixed above the distal 
region of the subject's bicep (Bachorik, 1982). Venous blood samples were drawn 
after sterilising the forearm with a sterilised swab saturated with 70% (v/v) isopropyl 
alcohol (Medi Swab, Smith and Nephew, UK), using the syringe method. For platelet 
aggregation blood samples the tourniquet was released and blood was collected. The 
first 5m1 of blood for platelet aggregation was discarded. 
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After immediate venous blood collection, blood was transferred to some or all of the 
following tubes (depending on the study) 
  di-potassium ethylene diamine tetra-acetic acid (K2EDTA) and mixed thoroughly. 
  Serum separation tube (allowed to clot at room temperature for 30 minutes before 
centrifugation) and mixed thoroughly. 
  Plain tubes containing sodium citrate as anti-coagulant (assessment of 
haemoglobin (Hb), haematocrit (Hct) and packed cell volume and platelet 
aggregation). 
  Blood (200pl of EDTA) placed into a plain tube for assessment of GSH. 
EDTA and serum separation tubes were then centrifuged at 3000rpm for 10 minutes. 
Plasma and serum were removed using a1 ml pipette and transferred to 1.5 ml plastic 
vials. Plasma and serum aliquots were stored at -70°C and -20°C before biochemical 
analysis. 
3.1.3 Collection of arterialised capillary blood 
The volunteer's finger-tip (usually index finger) was wiped clean with a sterilised swab 
saturated with 70% (v/v) isopropyl alcohol (Medi Swab, Smith and Nephew, UK) and 
then the sample site was punctured using a sterile stainless lancet (Lancet, Sheffield, 
UK). Subsequent blood was wiped clean with medical grade cotton wool. To obtain a 
blood sample, gentle pressure was applied to the site using the thumb and index finger. 
Arterialised capillary blood was used to measure glucose, Hct and Hb. 
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3.1.4 Packed cell volume (PCV) 
A 75mm (59µI) volume heparinised capillary tube (Hawksley and Sons Limited, 
Sussex, UK) was used to collect arterialised capillary blood from the subject's finger- 
tip. An air bubble free sample was then sealed at the distal end with cristaseal 
(Hawkley and Sons Limited, Sussex, UK) and carefully inserted into a micro Hct 
centrifuge (Hawkley and Sons Limited, Sussex, UK) with the sealed end facing 
outwards. The capillary sample was immediately centrifuged at 11,800 revolutions per 
minute (rpm) for four minutes and the subsequent packed erythrocytes were measured 
using a Hawksley Micro Hct Reader (Hawksley and Sons Limited, Sussex, UK). The 
value expressed in L. L" of whole blood was subsequently corrected by 1.5% for 
plasma trapped between erythrocytes (Dacie and Lewis, 1968). Packed cell volume 
was measured in duplicate. The intra- and interassay variation for packed cell volume 
using a Hawksley Micro Hct Reader are 1% and <5%, respectively. 
3.1.4.1 Packed cell volume (PCV): PlateletWorks® 
The PlateletWorks® machine (see Section 3.1.14.2) for assessment of platelet 
aggregation also provided a full blood count including a measure of Hct and Hb. The 
intra- and interassay variation for packed cell volume using PlateletWorks are 7% and 
8%, respectively. 
3.1.5 Haemoglobin (Hb) 
The concentration of Hb in whole blood was measured photometrically following the 
method outlined by Vanzetti (1966). The procedure involves the release of 
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haemoglobin from haemolysed erythrocytes by sodium deoxycholate. Hb is converted 
to methemoglobin by sodium nitrite, which together with sodium azide forms 
azidemethemoglobin. The absorbance was subsequently measured at 570 and 
880nm. This method has been validated against the established haemiglobincyanide 
(HiCN) method. Following calibration with an optical interference filter (Hb = 13.7 g. dL- 
1 (8.7mmol. L-1) ± 0.3g. dL-1 (0.2mmol. L-1), arterialised capillary blood was collected 
from the finger tip (10µI) in a microcuvette (HemoCue B-Haemoglobin, Sheffield, UK). 
The microcuvette was inserted into the photometer (HemoCue B-Hemoglobin, 
Sheffield, UK) and a digital result was obtained in approximately 25 seconds. The 
intra- and interassay variation for haemoglobin using HemoCue are 5.5% and 5.6%, 
respectively. 
3.1.5.1 Haemoglobin (Hb): PlateletWorks® 
The PlateletWorks® machine (Section 3.1.14.2) for assessment of platelet aggregation 
also provided a full blood count including a measure of Hb. The intra- and interassay 
variation for haemoglobin using PlateletWorks® are 7% and 8%, respectively. 
3.1.6 Glucose analysis 
Glucose was measured in either of two ways, which was dependent on the location of 
the research study. At the exercise physiology laboratories in Bedford, glucose was 
measured immediately following blood collection using a YSI 2300 Stat Plus Glucose 
and L-Lactate analyser. At the Centre for Obesity Research, plasma was stored in the 
freezer for later analysis using the glucose oxidase assay method. 
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3.1.6.1 YSI 2300 Stat Plus Glucose and L-lactate analyser (YSI Incorporated) 
This was a commercial analyser which measured glucose in whole blood samples 
(25pl). The YSI incorporates immbolized enzyme technology. Specific to glucose 
measurement, the enzyme glucose oxidase is immbolized between two membrane 
layers, polycarbonate and cellulose acetate. The glucose substrate and 02 molecules 
are oxidised in the presence of glucose oxidase as it enters the membrane layers of 
polycarbonate, producing H202, which passes through the cellulose acetate to a 
platinum electrode, where the H202 is oxidized. The resulting current is proportional to 
the concentration of the glucose substrate. Results were expressed as mmol/L. 
Glucose measurement 
D-Glucose + 02 
H202 measurement 
H202 
Platinum node 
glucose oxidase 
2H++02+2e' 
D-glucono-b-Iactone + H202 
The intra- and interassay variation for glucose using YSI are <3% and 5%, 
respectively. 
3.1.6.2 Glucose oxidase assay (enzymatic calorimetry) 
Plasma glucose was measured using the glucose oxidase method described by 
Barham and Trinder (1972). Glucose is oxidized to gluconate by atmospheric oxygen 
in the presence of glucose oxidase (GOD). The indicator 4-aminophenazone and 
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phenol are oxidized by the H202 formed in the presence of peroxidase 
(POD). The test 
principle of the glucose oxidase method is shown below: 
Glucose + 02 + H2O º gluconate + H202 
GOD 
H202+ 4-aminophenazone + phenol º 4-(p-benxoquinone-mono-imino)- 
POD 
phenazone + 4H20 
The intensity of the colour (red - violet quinoneimine dye) produced is proportional to 
the glucose concentration in the sample and colour intensity was measured at 546 nm. 
The glucose reagent was supplied by Randox Ltd, UK. Results were expressed as 
mmol/L. The intra- and interassay variation for glucose using the glucose oxidase 
assay are 1.8% and 2.6%, respectively. 
3.1.7 Fructosamine analysis 
Fructosamine is a time-averaged indicator of blood glucose levels and is used to 
assess the glycaemic status of diabetics (Armbruster, 1987). The concentration of 
glycated proteins such as glycohaemoglobin, glycoalbumin or glycated total protein is 
generally recognized to be valuable in evaluating the glycaemic status of diabetic 
patients. 
In the present studies serum fasting fructosamine concentration was measured 
according to the colorimetric assay method described by Johnson et a/ (1983). 
Fructosamine from the sample is present in an alkaline medium (reagent solution at pH 
10.3) in the enol form, which reduces nitrotetrazolium-blue (NBT) to a formazan 
compound. The rate of formation of formazan is directly proportional to the 
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concentration of fructosamine presence in the sample. The rate of reaction was 
measured at 546nm. The fructosamine reagent kit was supplied by Roche 
Diagnostics, UK. Results are expressed as mmol/L. The intra- and interassay 
variation for fructosamine are 0.9% and 2.9%, respectively 
3.1.8 Total cholesterol analysis 
Plasma cholesterol concentrations were measured by the method of Richmond (1973), 
Roeschlau et al (1974) and Trinder (1969). Cholesterol esters were first hydrolyzed 
into cholesterol and fatty acids in the presence of cholesterol esterase. Free 
cholesterol was then oxidized into cholestenone by atmospheric 02 in the presence of 
cholesterol oxidase, which also produces H202. This latter compound then oxidised an 
incorporated indicator 4-aminoantipyrine and phenol to quinoneimine and H2O in the 
presence of POD. 
Cholesterol-ester + H2O º Cholesterol + Fatty acids 
MMIAQfA71I AQtAlAQA 
Cholesterol + 02 º Cholestene-3-one + H202 
(: hnlnctnmi nvifl'. IQA 
2H202 + phenol + 4-Aminoantipyrine º quinoneimine + 4H20 
POD 
The intensity of the colour (blue coloured complex) produced was proportional to the 
cholesterol concentration in the sample and colour intensity was measured at 546 nm. 
The cholesterol reagent kit was supplied by Randox Ltd, UK and results were 
expressed as mmol/L. The intra- and interassay variation for cholesterol are 2.11 % 
and 2.52%, respectively. 
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3.1.9 Triglycerides analysis 
Plasma triglycerides were measured using the method described by Tietz (1990), 
Jacobs and Vandemark (1960) and Koditschek and Umbreit (1969). The triglycerides 
were first hydrolysed into glycerol and FFA by lipase. The glycerol was then 
phosphorylated into L-a-glycerol phosphate by glycerokinase (GK) and ATP in the 
presence of magnesium (Mg2+) ions. The glycerol phosphate was then oxidised by 
atmospheric oxygen into hydroxyacetone phosphate and H202 in the presence of L-a- 
glycerol phosphate oxidase (GPO). 
Triglycerides + H2O j glycerol + fatty acids 
lipases 
Glycerol + ATP P glycerol-3-phosphate + ADP 
GK 
Glycerol-3-phosphate + 02 º dihydroxyacetone phosphate + H202 
GPO 
2H202 + 4-aminophenazone +4 chlorophenol º quinoneimine + HCI + 4H20 
POD 
Finally, H202 oxidised an incorporated indicator 4-aminophenazone and 4 chlorophenol 
to quinoneimine, HCI and H2O in the presence of POD. The blue coloured complex 
was measured at 500nm. The triglycerides kit was supplied by Randox Ltd, UK and 
results were expressed as mmoVL. The intra- and interassay variation for triglycerides 
are 2.32% and 3.55%, respectively. 
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3.1.10 High density lipoprotein (HDL) cholesterol analysis 
Plasma HDL concentrations were measured by the method of Izawa (1990). The 
assay consists of two distinct reaction steps: 
1) Elimination of chylomicron, VLDL-Cholesterol and LDL Cholesterol by 
cholesterol esterase, cholesterol oxidase and subsequently CAT. 
The enzyme cholesterol esterase catalyses the cleavage of cholesterol esters into 
cholesterol and the corresponding fatty acid. In the presence of 02, free cholesterol is 
oxidized by means of cholesterol oxidase to produce cholesternone and H202. The 
non-HDL-derived peroxidase is then scavenged by the enzyme CAT to 02 and H20. 
Cholesterol ester o cholesterol + fatty acid 
Cholesterol esterase 
Cholesterol + 02 º Cholestenone + H202 
(: hnlactami nYVIaCa 
2H202 l 2H20 + 02 
CAT 
2) Specific measurement of HDL-Cholesterol after release of HDL-Cholesterol 
An inhibitor of CAT and a surfactant releases specifically HDL-C to produce 
cholestenone and H202. The H202 converts the reduced form of the indicator 4-(4- 
dim ethyl aminophenyl)-5-methyl-2-(4-hydroxy-3,5-dimethoxyphenyl)-imidazole 
dihydrochoride into a blue (oxidized) form, provided POD is present. The concentration 
of the blue dye is proportional to the concentration of HDL in the sample and the colour 
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intensity was measured at 500nm. The HDL kit was supplied by Randox Ltd, UK and 
results were expressed as mmoVL. 
HDL + CAT inhibitor Cholestenone + H202 
2H202 + *4-AA + *HDAOS º Quinone pigment + 4H20 
POD 
*Key 4-AA =4- Aminoantipyrine 
HDAOS =N- (2 - hydroxy -3- sulfopropyl) - 3.5 - dimethoxyaniline 
The intra- and interassay variation for HDL are 2.24 and 3.4% , respectively. 
3.1.11 Low density lipoprotein (LDL) cholesterol estimation 
Often LDL is calculated using the empirical equation of Friedewald et a/ (1972), which 
incorporates primary measures of total cholesterol, triglycerides and HDL cholesterol. 
In this study LDL concentration of the samples were estimated by the Friedewald 
equation which is shown below. Results were expressed as mmoVL. 
LDL Cholesterol = [Total cholesterol] - [HDL cholesterol] - Triglycerides 
2.2 
3.1.12 Lipid peroxidation measurements 
Lipid peroxidation is a repetitive process whereby PUFA molecules are degraded to a 
variety of end products as highlighted in Section 1.11. The following technique was 
used to determine peroxidation of lipids in human blood. 
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3.1.12.1 Serum lipid hydroperoxide (LH) 
Hydroperoxides in biological systems can be measured by High Performance Liquid 
Chromatography (HPLC) coupled with electrochemical determination, 
chemiluminescence, activation of cyclooxygenase and various methods that 
incorporate thiobarbituric acid (TBA). The TBA methods are most widely used, but are 
also criticised on grounds of both their ambiguity and underestimation of extent of LHs 
(Nourooz-Zadeh et al., 1994). There are two simple and reliable spectrophotometric 
methods in which LHs can be determined in vivo. Both methods are known as the 
`FOX' (Ferrous Oxidation of Xylenol orange) assays and are differentiated by the terms 
FOX 1 and FOX 2. 
Aqueous phase LHs were measured using the methods of Wolff (1994); FOX 1 assay, 
which is best suited for the determination of small levels of H202 in aqueous samples. 
At low pH (dilute acid) hydroperoxides oxidise Fe 2+ to Fe 3+ and the resultant Fe 3+ are 
used as an indirect measure of hydroperoxide content, which can be detected by ferric- 
sensitive dyes. A blue-purple coloured complex is produced with the selective binding 
of xylenol orange to the Fe3+. The absorption could then be measured at 560nm. 
Fe 3+ + XO º blue-purple complex (560nm) 
The LH assay method was as followed: 
Serum (90µI) was incubated with 10µI CAT for 30 minutes at room temperature. To 
this solution 900gI FOX reagent 1 (250µmol/L ammonium ferrous sulphate, 100µmoVL 
xylenol orange, 100µmol/L sorbitol, 25pmol/L sulphuric acid (H2SO4), was added and 
incubated for a further 30 minutes at room temperature in the dark. Standard solutions 
were prepared using 0-5. OpmoVL of H2O2, which were then incubated for 30 minutes 
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with the FOX 1 reagent after which the sample was centrifuged in a Beckman 
microfuge for 5 minutes to remove any flocculated material. The absorbance of the 
supernatant was read spectrophotometrically (U-2001, Hitachi, England) at 560nm 
against the standard curve that was linear over the range 0-5pmol/L. Plasma samples 
were spiked with the enzyme CAT (Sigma, Dorset) to discriminate between authentic 
hydroperoxides reacting with Fe2+ and H202 in the sample. All chemicals were 
purchased from Sigma-Aldrich (Poole, Dorest) unless otherwise stated. 
This assay may yield higher LH values compared to other methods because of the 
presence of iron ions in the assay (Young and McEneny, 2001). The FOX 1 assay was 
used in preference to the FOX 2 assay, following personal communication with Dr Jane 
McEneny, (Queen's Belfast University). The FOX 1 assay had been found to be very 
reproducible with intra- and interassay co-variances of less than 5%, whilst the FOX 2 
assay was less reliable. In this thesis, the intra- and interassay variation for LH are 2% 
and 4%, respectively. 
3.1.13 Determination of antioxidant capacity (non enzymatic and enzymatic) 
This section describes the various procedures and techniques employed to determine 
various antioxidant activity in venous blood. 
3.1.13.1 Total Antioxidant Status (TAS) 
It is impractical to measure all the potentially biologically active antioxidants in human 
samples, but because there is evidence that antioxidants can work simultaneously 
(Halliwell and Gutteridge, 1999), the concept of a 'global' assessment of antioxidant 
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capacity has proved attractive for use in clinical research. Several methods have been 
developed, which may take one of two main approaches; either the quenching or 
delayed production of a stable, measurable radical species, or the reductant properties 
of the antioxidants against a radical cation or a metal ion (Schlesier of al., 2002). An 
example of the former is the TRAP assay (Total radical-trapping antioxidant parameter 
assay) and the latter the FRAP assay (Ferric reducing/antioxidant power assay) 
(Benzie and Strain, 1996). Because these methods use different reaction principles, 
the same antioxidant can produce different contributions to each assay. Vitamins that 
can contribute to TAS are ascorbate, a-tocopherol, and 0-carotene. One major 
drawback of TAS methods is the variable contribution of common plasma constituents, 
particularly albumin and urate. Changes in circulation of these molecules due to 
changes in renal function can alter values without reflecting changes in antioxidant 
concentration. However this problem may be overcome by the use of the 'antioxidant 
gap', a derived value, which subtracts the trolox-equivalence of albumin and urate from 
the measured TAS (Miller of al., 1997). Although measures of TAS are unable to 
detect changes in individual antioxidants, they can be used as a tool to assess redox 
status and may be useful in providing information on the absorption and bioavailability 
of the nutritional complex (Ghiselli of al., 2000). 
In the present studies, the FRAP method was used to assess TAS (Benzie and Strain, 
1996). This test measures the ferric reducing ability of plasma. At low pH, when a 
ferric-tripyridyltriazine (Fe3+-TPTZ) complex is reduced to the Fe 2+ form, an intense blue 
colour with an absorption maximum at 593nm develops. 
The TAS method is as follows with some modification to the protocol of Benzie and 
Strain, (1996). Freshly prepared FRAP reagent (300µL) [300mmol/litre acetate buffer, 
82 
pH 3.6 (3.1 gC2H3NaO2.3H2O and 16ml C2H402 per litre of buffer solution; 10mmol/L 
TPTZ (2,4,6-tripyridyl-s-triazine) in 40mmol/L HCI; 20mmol/L FeCI3.6H20)]. Working 
FRAP reagent was prepared as required by mixing 25m1 acetate buffer, 2.5m1 TPTZ 
solution and 2.5ml FeCl3.6H2O solution and was warmed to 37°C which was then read 
at 593nm. Sample (10µL) was then added to the FRAP reagent along with 30µL H20- 
Absorbance readings were taken after two minutes. The change in absorbance 
(AA593nm) between the final reading (two minutes) and the initial reading was 
calculated for each sample and related to AA593nm of a Fe2+ standard solution tested 
in parallel. Benzie and Strain (1996) studied the FRAP reaction for up to 8 minutes, but 
selected 4-minute readings for calculations. The readings after 2 minutes were used in 
the present studies as it was found that the FRAP reactions in plasma samples 
reached an end-point around this time. The intra- and interassay variation for total 
antioxidant status are 1% and 3%, respectively. 
3.1.13.2 Superoxide dismutase (SOD) 
SOD was first identified and purified from red cells by McCord and Fridovich (1969). It 
has since been detected in a large number of tissues and its purpose is essential to the 
red cell for the detoxification of 02 and plays a protective role similar to that of the 
GSH-GSH Px system. 
In the present studies, SOD activity was assessed using a method developed by 
Winterbourn et al (1975). The assay is based on the method of Beauchamp and 
Fridovich (1971) and depends on the ability of the enzyme to inhibit the reduction of 
nitroblue tetrazolium (NBT) by 02", which is generated by the reaction of photoreduced 
riboflavin and 02. 
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SOD was measured as described below: 
Blood was collected in EDTA tubes and plasma and the majority of white cells were 
removed. The red cells were washed twice with saline (0.9% w/v), then haemolyzed 
by 
adding approximately 1.5 volumes of water. 
Hb concentrations were measured and samples adjusted to 10gm/100 ml. A 
chloroform-ethanol extract was prepared (0.5ml hemolysate, 3.5m1 ice-cold distilled 
water, 1.0ml ethanol and 0.6ml chloroform). When preparing the chloroform-ethanol 
extract, the solution was mixed at each addition and shaken for 1 minute. Tubes were 
then centrifuged for 10 minutes at 3000 rpm. 
Another stock solution was prepared (M/15 phosphate buffer, pH 7.8,0.11M EDTA 
containing 1.5mg of sodium cyanide per 100ml; 0.12mM riboflavin (4.5mg per 100ml) 
stored cold in a dark bottle; and 1.5mM NBT (12.3mg per 10 ml), stored cold (5°C). 
For each sample to be assayed, six tubes were set up containing 10,20,40,60,80 
and 500pl red cell extract, plus 0.2ml EDTA/NaCN, 0.1 ml NBT, 0.05m1 riboflavin 
(added last after tubes had been brought to ambient temperature, 20-22°C) and 
phosphate buffer to give a total volume of 3m1. Three tubes containing no red cell 
extract was also included per test run. The tubes were then placed in a light box to 
receive uniform illumination for a standard period of 12 minutes. Optical densities of 
the tubes were then measured using a spectrophotometer at 560nm. 
Results were expressed as units of SOD per gram of Hb. One unit is defined as the 
amount of enzyme causing half of the maximum inhibition of NBT reduction. This unit 
depends on the conditions of the assay, namely light intensity, riboflavin and NBT 
concentrations. Percentage inhibition is calculated from each optical density and the 
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value in the absence of enzyme and plotted against the amount of red cell extract 
(up 
to 80p1). The tube containing 500pL extract gives maximum inhibition (maximum 
inhibition is also given by 200NL of extract from normal cells, so 500PL is well in excess 
of the minimum requirement). The amount of extract (VpL) which gives half this 
inhibition (1 unit) is determined from the graph plotted above. Since the extract is 
equivalent to a1 Gm per 100ml Hb solution, the red cell enzyme activity is 
100,000 units per gram of Hb 
V 
The red cell SOD activity in healthy adults is between 2,400 to 3,700 units per gram of 
Hb with a mean value of 2,900 units. The intra- and interassay variation for superoxide 
dismutase are 4% and 5.5%, respectively 
3.1.13.3 Reduced glutathione (GSH) 
GSH -a tripeptide consisting of glutamic acid cysteine and glycine acts as a substrate 
for the enzyme GSH-Px. As such it is an important component of the body's 
intracellular antioxidant defences. In particular, GSH functions to protect cellular 
proteins from thiol oxidation. When challenged with oxidative stress, intracellular GSH 
rapidly oxidises to GSSG. Oxidised GSSG produced intracellularly is converted back 
to GSH by glutathione reductase, requiring NADPH as a cofactor. 
In the present studies, GSH was measured using a method developed by Beutler 
(1975). Viritually all of the nonprotein sulfhydryl compounds of red cells are in the form 
of GSH so the assay incorporates 5,5'-Dithiobis (2-nitrobenzoic acid) (DTNB) as a 
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disulfide compound to readily reduce sulfhydryl compounds to form a highly coloured 
yellow anion (Beutler, 1975). 
GSH was measured using the method described below: 
Whole blood (EDTA) (200pL) was added to 2. Oml of distilled water. Lyzate (200pL) 
was then removed and stored at -20°C for estimation of Hb. Precipitating solution 
(3m1) (one hundred millilitres containing 1.67g of glacial metaphosphoric acid, 0.2g of 
disodium EDTA and 30g of sodium chloride) was added to the remaining 2m1 of 
haemolyzate. After standing for 5 minutes the mixture was filtered through medium 
grade of filter paper and was stored in eppendorf tubes at -20°C. 
During analysis, 2. Oml of filtrate was added to 8ml of 0.3 M Na2HPO4 solution in a 
cuvette. The absorbance was read at 412nm against a blank (prepared by adding 2ml 
of 2: 5 water diluted precipitating solution to 8m1 of phosphate solution). A second 
optical density reading was taken after 1 ml of DTNB reagent (20 milligrams of DTNB 
per 100 ml of 1% sodium citrate solution) had been added to the blank cuvette and the 
cuvette containing filtrate. 
Results are expressed as GSH in micromoles / gram of Hb. The calculation used was 
as follows: 
C= (OD2 - OD, ) X Ei X 11 X5X 100 
1000 13,600 22 Hb 
C= (OD, - OD, ) X E, X 101 
Hb 
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E1 is the molar extinction coefficient of the yellow anion produced when GSH Interacts 
with DTNB. However this value changes when different light path and band widths are 
used for analysis. For example a band width greater than 6 nm may produce a lower 
extinction coefficient. The extinction coefficient can be calculated by performing a GSH 
determination and reading an aliquot in a spectrophotometer with a narrow slit in a1 
cm cuvette to obtain the extinction value D1. An aliquot of the same sample is then 
read in the system being calibrated, obtaining a second optical density reading D2. 
E1 = D, 
D2 
OD, is the optical density measured at 412nm before the addition of DTNB solution, 
and OD2 is the optical density after the addition of DNTB. 
The red cells of GSH activity in healthy adults is approximately 6.57±1.04gmoles of 
GSH /g Hb. The intra- and interassay variation for reduced glutathione are 5% and 
6%, respectively. 
3.1.13.4 Selenium 
Selenium concentrations in plasma were determined by a Varian model SprectrAA-880 
Zeeman graphite furnace atomic absorption spectrometer (GFAAS, Varian, UK) with 
software SpecrAA-880 following the method of Knowles and Brodie (1988). In brief, 
plasma samples were diluted 1/10 by using a sample diluent. The sample diluent was 
prepared by dissolving 0.56g of ascorbic acid (DBH/AnalaR g, Grade, UK), 0.88ml of 
TritonX-100 (BDH, UK), 1 ml of Antifoam B and 0.1 ml of hydrochloric acid, made up to 
1.0L with deionized water. The 20p1 of plasma sample was injected into the graphite 
furnace with a modifier solution (500mg palladium, 0.05% Triton X-100 and 0.1% 
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Antifoam B). By using the auto sampler facility of the GFAAS the calibration curve was 
prepared from the stock solution of selenium (1 mg/L) by mixing the appropriate 
volume. The hallow cathode lamp from selenium was operate at 20mA and 
absorbance was measured at 196nm. The analysis was performed in duplicate and 
results expressed as pg/L. Reagents were supplied by Sigma-Aldrich, UK. The intra- 
and interassay variation for total antioxidant status are 1% and 3%, respectively. 
3.1.14 Platelet aggregation assessment 
Platelet aggregation was assessed by several methods in a preliminary experiment to 
determine a suitable protocol to assess platelet function (see methodology section . 10). 
The two platelet aggregation methods include platelet aggregometry and 
PlateletWorks®, which are both explained in detail below. 
3.1.14.1 Platelet Aggregometry 
Platelet aggregometry is the `gold-standard' for assessment of platelet function, which 
measures platelet aggregation in the presence of an agonist by optical methods. In 
general there are four independently operated aggregation channels. Platelet poor 
plasma (PPP) is inserted into the machine and platelet aggregation is started at 0%. 
This activates the printer to record platelet aggregation and then the platelet rich 
plasma (PRP) is placed into the machine. The reagent (agonist, ADP) is then added to 
the PRP and platelet aggregation is stimulated which is recorded and printed until 
aggregation is completed. 
Platelet aggregation was measured using the method of Born (1962). 
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Whole blood (4.5m1) was added to 0.5m1 sodium citrate in a plain plastic tube which 
was centrifuged for 10 minutes at 1000 rpm to obtain PRP. The remaining blood was 
centrifuged for a further 10 minutes at 3000 rpm to obtain PPP. 
PRP (200µL) was pipetted into an aggregation cuvette and placed in an incubation 
block for 3 minutes. PPP (200µL) was pipetted into an aggregation cuvette and placed 
in the aggregometer to set '100%' transmission. After 3 minutes, the PRP cuvette 
(including magnetic stir bar) was inserted into the aggregometer to set 0% 
transmission. When the platelet aggregometer was zeroed, the stable baseline was 
obtained with PRP for 30 seconds to 1 minute before the agonist was added to record 
the platelet aggregation response. 
For the assessment of platelet aggregation, several ADP concentrations were used. 
The ADP stock solutions were prepared on the day of testing using stock solutions 
equivalent to 10mM, which were kept stored at -20°C. Final ADP concentrations of 20, 
15 and 1 0pM were used. 
Results for platelet aggregation tests were calculated for percent maximum following 4 
minutes. The intra- and interassay variation for platelet aggregation using a platelet 
aggregometer are 8.7% and <10%, respectively. 
3.1.14.2 PlateletWorks® 
Plateletworks® methodology is an adaptation of platelet aggregometry, which is 
extremely simple, inexpensive and quick to perform. This two-step method involved 
using an automated cell counter to measure total platelet count in whole blood and 
then re-determines the number of platelets on a second sample that has been exposed 
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to a known platelet agonist. The agonist stimulates the platelets which are functional to 
aggregate in clumps, and they will therefore be counted as platelets in the second 
sample. The difference in the platelet count between samples one and two provides a 
direct measurement of platelet aggregation and is reported as percent aggregation as 
per the following equation. 
Baseline Platelet Count - Agonist Platelet Count x 100% =% Aggregation 
Baseline Platelet Count 
Whole blood (1 ml) was added to 4 plain plastic tubes each containing 111 pL sodium 
citrate, and varying degrees of ADP concentration added to give a final concentration 
of 20pM, 15pM and 10pM or OpM. The ADP stock solutions were prepared on the day 
of testing using stock solutions equivalent to 10mM, which were kept stored at -20°C. 
The baseline tube (no agonist) was inverted 3-5 times to mix the whole blood with the 
anticoagulant which was then run on PlateletWorks® and platelet count recorded. The 
remaining tubes with varying ADP concentrations were Inverted 3-5 times and run on 
PlateletWorks® and platelet count recorded. The percentage aggregation was then 
calculated. The intra- and interassay variation for platelet aggregation using 
PlateletWorks® are 7.2% and <10%, respectively. 
3.2 Anthropometric measurements 
Several different techniques were used for anthropometric measurements, which were 
dependent on the location of the research studies. However all these measurements 
are described below. 
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3.2.1 Height 
Each subject was instructed to remove footwear prior to height measurement. Height 
was measured to the nearest 0.1cm using a wall-mounted stadiometer in the Exercise 
Physiology laboratories at De Montfort University in Bedford and a free-standing 
stadiometer at the Centre for Obesity Research, Luton and Dunstable Hospital. 
3.2.2 Weight 
Each subject was instructed to wear light clothing and remove footwear prior to weight 
measurement. Weight was measured to the nearest 0.1 kg using a free-standing 
stadiometer (Seca model 713, Cophenhagen, Denmark) in the Exercise Physiology 
laboratories at De Montfort University in Bedford and a Tanita weighing scale at the 
Centre for Obesity Research, Luton and Dunstable Hospital. 
3.2.3 Waist Circumference 
Waist circumference was measured at a point midway between the costal margin and 
the iliac crest and in line with the mid-axilla (WHO, 1995). The tape was pulled taut 
and a measurement to the nearest 1 mm was taken in mid-expiration with subjects 
standing straight with feet together, arms hanging loosely, and looking straight ahead. 
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3.2.4 Body fat 
3.2.4.1 Bioelectrical Impedance (BIA) 
BIA measurements were carried out with the subject lying in a supine position on a flat, 
nonconductive bed by using a multifrequency tetrapolar technique (QuadScan 4000; 
Bodystat, Douglas, United Kingdom). The Bodystat QuadScan 4000 unit has 4 
electrodes. Two electrodes were placed on the right wrist with one just proximal to the 
third metacarpophalangeal joint (positive) and one on the wrist next to the ulnar head 
(negative). Two electrodes were placed on the right ankle with one just proximal to the 
third metatarsophalangeal joint (positive) and one between the medial and lateral 
malleoli (negative). Multifrequency (5,50,100, and 200 kHz) currents were introduced 
from the positive leads and travelled throughout the body to the negative leads. Body 
fat percentage was calculated using the manufacturer's software. It is known that 
resistance depends positively on fat content of the body and negatively on total body 
fluids (Donadio et al., 2005). In addition, reactance, which expresses the capacitance 
of the body, is positively dependent from the number of cell membranes. Impedance is 
also low in the presence of high volumes of body fluids. In particular, impedance to the 
passage of a high-frequency current depends on total body fluids, whereas impedance 
to introduction of a low-frequency current depends only on extracellular fluids (Donadio 
et al., 2005). 
The intra- and interassay variation for body fat using bioelectrical impedance are 1.18% 
and <5%, respectively. 
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3.2.4.2 BodPod 
Whole body air displacement plethysmography was performed using the BodPod body 
composition system (Life Measurement Instruments, California, USA) according to the 
manufacturer's instructions and recommendations. Subjects wore a tight fitting 
swimsuit and swimming cap. The procedure involved a volume calibration with and 
without a 50 litre metal cylinder. Subjects entered the BodPod and sat inside the 
anterior chamber (450 litres), which was connected to a rear measuring chamber (300 
litres) via oscillating diaphragms (used to induce pressure changes in the anterior 
chamber), and breathed normally (relaxed tidal breathing). The recommended 
procedure, consisting of two measurements of body volume (50 seconds each), was 
adopted and when, occasionally, body volumes differed by more than 150 ml, the 
system required that a third measurement be performed. The final result reported by 
the BodPod instrumentation was the mean of the two (or the two closest) 
measurements. 
In summary the operating principles of whole body air displacement plethysmography 
technique is described below. In air-displacement plethysmography, the body volume 
is measured indirectly by the volume of air which is displaced inside an enclosed 
chamber (plethysmograph). Human body volume is therefore measured when a 
subject sits inside a chamber and displaces a volume of air equal to his or her body 
volume. Body volume is calculated indirectly by subtracting the volume of air remaining 
inside the chamber when the subject is inside from the volume of air in the chamber 
when it is empty. The air inside the chamber is measured by applying relevant physical 
gas laws. Boyle's Law states that at a constant temperature, volume (V) and pressure 
(P) are inversely related: P, / P2 = V2 / V1. However because body volume is affected 
by adiabatic conditions created by the subject's presence (this warmer air, 
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approximately 37°C, is more compressible than the ambient air), the BodPod software 
applies certain corrections to the thoracic gas volume (TGV; litres) and air next to the 
skin (using the surface area artefact, SAA; litres) to adjust to isothermal conditions to 
obtain each subject's actual body volume (Dempster et at, 1995). The final body 
volume calculation in the BodPod is as followed: 
Vbcorr (L) = Vbr, N (L) - SAA (L) + 40% VTQ (L) 
where Vb, 0R is the body volume corrected for SAA (the effect of isothermal air near the 
skin's surface is estimated by calculating a surface area artefact) and VTG (the average 
amount of air in the lungs during normal tidal breathing, thoracic gas volume, which is 
measured or predicted). 
Once body mass (M) and Vbcorr are known, the principles of densitometry are applied 
(Behnke et al., 1942; Sid, 1961). Body density is calculated as MNbcon and body 
density (Db) is then inserted into a standard formula for estimating percentage body fat 
based on a 2-compartment model, such as the models of Siri equation. 
% body fat = (495/Db) - 450 Siri equation 
The intra- and interassay variation for body fat using BodPod are 6.7% and 7.8%, 
respectively. 
3.3 Cardiovascular measurements 
3.3.1 Heart rate 
Two methods of calculating heart rate were utilised. One method involved calculating 
resting heart rate by palpating the radial artery at the wrist. Pulse was counted for 20 
seconds, then multiplied by three to give beats/min. The other method involved using a 
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Polar heart rate transmitter belt, worn over the chest. The transmitter belt detects the 
electrocardiogram of the heart and sends an electromagnetic signal to either the Polar 
wrist receiver or Metamax 3B CPX system (if being used) where heart rate information 
appears. 
3.3.2 Blood pressure 
Systemic arterial blood pressure (BP-mmHg) was measured in the brachial artery using 
a mercury sphygmomanometer and stethoscope. Systolic blood pressure was noted 
when clear muffling of repetitive tapping sounds (Korotkoff) became apparent and 
diastolic pressure was noted when the repetitive sounds (Korotkoff) diminished (Tortora 
and Grabowski, 1996). 
3.4 Respiratory measurements 
3.4.1 Douglas Bag method 
Off-line gas analysis was determined using the `gold standard', Douglas Bag method. 
Subjects breathed through a large 2-way non-returnable breathing valve. Expired air 
was directed into a Douglas bag through plastic tubing and a two-way stopcock valve. 
The collection of expired gas was hand timed using chronography to the nearest whole 
breath for a specific time period. Samples of expired air were dried using 97% 
anhydrous calcium sulfate (CaSO4) crystals and presented to a paramagnetic 02 and 
infra-red CO2 analyzer for the determination of percentage 02 and CO2. Before use, 
the analysers were calibrated using specialised gas mixtures. Computation of 02 
uptake and CO2 production corrected to STPD [STDP correction means conversion of 
the measuring environment BTPS (Body Temperature, Pressure Saturated) to STPD 
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(Standard Temperature, Pressure Dry) environment] was computed using the Haldane 
transformation equation (Wasserman of al., 1994). 
3.4.2 On-line gas analyser 
On-line V02 was measured using a Cortex gas analysis system (Metamax 3B, 
Birmingham, UK), which provided real-time breath-by-breath V02. Subjects breathed 
through a rubber mask attached to a DVT volume transducer, which was attached to 
the MetaMax Portable CPX system via a sample line. The MetaMax 3B was calibrated 
before each test using the Hans Rudolph 3 litre syringe for ventilation volume and 
standard gases of known 02 and VCO2 concentration. Respiratory parameters were 
converted from BTPS to STPD. The measured and calculated data was also 
smoothed (every two points) before obtaining numerical printouts. 
3.5 Treadmill 
The treadmill used at De Montfort University in Bedford was the PowerJog JX200 and 
at the Centre for Obesity Research, Luton and Dunstable Hospital, the Marquette 2000. 
Both treadmills were serviced and calibrated regularly. 
3.6 Rating of perceived exertion (RPE) 
Rating of perceived exertion (RPE) was estimated using Borg's Scale (1973). A 
numeric value which ranges from 6-20 could be selected to indicate a perceived rate of 
exertion from 'very very light' to 'maximum'. 
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3.7 Temperature and humidity regulation 
Room temperature was measured using a wall-mounted temperature and humidity 
gauge (Thermo-Hydro), which measured temperature and humidity to the nearest 
0.10C and 0.1% respectively. Barometric pressure was obtained from a wall-mounted 
barometer. 
3.8 Dietary analysis 
In the present studies, subjects were asked to record the quantity and type of food and 
beverage they consumed over several days or a week. This data was analysed using 
a computerised software package (Compeat, Nutrition Systems, Carlson Bengston 
Consultants Limited). 
3.9 Physical activity questionnaire 
The Baecke questionnaire (Baecke of al., 1982) was used as a short questionnaire for 
the measurement of habitual physical activity. The questionnaire was self- 
administered although if necessary help from an observer was provided. In summary 
this questionnaire contained 13 questions with three distinct dimensions; physical 
activity at work, sport during leisure centre and other physical activity during leisure 
time. The sum of all these dimensions allow calculation of a total physical activity 
score which refers to habitual physical activity. Each evaluation on the questionnaire 
allows the calculation of four different physical activity scores; a total physical activity 
score (Btoto,... 60), a sport-related physical activity sub- score (Bsporto,... so), a leisure-time- 
related physical activity sub-score (Bleisureo,... so) and an occupation-related physical 
activity sub-score (Boccupo,... 60)" 
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3.10 Preliminary experiment to develop and evaluate PlateletWorks®(1) 
3.10.1 INTRODUCTION 
The platelet aggregometer is the 'gold' standard method for the assessment of platelet 
aggregation (Born, 1962). But its methodology is highly labour intensive, expensive 
and the reproducibility of results is dependent on controlling many factors; temperature, 
pH, aggregometer speed, platelet count, sample volume and venepuncture technique 
(White and Jennings, 1999). This necessitated the development of several whole 
blood assays, such as PlateletWorks® which is an adaptation of platelet aggregometry 
and is extremely simple, inexpensive and quick to perform (Lau et al., 2002). Its use in 
exercise physiology per se is a relatively new phenomenon. With this in mind a 
preliminary experiment was completed to supplement the validity of platelet 
aggregation data reported in this thesis. 
This study assessed platelet aggregation techniques; platelet aggregometry and 
PlateletWorks® and established whether PlateletWorks® was a cost-effective, quick and 
reproducible measure of platelet aggregation, which could be used to predict clinical 
outcomes for research purposes. 
3.10.2 METHODOLOGY 
Subject Characteristics 
Ten (n=10) apparently healthy male and females (n=5/5, respectively) were recruited 
from the Luton and Dunstable Hospital to participate in the present study (see table 3.0 
for subject characteristics). Ten subjects were chosen as it had previously been 
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suggested that the generation and application of data on biological specimens could be 
obtained from a relatively small group of subjects over a reasonably short period of 
time (Fraser and Harris, 1989). The subjects had no known physician-diagnosed 
diseases or ailments as assessed by a medical history questionnaire. Subjects with 
hypertension, with or without hypertensive treatments, dyslipidaemia or CVD, any of 
those taking any antioxidant supplementations, nonsteroidal anti-inflammatory drugs or 
lose-dose aspirin and smokers were excluded from the study. Written informed 
consent was obtained from all the subjects after they were given a full explanation of 
the study. The research was given ethical approval by Bedfordshire Local Research 
Ethics Committee. 
Table 3.0. Subject characteristics 
Characteristic 
Age, yr 33 t 3.1 
BMI, kg/m2 25.4 1.1 
Weight, kg 74.1 t 3.1 
Values expressed as the mean±SEM. BMI, body mass index. 
Experimental design 
This study was broken up into two stages. 
Stage 1: Familiarisation and developmental 
Stage 2: Validity and reliability 
Stage 1 
Three of the ten subjects recruited visited the Centre for Obesity Research at the 
beginning of the study to enable the familiarisation and development of platelet 
aggregation methods to take place. Subjects attended the centre between 9-12am and 
were instructed to fast for 10-12 hours and refrain from exercise, caffeine and alcohol 
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for 48 hours before the study visit. Subjects were also told to maintain their usual 
dietary regimen. 
Stage 2 
Following the development stage, all ten subjects visited the Centre for Obesity 
Research on 3 separate occasions over a 3-week period. Subjects attended the centre 
between 8-10am and were instructed to fast for 10-12 hours and refrain from exercise, 
caffeine and alcohol for 48 hours before the study visit. Subjects were also told to 
maintain their usual dietary regimen. 
Anthropometric measures 
During visit one at stage two, height was measured without shoes using a stadiometer. 
Weight was measured using a Tanita weighing scale (see methodology section 3.2.1 
and 3.2.2). 
Venous blood sampling 
At each visit, in the supine position, blood samples (exactly 13.5m1) were collected from 
an antecubital vein using the syringe method (see methodology section 3.1). During 
venepuncture the tourniquet was released and the first 5m1 of blood for platelet 
aggregation was disposed of. 
PLATELET AGGREGATION METHODS 
Platelet aggregometry 
Platelet aggregation was measured using the method of Born (1962), as described in 
the methodology section 3.1.15.1. 
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PlateletWorksm 
Platelet aggregation was measured using a modified version of the manufacturer's 
guidelines, as described in the methodology section 3.1.15.2. 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value). The Shapiro-Wilk test confirmed that 
the data was normally distributed. The agreement between the two platelet 
aggregation methods was assessed using correlation analysis, Pearson, Kendal tau 
and Spearman rho and a statistical measure of agreement as reviewed by Bland and 
Altman (1986). The Bland and Altman approach allows for calculation of bias (mean of 
the individual differences between estimates) and the limits of agreement (+2 SD from 
the mean bias). Repeated measures ANOVA was used to test the significance of 
differences in % platelet aggregation between time periods. The data was analysed 
with two way (AxB) mixed analysis of ANOVA which incorporated one between 
(PlateletWorks® vs platelet aggregometer) and one within (time: Wk 1 vs Wk 2 vs Wk 
3) subject factor. Precision data are reported as mean (± SD) with coefficient of 
variation. P-values < 0.05 were regarded as statistically significant. Analyzes of data 
was performed using a computer software package (SPSS for Windows, Version 13.0). 
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3.10.3 RESULTS 
Stage 1 
Some minor changes were made to the PlateletWorks® methodology. The 
PlateletWorks® methodology uses two PlateletWorks® tubes (EDTA baseline tube 
(0.024mL of 7.5 % K3 EDTA solution (1.80mg) and an ADP tube (approximately 20µM 
ADP) to which 1. OmL fresh whole blood was added. In this study, four plain tubes with 
111µL sodium citrate (3.8% w/v) and varying concentrations of ADP (final 
concentration of 20,15,10 and OµM) were set up to obtain a detailed ADP-stimulated 
platelet aggregation response. 
Stage 2 
PlateletWorks® vs Platelet aggregometer 
Platelet aggregation in whole blood samples was determined using PlateletWorks® and 
compared with aggregation using PRP on the aggregometer at three ADP-induced 
platelet aggregation concentrations. Table 3.1 presents the established reference 
range of platelet aggregation at three different ADP concentrations (Final concentration 
of ADP was 10,15 and 20µM). It was demonstrated that the reference range for 
platelet aggregation at ADP-induced platelet aggregation 20µM was 81±3.0% for the 
platelet aggregometer and 81±1.3% for PlateletWorks®. At ADP concentration of 
15µM, platelet aggregation was 69.03±3.03% for the platelet aggregometer and 
68.1±4.1% for PlateletWorks®. At ADP concentration of 10µM, platelet aggregation 
was 60.87±3.68% and 53.1±5.3% for PlateletWorks®. 
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Regression analysis was performed on the ADP agonist data to evaluate the 
relationship between the two test modalities, namely platelet aggregometer and 
PlateletWorks® (r=0.64). The results from this analysis are shown in figure 3.0. Since 
correlation coefficients measure the strength of the relationship and not the agreement 
between them, these data were also analyzed using the non-parametric statistical 
analyzes of both Kendall tau (r=0.506) and Spearman rho (r=0.682) (see table 3.2). 
Table 3.1. Established reference range of platelet aggregation using platelet 
aggregometer and PlateletWorks® at various ADP-induced platelet aggregation 
concentrations. 
Method % Platelet aggregation 
N Mean SEM 
Platelet aggregometer 
10 4M 30 60.87 3.68 
15 µM 30 69.03 3.03 
20 µM 30 81.17 3.31 
PlateletWorks® 
10µM 30 53.1 5.3 
15µM 30 68.1 4.1 
20 µM 30 81.2 1.3 
Values expressed as the mean±SEM. 10,15 and 20µM, Final concentrations 
of ADP-induced platelet aggregation. For further details see text 
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Figure 3.0. Regression analysis to evaluate the relationship between two test 
modalities, namely platelet aggregometer and PlateletWorks®. Results were 
analyzed using Spearman rank correlation test. For further details see text. 
Table 3.2. Comparative analyzes to compare platelet aggregometer and 
PlateletWorks® for ADP-induced platelet aggregation. 
Agonist N Pearson ® Spearman rho Kendall tau 
ADP 90 0.64* 0.682* 0.506* 
ADP, platelet-induced agonist. Results analyzed using Pearson correlation test, 
Spearman rank correlation test and Kendall tau coefficient test and r values are given 
in the Table. (*, P<0.01). For further details see text. 
Using the Bland and Altman approach, figure 3.1 shows a comparison of platelet 
aggregation measured by a platelet aggregometer and PlateletWorks®. The mean 
difference was -2.9% with a 95% confidence interval between -29.7 to 23.9%. There 
was a clear tendency for the Plateletworks® to under-report platelet aggregation, by an 
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average of -2.9%. Despite this, the 95% confidence interval for the 
lower limit of 
agreement was from -34.5% to -24.9% and the 95% confidence interval for the upper 
limit of agreement was 19.1 to 28.7%. 
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Figure 3.1. Scatter plot (Bland-Altman plot) of PlateletWorks® ADP-induced platelet 
aggregation minus platelet aggregometer ADP-induced platelet aggregation (vertical 
axis) against mean of PlateletWorks® and platelet aggregometer ADP-induced platelet 
aggregation. The dashed horizontal line represents the mean difference and the dotted 
lines represent the 95% limits of agreements (n=90). For further details see text. 
Table 3.3. Intra- and interassay for ADP-induced platelet aggregation using two test 
modalities, namely platelet aggregometer and PlateletWorks®. 
Method Sample % Platelet aggregation CV (%) 
N Mean SD Mean SD 
Platelet aggregometer 90 70.36 13.5 8.66 5.03 
PlateletWorks® 90 67.45 16.76 7.20 6.86 
Values expressed as the meantSD. Reproducibility of % platelet aggregation 
analyzed using the coefficient of variation (CV %). For further details see text. 
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Intra- and interassay was tested for ADP-induced platelet aggregation (%) using the 
platelet aggregometer and PlateletWorks®. Intrassay was 67.5±16.8% for 
PlateletWorks® and 70.4±13.5% for the platelet aggregometer. The interassay was 8.7 
(SD 5.03)% for the platelet aggregometer and 7.2 (SD 6.86)% for PlateletWorks® and 
CV of % platelet aggregation ranged from 1.2 to 22% and 0.6 to 35.2% respectively 
(see table 3.3). There was no evidence of significant differences in % platelet 
aggregation between time periods for both the platelet aggregometer and 
PlateletWorks® (ANOVA, P>0.05) (see table 3.4). 
Table 3.4. Analysis of variance of ADP-induced platelet aggregation for two test 
modalities, namely platelet aggregometer and PlateletWorks®. 
Method Sum of 
squares 
Df Mean Square F P 
Value 
Platelet Between groups 36.16 2 18.08 0.86 0.92 
Aggregometer Within groups 18252.47 87 209.80 
Total 18288.62 
PlateletWorks® Between groups 125.27 2 62.63 0.21 0.81 
Within groups 25611.64 87 294.39 
Total 25736.90 89 
esults analyzed using repeated measured ANOVA and P values are given in the 
Table. For further details see text. 
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3.10.4 DISCUSSION 
This study was designed to assess the platelet aggregation techniques, platelet 
aggregometry and PlateletWorks® and to establish whether the PlateletWorks® was a 
cost-effective, quick and reproducible measure of platelet aggregation, which could be 
used to predict clinical outcomes for research purposes. 
Platelets have an increasingly well-defined role in haemostasis both in health and 
disease e. g. coronary artery thrombosis (Ruggeri, 2002) and other CVDs, including 
stroke and micro- or macro-angioplastic complications due to diabetes mellitus 
(Michelson, 2002). In addition platelets also have a role in the underlying 
atherosclerotic process (Ruggeri, 2002). Platelet function tests have been studied 
extensively in CVD as a means to predict both clinical outcomes and to monitor 
treatment therapies. 
Primary haemostasis may be assessed in two ways: 1) by measuring platelet count 
and 2) by testing platelet function (platelet aggregation) (Lau of al., 2002). Platelet 
aggregometers are the `gold standard' for assessment of platelet aggregation (Born, 
1962) but as an assay has several limitations. For example, platelet aggregometers, 
use large volumes of blood and a complex, lengthy analytical process. Furthermore 
PRP aggregometry is limited by the concentration of platelets (only samples of z50 x 
103/µL platelets can be tested) and also it cannot detect micro-aggregates of <100 
platelets (Storey et al., 1998). These limitations may be overcome by a new test 
platform, PlateletWorks®, which directly evaluates platelet aggregation using whole 
blood. In addition to its rapid turn-around time, it provides a full haematology profile 
(including platelet count), which is extremely useful in the clinical research 
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environment. Lau et al (2002) summarised PlateletWorks® as a novel-bedside assay 
of platelet function suitable for the clinical environment. 
Despite PlateletWorks® not being studied extensively, this study supports the finding of 
Lau et al (2002) in that the PlateletWorks® system may be used as an alternative to 
platelet aggregometry. In this study, the mean difference between the two methods 
was -2.9% with a 95% confidence interval -29.7 to 23.9%. The reference range for 
platelet aggregation following 20µM ADP-induced platelet aggregation was 70-96% for 
platelet aggregometry and 76-89% for PlateletWorks®. Similarly Lau et al (2002) found 
that the reference range for the platelet aggregation response to 20µM ADP induced 
platelet aggregation was 80-97% with PlateletWorks®. This study showed that at lower 
ADP concentrations, platelet aggregation decreased compared to ADP-induced platelet 
aggregation at 20µM. For example at ADP concentrations of 15µM and 20µM, platelet 
aggregation was 69.03±3.03% and 60.87±3.68% respectively for the platelet 
aggregometer and 68.1±4.1 % and 53.1±5.3% respectively for PlateletWorks®. 
Intra- and interassay was tested for ADP-induced platelet aggregation for each platelet 
function method. Intraassay (% aggregation) was 67.5±16.8% for PlateletWorks® and 
70.4±13.5% for the platelet aggregometer. The interassay was 8.7 (SD 5.03)% for the 
platelet aggregometer and 7.2 (SD 6.86)% for PlateletWorks®. The slight variation 
observed may be attributed to natural, diurnal physiological processes during the test 
period or a change in factors which may compromise the sample, for example 
temperature, pH, aggregometer stir speed, platelet count, sample volume and 
venepuncture technique all affect platelet aggregation (White and Jennings, 1999). 
The anticoagulant used will also affect platelets, for example in this study sodium 
citrate was used rather than EDTA as recommended by the PlateletWorks® 
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manufacturer's guidelines. EDTA has been shown to cause falsely low platelets counts 
known as platelet agglutination, irrespective of the presence or absence of any disease 
process (George, 2000). 
3.10.5 CONCLUSION 
To conclude, PlateletWorks® has demonstrated utility in the clinical / research setting to 
provide information on overall primary haemostasis (platelet aggregation and platelet 
count) by using a whole blood sample, which is devoid of long laborious techniques, 
excessive blood volume and the limitations associated with PRP. To confirm 
PlateletWorks® as a clinical research tool, future research should carry out large scale 
clinical studies using PlateletWorks® to assess primary haemostasis between 
population groups and following clinical treatment known to reduce platelet aggregation 
levels. Furthermore, further studies should investigate whether PlateletWorks® has the 
potential to diagnose inherited platelet irregularities (Lau et al., 2002). 
109 
3.11 Preliminary experiment to determine the reliability of the Bloelectrical 
Impedance (Bodystat QuadScan 4000) (2) 
3.11.1 INTRODUCTION 
Body composition assessment is often an integral part of obesity research since basic 
descriptive information on body composition is linked to energy intake, physical activity, 
energy metabolism and incidence of chronic disease (Brodie of al., 1998). BIA is a 
widely used method to assess body composition (National Institute of Health, 1994). 
The analysis determines the electrical impedance of body tissue, which provides an 
estimate of total body water. From this, fat-free mass (FFM) and body fat (BF) can be 
estimated (Ackmann and Seitz, 1984). Several other techniques, measure body 
composition such as hydrodensitometry, skinfold calipers and DEXA (Brodie of al., 
1998). Some body composition techniques are restricted to research institutes with 
high capital, but low cost body composition systems such as bioelectrical systems can 
be applied rapidly and non-invasively for research purposes and clinical practice. 
It is recognised that the measurement of bioelectrical impedance is influenced by other 
factors that should either be controlled or reported. These include the menstrual cycle 
(Mitchell et al., 1993), skin temperature (Caton et al., 1988), exercise-induced 
dehydration (Brodie et al., 1991), prior food (Fogelholm et al., 1993) and different 
positions (Pinilla et al., 1992). If such features are controlled the prediction errors to 
calculate body fat are 3-5% (Brodie et al, 1998). Most studies report that the 
impedance method is reliable and valid (van Marken-Lichtenbelt, 1994), which is 
extremely important because poor reliability may reduce the precision of a single 
measurement and the ability to track changes in measurements in experimental studies 
may be reduced (Zemel et al., 1996). 
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The purpose of this preliminary study was to assess the reliability of the BodyStat 
QuadScan 4000 for assessment of body composition. 
3.11.2 METHODOLOGY 
Subject characteristics 
Six (n=6) healthy male and females (n=2/4) were recruited from the Department of 
Sport Sciences, De Montfort University (see table 3.5 for subject characteristics). All 
subjects had previously been involved in studies involving the BIA and so were familiar 
with all the experimental procedures. Written informed consent was obtained from all 
the subjects after they were given a full explanation of the study. All subjects were fully 
informed that they were free to withdraw from participation at any time. The study was 
approved by De Montfort University Research Ethics Committee. 
Table 3.5. Subject characteristics 
Characteristic 
Age, yr 23.7: t 3.2 
BMI, kg/m2 24.1 t 1.0 
Weight, kg 72.0: t 4.9 
Body fat, kg 17.8 t 3.1 
Values expressed as the mean ± SEM. BMI, body mass index. 
Experimental design 
Subjects visited the Exercise Physiology laboratories on three separate days over one 
week between 9-12am and were instructed to fast for 10-12 hours beforehand and 
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refrain from exercise, caffeine and alcohol for 48 hours before the experimental period 
began. Subjects were also told to maintain their usual dietary regimen. 
Anthropometric measurements. 
Height and weight measurements are described in detail in the methodology chapter 
(section 3.2.1,3.2.2,3.2.3). Body composition was analyzed using the BIA (BodyStat® 
Quadscan 4000) which is outlined in the methodology chapter (section 3.2.4.1). 
BIA measurements 
Subjects rested in a supine position for 5-10 minutes before assessment of body 
composition. Three measurements of body composition were made in each subject. 
This was repeated twice and the average between the two measurements were 
obtained. 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value) The Shapiro-Wilk test confirmed that 
the data was normally distributed. The significance of differences in BIA 
measurements between time periods was analyzed using one-way ANOVA which 
incorporated one within (time: Wk 1 vs Wk 2 vs Wk 3) subjects factor. Precision data 
are reported as mean (t SD) with coefficient of variation. P-values < 0.05 were 
regarded as statistically significant. Analyzes of data was performed using a computer 
software package (SPSS for Windows, Version 13.0). 
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3.11.3 RESULTS 
Results for the reproducibility tests and analysis of variance for BIA are shown in table 
3.6 and Table 3.7, respectively. 
Table 3.6. Intra- and interassay variation for body fat (kg) using the BIA method. 
Sample CV (%) 
Equipment N Mean SD Mean SD 
BIA (Body fat, kg) 18 17.80 7.69 1.18 1.17 
Values expressed as the mean±SD. Reproducibility of body fat (kg) analyzed using the 
coefficient of variation (CV%). For further details see text. 
Intra- and interassay was tested for body fat (kg) using the bioelectrical impedance. 
Intraassay was 17.80±7.69kg and the interassay was 1.18 (SD 1.17)kg and ranged 
from 0.17 to 3.0%. There was no evidence of significant differences in body fat levels 
between time periods when using BIA (ANOVA, P>0.05) (see table 3.7) 
Table 3.7. Analysis of variance of body fat (kg) for BIA method. 
Parameter Sum of squares Df Mean Square F Sig. 
BIA Between groups 0.214 2 0.107 0.002 0.998 
Within groups 887.284 15 59.152 
Total 887.497 17 
Results analyzed using repeated measured ANOVA and P values are given in the 
Table. For further details see text. 
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3.11.4 DISCUSSION 
This study was designed to assess the reproducibility of the BIA (BodyStat QuadScan 
4000) for assessment of body composition. 
This study found that the BodyStat QuadScan 4000 was highly reproducible. This is 
crucial for single measurement precision and for the ability to track changes in 
measurements during experimental studies. In this study many factors associated with 
influencing the measurement of bioelectrical impedance were controlled, such as 
menstrual cycle (Mitchell of al., 1993), skin temperature (Caton et al., 1988), exercise- 
induced dehydration (Brodie et al., 1991), prior food (Fogelholm et al., 1993) and 
different positions (Pinilla et al., 1992). According to Brodie et al (1998), controlling for 
the above factors whilst using a BIA, obtain a prediction error to calculate body fat of 
around 3-5%. In this study the BIA possessed a day-to-day variation of around 0.3-3% 
(ANOVA, P>0.05). In general most studies report that the BIA method is reliable and 
valid (van Marken-Lichtenbelt, 1994) but highlight that caution should be used with 
single frequency BIA in a clinical setting (Tagliabue et al., 1992). In this study, the 
multiple frequency BIA was used, which is able to differentiate between total and 
extracellular fluid compartments in the body (Chumlea and Guo, 1994). Multi- 
frequency BIA increases the value of assessing clinical and nutritional status (Brodie of 
al., 1998) and has been shown to produce significant improvements in the prediction of 
body water (Cornish of al., 1994). However the application of the BIA to special groups 
must also be interpreted with caution. For example BIA tends to overestimate fat in the 
lean and underestimate fat mass in the obese (Brodie of al., 1998). This is because 
the geometric proportions of obese individuals compared with leaner individuals are 
such that a greater proportion of body mass and body water is accounted for by the 
trunk in relation to the extremities; the trunk however contributes a relatively minor 
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amount to total body impedance. However the advantages of the BIA include speed of 
operation, portability, simplicity and lack of intrusion (Brodie et aL, 1998). 
3.11.5 CONCLUSION 
In conclusion, the BIA method to assess body composition was sufficiently reproducible 
for research purposes. However, for BIA assessments, prior to and during, 
measurement conditions must be standardized. 
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Chapter FOUR 
Study 1 
Lipid peroxidation and antioxidant status at rest in healthy 
normal-weight, overweight and obese subjects 
4.0 INTRODUCTION 
Oxidant stress in obesity may be an important pathogenic mechanism in the obesity- 
associated metabolic syndrome (Furukawa et al., 2004) which includes co-existence of 
several risk factors for atherosclerosis, including hyperglycaemia, dyslipidaemia and 
hypertension. Oxidant stress has also been shown to play a critical role in the 
pathogenesis of various diseases such as cancer, CVD and diabetes (Niki, 2000). 
Several research studies have reported that obesity is associated with increased 
oxidant stress in humans (Yesilbursa et al., 2005; Mohn et aL, 2005; Keaney et al., 
2003; Ozata et aL, 2002; Davi et al., 2002; Dandona et al., 2001; Präzny at al., 1999) 
i. e. increased free-radical production and/or depleted cellular antioxidant defence 
systems (Powers et aL, 2004). The mechanisms suggested that may underlie the 
obesity-associated oxidant stress include increased V02 (i. e. mechanical overload) and 
subsequent radical production via mitochondrial respiration, diminished antioxidant 
capacity, increased fat deposition and cell injury causing increased rates of radical 
formation such as 02 and OH" (Vincent et al., 2001). In addition, hyperglycaemia, 
hypertension and hyperleptinemia are also possible sources of increased oxidant 
stress in obesity (Vincent and Taylor, 2006). It remains unknown if the obesity- 
associated oxidant stress is a cause and effect relationship or of it is due to the obesity- 
related diseases i. e. hypertension, hyperlipidaemia, hyperleptinemia and 
hyperglycaemia (Facchini at aL, 2000). 
Lifestyle factors also influence oxidant stress levels in obese subjects (Moller et al., 
1996). Non-smoking, vitamin and/or trace element supplementation, regular physical 
activity and limited UV light exposure also contributes to an increased antioxidant 
defence potential, whilst tobacco smoking, high psychological stress, heavy alcohol 
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drinking and low/moderate vegetable, low fruit and little fish consumption contribute to 
a decreased antioxidant potential (Lesgards et al., 2002). 
This study investigated the levels of LH, TAS, SOD and GSH in normal-weight, 
overweight and obese subjects. This study also sought to identify physiological and 
lifestyle factors that may contribute to the normal variability of the overall oxidant stress 
status. The evaluation of oxidant stress, taking into account physiological factors, 
nutritional habits and lifestyle factors, may be useful in preventative medicine as a 
precocious diagnosis to identify healthy subjects who are at risk of oxidant stress- 
associated diseases. 
4.1 METHODOLOGY 
Subject Characteristics 
The study group consisted of 90 subjects who were sex-matched between groups [30 
normal-weight (BMI: 23.4t0.46kg/m2), 30 overweight (BMI: 26.6t0.36kg/m2) and 30 
obese (BMI: 33.2±2.82kg/m2) healthy male and females (n=24/66)] (see table 4.0 for 
subject characteristics). Volunteers were invited to take part in the study by local 
advertisement. An inclusion criterion was age between 18 and 50 years old and BMI 
between 20 and 40 kg/m2. Subjects with a history of diabetes, cardiovascular or 
cerebrovascular disease, hepatic or renal disease, tobacco abuse, or those on hormone 
replacement therapy were excluded. In addition subjects were excluded if they were 
hypertensive (with or without treatment), taking treatment for dyslipidaemia, taking any 
antioxidant supplementations or a smoker. Written informed consent was obtained 
from all the subjects after they had been given a full explanation of the study. The 
research was given ethical approval by Bedfordshire Local Research Ethics 
Committee. 
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Table 4.0. Subject characteristics 
P Value 
Characteristic Normal-Weight Overweight Obese NW NW OW 
(NW) (n=30) (OW) (n=30) (0) (n=30) vs vs vs 
(m/f; 8/22) (m/f; 8/22) (m/f; 8/22) OW 00 
Age, yr 30.83 t 1.65 34.67: t 1.56 37.93: t 1.91 . 18 <. 
05 . 06 
Body mass, kg 64.55: t 1.26 77.85: t 1.66 91.66 t 2.11 <. 001 <. 001 <. 001 
BMI, kg/m 22.82: t 0.25 26.90: t 0.21 33.03t 0.51 <. 001 <. 001 <. 001 
Body fat, kg 16.79: t 1.04 23.45 t 1.12 35.97: t 1.48 <. 001 <. 001 <. 001 
Waist, cm 75.42 t 1.14 87.59: t 1.49 101.56: t 2.00 <. 001 <. 001 <. 001 
Systolic BP, mmHg 114.67 t 1.97 124.23: t 2.43 127.93 t 2.97 <. 01 <. 001 . 55 
Diastolic BP, mmHg 74.50 ± 1.33 81.03 ± 1.75 86.03 ± 1.65 <. 01 <. 001 <. 05 
Fasting glucose, mmol/L 5.89t 0.29 5.57 t 0.24 5.73t 0.33 . 30 . 22 . 63 
Fructosamine, mmol/L 210.00: t 10.67 223.33: t 8.30 241.35: t 13.06 . 33 . 07 . 25 
Total cholesterol, mmoVL 4.36 t 0.24 5.01 t 0.22 5.46: t 0.29 <. 05 <. 01 . 29 
HDL-cholesterol, mmol/L 1.88 t 0.11 1.57 t 0.12 1.33 t 0.12 <. 05 <. 001 . 10 
LDL-cholesterol, mmol/L 2.23 ± 0.23 3.01 ± 0.23 3.59 ± 0.25 <. 02 <. 001 . 07 
Triglycerides, mmol/L 0.76 ± 0.05 0.95 ± 0.07 0.99 ± 0.07 . 10 <. 05 . 53 
Values expressed as the meantSEM. BMI, body mass index; BP, blood pressure; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein. Results were compared 
using a Mann Whitney U-Test and P values are given in the Table. P values < 0.05 
were considered significant. For further details see text. 
Experimental design 
Subjects visited the Centre for Obesity Research on one occasion between 9-12am 
and were instructed to fast for 10-12 hours and refrain from exercise, caffeine and 
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alcohol intake for 48 hours before the study visit. Subjects were also asked to maintain 
their usual dietary pattern. 
Anthropometric measurements 
Height was measured without shoes using a stadiometer. Weight and body 
composition was assessed using the BodPod and waist measurements were also 
taken (see methodology section 3.2.1,3.2.2,3.2.3 and 3.2.4.2). 
Cardiovascular measurements 
Heart rate was measured at the radial artery and blood pressure was measured using 
a mercury sphygmomanometer (see methodology section 3.3). 
Food diary 
Dietary intake was monitored using a 7-day weighed food diary, which was 
subsequently analyzed for macro- and micro-nutrient content using dietary analysis 
software, Compeat (see methodology section 3.8). 
Physical activity 
Subjects completed a Baecke Physical activity questionnaire which was used to assess 
physical activity levels (see methodology section 3.9). 
Venous blood sampling 
Blood samples were collected following a 10-12hr fast using the syringe method (see 
methodology section 3.1). Blood samples were divided between EDTA and serum 
tubes. Samples were centrifuged (3000 rpm for 10 minutes), and then divided and 
stored at both -70°C and -20°C. For preparation of SOD and GSH assays, see 
methodology section 3.1.14.2 and 3.1.14.3, respectively. 
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Biochemical measurements included LH, TAS, SOD and GSH as described in the 
methodology chapter (section 3.1.12.1,3.1.13.1,3.1.13.2,3.1.13.3). In addition fasting 
plasma glucose, plasma fructosamine, plasma cholesterol, plasma LDL, plasma HDL 
and plasma triglycerides was measured (see methodology section 3.1.6,3.1.7,3.1.8, 
3.1.9,3.1.10 and 3.1.11, respectively). 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value). The Kolmogorov-Smirno test 
confirmed that the data was not normally distributed so was analyzed by non- 
parametric methods to avoid assumptions about the distribution of the measured 
variables. The Kruskal Wallis analysis of variance test was used to compare groups 
and the Mann-Whitney U-Test was used to evaluate the differences between two 
independent groups. Associations between parameters were assessed using the 
Spearman rank correlation test. For multiple regression analysis, LH was log- 
transformed. Multiple regression analysis was conducted after examination of potential 
effect modifiers and variables were included if they were significantly associated with 
LH levels, P<0.05. Differences were considered statistically significant at P<0.05. 
Statistical analysis was performed using a computer software package (SPSS for 
Windows, Version 13.0). 
4.2 RESULTS 
Subject characteristics for the normal-weight, overweight and obese groups are shown 
in table 4.0. Body mass, body fat, waist circumference and resting diastolic blood 
pressure all progressively increased significantly (P<0.01) with higher BMI values. 
Other significant differences between groups with increasing BMI values include 
120 
increased resting systolic blood pressure (normal-weight vs overweight, P<0.01 and 
normal-weight vs obese, P<0.001), increased cholesterol (normal-weight vs 
overweight, P<0.05 and normal-weight vs obese, P<0.01), decreased HDL 
concentration (normal-weight vs overweight, P<0.05 and normal-weight vs obese, 
P<0.001), increased LDL concentration (normal-weight vs overweight, P<0.02 and 
normal-weight vs obese, P<0.001), increased triglycerides (normal-weight vs obese, 
P<0.05) and increased age (normal-weight vs obese, P<0.02). Fasting blood glucose 
and fructosamine levels were similar in all subjects. 
Table 4.1 highlights the mean values for habitual physical activity and energy intake for 
the normal-weight, overweight and obese groups. Percentage carbohydrate intake 
progressively decreased with higher BMI values (Kruskall Wallis test, P<0.001) with the 
overweight and obese group demonstrating significantly lower percentage 
carbohydrate intake when compared to the normal-weight group (P<0.01 and P<0.001, 
respectively) [normal-weight vs overweight vs obese (48.41±0.80 vs 43.43±1.39 vs 
43.19±1.19%)]. However no differences between groups were found when 
carbohydrate intake was expressed in grams. Percentage fat intake increased 
progressively with higher BMI values (Kruskall Wallis test, P<0.001) with the 
overweight and obese group demonstrating significantly increased percentage fat 
intake when compared to the normal-weight group (P<0.01 and P<0.001, respectively) 
[normal-weight vs overweight vs obese (31.25±0.73 vs 35.56±1.30 vs 37.14±0.99%)]. 
However when fat intake was expressed in grams, fat intake was only significantly 
greater in the obese group compared to the normal-weight group [normal-weight vs 
obese (60.42±2.94 vs 80.01±6.83g)]. Saturated, polyunsaturated and monosaturated 
fat intake expressed in grams all progressively increased with higher BMI values 
(Kruskall Wallis test, P<0.001, P<0.01, P<0.02, respectively) with the overweight and 
obese group demonstrating significantly increased saturated, polyunsaturated and 
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monosaturated fat intake when compared to the normal-weight group [overweight vs 
obese (P<0.001, P<0.02, P<0.02 and P<0.001, P<0.01, P<0.01, respectively)]. 
The mean values for LH, TAS, SOD and GSH for the normal-weight, overweight and 
obese groups (classified by BMI) are given in table 4.2. LH progressively increased 
with higher BMI values (Kruskall Wallis test, P=0.025) with the obese group 
demonstrating significantly higher LH levels when compared to the normal-weight 
group (0.86±0.05 vs 0.68±0.03pmol/L, P<0.01) but the increased level was not 
statistically significant when compared to the overweight group (0.86±0.05 vs 
0.79±0.06pmol/L, P>0.05) (see table 4.2 and figure 4.0). No other significant 
differences in TAS, SOD and GSH were identified between groups for BMI (Kruskal 
Wallis test, P=0.70, P=0.93, P=0.14 respectively). 
Further analyses was also carried out to identify the impact of waist circumference on 
LH, TAS, SOD and GSH levels (see table 4.3). Current guidelines suggest a cut-off of 
greater than 102 cm in men and 88 cm in women on the basis of causing increased 
risk of many metabolic risk factors such as hyperinsulaemia and hyperlipidaemia (Han 
et a/., 1995). Interestingly LH levels above the cut-off waist circumference guidelines 
were significantly higher compared to those below the cut-off waist circumference 
guidelines (0.84±0.04 vs 0.74±0.04pmol/L, P<0.05). However no significant 
differences in TAS, SOD and GSH were identified between these two groups. 
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Table 4.1. Mean values for habitual physical activity and dietary intake between 
normal-weight, overweight and obese groups. 
P value 
Variable Normal-Weight Overweight Obese NW NW OW 
(NW) (OW) (0) Vs vs vs 
(n=30) (n=30) (n=30) OW 00 
Baecke questionnaire 55.58 t 2.13 53.83: t 1.86 50.73 t 1.69 . 50 . 06 . 22 
Total energy intake, 1680.50: t 68.80 1739.55: t 79.06 1815.92 t 86.56 . 60 . 27 . 74 
kcals 
Carbohydrate, % 48.41 ± 0.80 43.43 ± 1.39 43.19 ± 1.19 <. 01 <. 001 . 62 
Carbohydrate, g 217.29: t 10.56 198.29. t 10.52 205.39: t 12.19 . 21 . 57 . 54 
Fat, % 31.25 ± 0.73 35.56 ± 1.30 37.14 ± 0.99 <. 01 <. 001 . 25 
Fat, g 60.42 ± 2.94 70.99 ± 4.61 80.01 ± 6.83 . 06 <. 01 . 44 
Protein, % 16.92 ± 0.39 16.50 ± 0.58 16.64 ± 0.56 . 22 . 10 . 99 
Protein, g 69.62 ± 2.82 71.16 ± 3.85 73.52 ± 3.26 . 72 . 38 . 54 
Saturated fat, g 19.10 ± 1.52 25.40 ± 1.43 26.69 ± 2.01 <. 001 <. 001 . 88 
Polyunsaturated fat, g 8.45 ± 0.48 11.63 ± 0.94 12.21 ± 0.93 <. 05 <. 01 . 62 
Monosaturated fat, g 16.59* 0.97 21.25. t 1.54 22.23 t 1,57 <. 05 <. 01 . 58 
Alcohol, % 2.95 ± 0.41 4.23 ± 0.66 3.74 t 0.77 . 25 . 98 . 42 
Alcohol, g 7.48: t 1.10 10.70: t 1.66 9.25: L 1.87 . 26 . 81 . 42 
Selenium, g 37.51 ± 2.70 39.61 ± 3.04 42.42 ± 2.55 . 77 . 19 . 16 
Vitamin A, g 608.62: t 63.62 745.60: t 128.68 674.58 t 73.43 . 91 . 68 . 51 
Vitamin C, g 79.26 t 7.21 72.76 t 6.42 77.93 ± 9.13 . 57 . 85 . 91 
Vitamin D, g 3.37t 0.55 2.94: L 0.38 3 . 17 t 0.30 . 95 . 26 . 32 
__-- Vitamin E, g 6.54: t 0.53 7.12: t 0.54 7.47 t 0.58 . 45 . 29 . 68 
Values expressed as the mean±SEM. Results were compared using a Mann Whitney 
U-Test and the P values are given in the Table. P values < 0.05 were considered 
significant. For further details see text. 
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Table 4.2. Mean values for LH, TAS, SOD and GSH between normal-weight, 
overweight and obese groups. 
P value 
Variable Normal-Weight Overweight Obese NW NW OW 
(NW) (OW) (0) Vs vs vs 
(n=30) (n=30) (n=30) OW 00 
LH, pmol/L 0.68 ± 0.03 0.79 ± 0.06 0.86 ± 0.05 . 26 <. 
01 . 17 
TAS, mmol/L 678.51 ± 31.22 698.51 ± 49.73 676.41 ± 55.53 . 
98 . 43 . 51 
SOD, U/g Hb 3137.24 t 161.74 3187.61 ± 170.49 3198.18 ± 178.72 . 59 . 92 . 91 
GSH, pmol/g Hb 14.31 ± 1.71 15.07 ± 1.64 11.2 ± 1.90 . 80 . 19 <. 05 
Values expressed as the mean±SEM. LH, lipid hydroperoxide; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione. Results were 
compared using a Mann Whitney U-Test and the P values are given in the Table. P 
values < 0.05 were considered significant. For further details see text. 
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Figure 4.0. LH levels (pmol/L) in normal-weight, overweight and obese groups 
(classified by BMI). Results (mean±SEM) were compared using Mann-Whitney 
U Test. (`, P<0.01, NS: not significant). For further details see text. 
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Table 4.3. Mean values for LH, TAS, SOD and GSH according to waist circumference 
guidelines [cut-off points, reduced CVD risk (<88cm for women and <102cm for men) 
and increased CVD risk (>88cm for women and >102cm for men)]. 
Variable Reduced CVD risk waist increased CVD risk waist 
T P-Value 
LH, pmol/L 
TAS, mmol/L 
circumference (n=52) circumference (n=38) 
0.74 ± 0.04 0.84 ± 0.04 . 025 
i 
3246 ± 128.91 3076.28 ± 148.96 SOD, U/g Hb . 93 
GSH, pmol/g Hb 14.80 ± 1.23 11.76 t 1.71 . 14 
Values expressed as the mean±SEM. LH, lipid hydroperoxide; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione. Results were 
compared using a Mann Whitney U-Test and P values are given in the Table. P values 
< 0.05 were considered significant. For further details see text. 
The Spearman rank correlation test found several variables to be strongly and 
positively associated with LH levels (see table 4.4 and 4.5): BMI (r=0.320, P<0.01), 
body fat (kg) (r=0.214, P<0.05), waist circumference (r=0.357, P<0.001), resting 
diastolic blood pressure (r=0.420, P<0.001) and resting systolic blood pressure 
(r=0.417, P<0.001), fasting triglycerides (r=0.490, P<0.001) and vitamin A (r=0.272, 
P<0.01). HDL and fasting blood glucose were strongly and negatively associated with 
an increase in LH (r=-0.212, P<0.05 and r=-0.316, P<0.01, respectively). Variables 
found to be strongly and positively correlated with TAS levels (see table 4.4 and 4.5) 
included systolic blood pressure (r=0.331, P<0.01), fasting blood glucose (r=0.326, 
P<0.01), triglycerides, (r=0.250, P<0.02). Body fat (kg) and resting heart rate were 
strongly and negatively associated with an increase in LH (r=-0.227, P<0.05 and r=- 
0.212, P<0.05, respectively). As shown in table 4.5, vitamin C was shown to be 
strongly and positively correlated with SOD levels but vitamin A and triglycerides levels 
were shown to be strongly and negatively correlated with SOD levels (-0.270, P<0.01 
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and -0.288, P<0.01, respectively). GSH levels were found to be strongly and positively 
correlated with a number of variables including: fasting glucose (r=0.561, P<0.001), 
physical activity levels (r=0.332, P<0.001), total energy intake (kcals) (r=0.299, 
P<0.01), polyunsaturated fat (r=0.277, P<0.01), carbohydrates (r=0.372, P<0.001), 
protein (r=0.282, P<0.007), selenium (r=0.323, P<0.01) and vitamin E (0.372, 
P<0.001). However the following variables were shown to be strongly and negatively 
associated with GSH: body fat (kg) (r=-0.345, P<0.001), total cholesterol (r=-0.360, 
P<0.001), LDL-cholesterol (r=-0.307, P<0.01). 
A multiple linear regression analysis was performed to quantify further the relationship 
between LH levels, subject characteristics, biochemical status, dietary intake and level 
of physical activity (see table 4.6). A significant model emerged (F4,85=10.667, 
P<0.001) which revealed that 30.3% of the variance in LH was explained by the 
following variables; weight (standardized beta, 0.250, P<0.05), fasting glucose 
(standardized beta, -0.276, P<0.01), triglycerides (standardized beta, 0.234, P<0.05), 
vitamin A (standardized beta, 0.258, P<0.01). 
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Table 4.4. Correlation coefficients for the relationship between LH, TAS, SOD, 
GSH and BMI, body fat, waist circumference, blood pressure, fasting glucose, 
fructosamine and lipid profile in healthy subjects. 
Variable LH TAS SOD GSH 
Regression coefficients (P Value) 
Weight, kg . 387 
(. 000) . 
164 (. 123) -. 093 (. 386) . 
025 (. 812) 
BMI, g/M2 . 320 
(<. 01) -. 031 (. 774) -. 043 (. 689) -. 139 (. 192) 
Body fat, kg . 214 
(<. 05) -. 227 (. 031) . 088 
(. 411) -. 345 (. 001) 
Waist circumference, cm . 357 (<. 001) . 068 (. 527) -. 206 
(. 051) -. 052 (. 627) 
Resting HR, beats/minute . 025 
(. 81) -. 212 (. 045) . 118 
(. 268) -. 173 (. 103) 
Diastolic BP, mmHg . 420 
(<. 001) 
. 084 
(. 430) -. 092 (. 388) -. 109 (. 304) 
Systolic BP, mmHg . 417 
(<. 001) . 331 
(. 001) -. 068 (. 526) . 088 
(. 410) 
Fasting glucose, mmol/L -. 316 (<. 01) . 326 (. 002) -. 124 (. 244) . 561 
(. 000) 
Fructosamine, mmol/L -. 119 (. 437) . 087 (. 570) -. 002 (. 992) -. 138 
(. 366) 
Total cholesterol, mmo/L . 165 
(. 12) -. 197 (. 063) . 043 
(. 690) -. 360 (. 000) 
HDL-cholesterol, mmo/L -. 212 (<. 05) . 081 (. 449) -. 131 
(. 218) . 083 
(. 435) 
LDL-cholesterol, mmo/L . 164 (. 12) -. 197 (. 063) . 094 
(. 380) -. 307 (. 003) 
Triglycerides, mmo/L . 490 (<. 001) . 250 (. 017) -. 288 
(. 006) -. 025 (. 817) 
TAS, mmo/L . 161 
(. 129) 1.000 (. ) -. 231 (. 029) . 477 
(. 000) 
SOD, U/g Hb -. 129 (. 224) -. 231 (. 029) 1.000 (. ) -. 080 (. 456) 
GSH, pmol/g Hb -. 059 (. 580) . 477 
(. 000) -. 080 (. 456) 1.000 (. ) 
LH, pmol/L 1.000 (. ) . 067 (. 531) -. 110 
(. 304) -. 049 (. 649) 
BMI, body mass index; HR, heart rate; BP, blood pressure; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione and LH, lipid 
hydroperoxide. Results were analyzed using the Spearman rank correlation test and P 
values are given in the Table. For further details see text. 
127 
Table 4.5. Correlation coefficients for the relationship between LH, TAS, SOD and 
GSH and lifestyle variables; physical activity levels, energy intake, dietary macro- and 
micro-nutrient composition in healthy subjects. 
Variable LH TAS SOD GSH 
Regression coefficients (P Value) 
Baecke questionnaire -. 019 (. 856) . 
041 (. 701) -. 115 (. 280) . 
332 (. 001) 
Total energy intake, kcals -. 021 (. 842) . 272 
(. 010) . 096 
(. 370) . 299 
(. 004) 
Fat, g 
Saturated, g 
Poly, g 
Mono, g 
-. 001 (. 990) 
. 
087 (. 415) 
-. 030 (. 781) 
-. 001 (. 991) 
. 
155 (. 143) 
-. 072 (. 500) 
. 
162 (. 128) 
. 
115 (. 280) 
. 
075 (. 482) 
. 
122 (. 253) 
-. 018 (. 864) 
. 
040 (. 707) 
. 
137 (. 197) 
-. 025 (. 813) 
. 
277 (. 008) 
. 
078 (. 464) 
Carbohydrate, g -. 023 (. 827) . 216 
(. 041) . 096 
(. 370) . 372 
). 000) 
Protein, g . 059 
(. 581) . 348 
(. 001) . 092 
(. 390) . 282 
(. 007) 
Alcohol, g . 098 
(. 358) . 322 (. 002) -. 199 (. 059) . 
092 (. 388) 
Selenium, g . 166 (. 118) . 269 (. 010) -. 004 (. 968) . 
323 (. 002) 
Vitamin A, g . 272 
(<. 01) -. 007 (. 945) . 196 
(. 064) . 032 
(. 768) 
Vitamin C, g -. 045 (. 675) . 143 (. 178) . 243 
(. 021) . 203 
(. 055) 
Vitamin D, g . 152 
(. 152) . 341 (. 001) -. 270 
(. 010 . 205 
(. 053) 
Vitamin E, g . 036 (. 733) . 206 (. 051) -. 062 
(. 565) . 375 
(. 000) 
g, weight. Results were analyzed using the Spearman rank correlation test and P 
values are given in the Table. For further details see text. 
Table 4.6. Determinants of LH level in healthy subjects. 
Variable Beta P value 
Fasting glucose, mmol/L -0.276 . 003 
Vitamin A, mmol/L 0.258 . 007 
Weight, kg 0.250 . 014 
Triglycerides, mmol/L 0.234 . 023 
Adjusted 0.303 
Results were analyzed using the multiple regression analysis model (Enter model) and 
standardized beta and P values are given in the Table. For further details see text. 
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4.3 DISCUSSION 
This study investigated the levels of LH, TAS, SOD and GSH in normal-weight, 
overweight and obese subjects. It is the first study to identify the impact of being 
overweight on oxidant stress parameters. This study also sought to identify 
physiological and lifestyle factors that may contribute to the normal variability of the 
overall oxidant stress status. 
This study clearly identified that the level of LH was markedly higher in the obese group 
compared to the normal-weight group. The overweight group did not show a significant 
increase in LH levels when compared to the normal-weight group. No other consistent 
relationships between BMI, TAS, SOD and GSH were reported. Further analyses also 
showed that LH levels was markedly higher above the cut-off waist circumference 
guidelines for increased risk of CVD (women, >88cm and men, >102cm) compared to 
below the cut-off waist circumference guidelines. No other relationships between waist 
circumference, TAS, SOD and GSH were found. 
In comparison to other research studies investigating obesity-associated oxidant 
stress, this study found similar findings. Increased markers of lipid peroxidation in 
obesity have been frequently observed in other human studies (Yesilbursa et al., 2005; 
Keaney et al., 2003; Ozata et al., 2002; Davi et al., 2002; Dandona et al., 2001; Präznj' 
et al., 1999). Yesilbursa et al (2005), Dandona et al (2001) and Ozata et al (2002), 
recorded significantly higher levels of MDA and TBARS, respectively in obese adults 
compared to normal-weight controls [obese vs normal-weight (Yesilbursa et al., 2005; 
MDA, 2.0±0.77 vs 0.63±0.14nmoi/ml, Dandona et al., 2001; TBARS, 1.68±0.17 vs 
1.29±0.12imol/L and Ozata et al., 2002; TBARS, 7.77±3.41 vs 3.92±0.93mmol/ml)]. 
Keaney et al (2003) and Präznj' et al (1999) concluded that BMI was independently 
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associated with increased levels of urinary concentrations of 8-iso PGF2a in healthy 
individuals, and plasma MDA concentration in both Type I and Type II diabetics 
(r=0.68, P<0.001), respectively. Similarly, Davi et al (2002) found that obese women 
had high levels of urinary 8-iso PGF2a compared to non-obese counterparts, which was 
also significantly higher in android (523 (393-685) pg/mg of creatine) than gynoid (275 
(220-349) pg/mg of creatine) obesity compared to non-obese women (187 (140-225) 
pg/mg of creatine). The findings in this study also supports that android obesity 
increases LH levels because LH levels above the cut-off waist circumference 
guidelines for increased risk of CVD were significantly higher compared to those below 
the cut-off waist circumference guidelines (0.84±0.04 vs 0.74±0.04pmol/L, P<0.05). 
These findings are also confirmed by Keaney et al (2003) who found in a community- 
based cohort, the Framingham Heart Study, a strong association between markers of 
oxidant stress and both BMI and waist-hip ratio, implicating adiposity as the main factor 
for increased oxidant stress. On the contrary, Vincent et al (2004,2005) highlighted no 
significant difference in both plasma TBARS and lipid hydroperoxide levels at rest 
between non-obese and obese counterparts. However the BMI levels in each of these 
studies were 24.9±2.5kg/m2 (non-obese) vs 33.3±2.3kg/m2 (obese) and 22.0±0.9kg/m2 
(non-obese) vs 28.0.3±1.2kg/m2 (obese), respectively. This shows that the studies 
undertaken by Vincent et al (2004,2005) did not include subjects with morbid obesity 
hence LH levels in the obese group were not significantly higher than the non-obese 
group. Although Vincent et als (2005) study did not intend to identify the impact of 
being overweight on oxidant stress levels (objective of the study was to identify the 
impact of obesity on exercise-induced oxidant stress), the study supports the finding 
that overweight subjects do not have significantly enhanced LH levels compared to 
normal-weight subjects. Interestingly, all those studies that show a significant 
increased LH response in obese subjects compared to normal-weight subjects have 
included subjects with a mean BMI of around 33-40kg/m2 (Yesilbursa et al., 2005; 
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Keany of al., 2003; Ozata et al., 2002; Davi of al., 2002; Dandona et al., 2001; Präzny 
et al., 1999). 
This study did not highlight any major significant differences in TAS, SOD and GSH 
levels between normal-weight, overweight and obese groups or between gynoid and 
android obesity, but other research studies have suggested otherwise. Olusi (2002) 
found that erythrocyte Cu/ZnSOD activity and GSH-Px were significantly lower in 
obesity than in the non-obese state (Cu/ZnSOD: 1005±26 vs 1464±23U/g Hb and 
GSH-Px: 84.3±6.7 vs 98.4±3.3U/g Hb). Similarly, Ozata et al (2002) also reported 75% 
and 42% lower erythrocyte GSH-Px and Cu/ZnSOD activities in obese men (n=76) 
than in non-obese men (n=24). In rat models of diet-induced obesity, erythrocyte SOD 
and GSH-Px activities were reduced by 29-42% in the HFHC group compared with the 
control animals after the 8-week diet-induced obesity period (Beltowski et al., 2000). 
Other research have shown that individual antioxidant enzymes were enhanced in 
obesity (Vincent et al., 2001, Dobrian at al., 2000). Vincent et al (2001) found that 
Cu/ZnSOD activity in the left ventricles of rats was greater in the obese animals 
compared to lean controls (135 vs 117 IU/mg protein, P<0.05). Dobrian et al (2000) 
also reported increased activities of erythrocyte Cu/ZnSOD and GSH-Px after 10 
weeks of diet-induced obesity. They attributed the increases in these erythrocyte 
cytoprotective enzymes to their stimulation by oxidant stress. Olusi (2002) believed the 
discrepancies in antioxidant enzymes in obesity could be due to the duration of the 
obesity. For example, in the early days of the development of obesity, antioxidant 
enzymes may be stimulated whereas chronic obesity continually depletes antioxidant 
enzymes. Other antioxidant measures such as TAS and FRAP have been shown to be 
lower in obese persons compared to non-obese persons (Lopes et al., 2003; Fenkci et 
al., 2003). For example, FRAP values were 22% lower in obese than in non-obese 
matched controls [obese vs non-obese (271±15 vs 333±29pmol/L, P<0.05) (Lopes et 
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al., 2003)] and TAS values were moderately lower in obese persons compared to non- 
obese persons [obese vs non-obese (1.15±0.01 vs 1.30±0.02mmol/L, P<0.001) (Fenkci 
et al., 2003)]. It is unknown why this study did not demonstrate any significant 
differences between the normal-weight, overweight and obese groups for TAS, SOD 
and GSH levels. We can only speculate that it is possible that the obese group were 
averaging a transitional phase from developmental obesity to chronic obesity. 
Several mechanisms have been suggested to explain obesity-associated oxidant 
stress, which include increased 02 consumption, compromised antioxidant defence, 
cell injury/inflammation and increased fat deposition (Vincent et al 2001). In addition, 
hyperglycaemia, hypertension and hyperleptinaemia are also possible sources of 
increased oxidant stress in obesity (Vincent and Taylor, 2006). However, whether 
obesity-associated oxidant stress is a cause and effect relationship or due to obesity- 
related diseases i. e. hypertension, hyperlipidaemia, hyperleptinaemia and 
hyperglycaemia (Facchini et al 2000) remains unclear. Since all the subjects in this 
study were healthy (free of obesity-related diseases), it is possible that obesity in this 
study or other unknown factors caused increased oxidant stress. However, this study 
did not intend to identify the primary pathways linking obesity with increased oxidant 
stress levels. 
The study did set out to identify physiological and lifestyle factors that may contribute to 
the normal variability of the overall oxidant stress status in healthy subjects. To date, it 
is thought that only two studies (Keaney et al., 2003; Lesgards et al., 2002) have 
investigated the relationships between intrinsic, lifestyle and environmental factors and 
oxidant stress parameters. Since LH levels were shown to be significantly greater in 
the obese group compared to both the normal-weight and overweight-group, it seemed 
important to discuss potential physiological and lifestyle factors that may contribute to 
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the normal variability of LH levels in healthy subjects. Increased LH levels were 
positively associated with BMI, body fat, waist circumference, resting systolic blood 
pressure, resting diastolic blood pressure, triglycerides and vitamin A. In contrast, 
fasting glucose and HDL were negatively correlated with LH levels. Calorie intake, 
dietary composition intake and physical activity levels were not shown to correlate with 
LH levels. However, Lesgards et al (2002) assessed lifestyle factors in relation to 
overall antioxidant capacity and emphasised that non-smoking, vitamin and mineral 
supplementation, regular physical activity, high fruit consumption were all positively 
related to the individual antioxidant capacity. Keaney et al (2003) identified the clinical 
conditions associated with oxidant stress. In an age-adjusted model, increased urinary 
creatinine-indexed 8-epi-PGF2a was positively associated with female sex, hypertension 
treatment, smoking, diabetes, blood glucose, body mass index and a history of 
cardiovascular disease. Age and total cholesterol were negatively correlated with 
urinary creatinine-indexed 8-epi-PGF2q. The main differences in findings in this study 
compared to Keaney and colleagues and Lesgards and colleagues include the 
negative association between fasting blood glucose and LH levels and the lack of 
association between lifestyle and nutritional intake with LH levels. The variables found 
to be associated with LH in this study are discussed below, alongside other 
observational and interventional studies. 
This study and others (Yesilbursa et al., 2005; Keaney et al., 2003; Ozata et al., 2002; 
Davi et al., 2002; Dandona et al., 2001; Präznj' et al., 1999) have confirmed that a high 
BMI, waist circumference and body fat levels are associated with increased oxidant 
stress levels. The possibility of the obesity-associated oxidant stress has already been 
discussed. Both a high level of diastolic and systolic blood pressure was shown to be 
positively associated with increased LH levels in this study. However although 
Reckelhoff et al (2000) found a positive association between hypertension and LH in 
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hypertensive rats, this was not supported by Keaney et al (2003) in healthy men and 
women. But the lack of association between LH and hypertension in the study by 
Keaney et al (2003) may be a result of a third of subjects receiving anti hypertensive 
therapy, contributing to the discrimination of BP as a correlate of oxidant stress 
(Keaney et al., 2003). Other research suggests that the association of hypertension 
with oxidant stress only applies to certain causes of hypertension, such as those with 
high renin levels (Laursen et al., 1997) or salt sensitivity (Somers et al., 2000). 
In this study triglyceride levels were positively associated with LH levels. Similar 
findings were found by Bae et al (2001) who investigated the effect of postprandial 
hypertriglyceridemia in healthy individuals on endothelial function as related to 
enhanced oxidant stress, by measurement of vascular endothelial function and 
leukocyte 02 production. In response to hypertriglyceridemic stimuli (high fat meal), 
02 formation by leucocytes correlated with the degree of hypertriglyceridemia. In 
addition Hiramatsu and Arimori (1998) found that monocytes and polymorphonuclear 
cells released more 02 when exposed to plasma from hypertriglyceridaemic patients. 
Vitamin A was positively associated with LH levels in this study which supports 
epidemiological observational studies that low levels of vitamins A, E and C are 
associated with increased oxidant stress and CVD (Meagher, 2003; Dagenais et al., 
2000). However Block et al (2002) observed a significant inverse association between 
plasma vitamin A levels and malondialdehyde and F2-isoprostanes in healthy adults. 
Other investigators have also reported that plasma vitamin A is inversely associated 
with smoking (Ayaroi et al., 2000; Food and Nutrition Board, Institute of Medicine, 
2000). According to Chertow (2004) under some conditions, a vitamin may have 
oxidant effects. Giving too much of one vitamin in an altered redox environment may 
change its effect from an antioxidant to a pro-oxidant (Olson, 1996). Very little cross- 
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sectional population research on vitamin A and oxidative damage has been carried out, 
so arising to conclusions regarding vitamin A levels and oxidant stress is difficult. In 
view of this it would seem prudent not to supplement diets with vitamin A or carotene 
unless levels are pathologically low (Chertow, 2004). 
Research has indicated that hyperglycaemia is associated with increased levels of 8- 
epi-PGF2a (Keaney et al., 2003; Davi et al., 1999; Gopaul et al., 1995) and LHs 
(Nourooz-Zadeh et al., 1995). Similarly, urinary levels of 8-epi-PGF2a are increased in 
patients with type I and II diabetes and decrease significantly with aggressive control of 
hyperglycemia (Davi et al., 1999). Several mechanisms have been proposed to 
explain the link between hyperglycaemia and lipid peroxidation. Glucose may combine 
directly with LDL phospholipids or apo B lysine groups to form advanced glycation end 
products that facilitate lipid peroxidation (Bucala et al., 1993). In addition, auto- 
oxidation of glucose and nonenzymatic glycation of proteins may also generate 02 
(Baynes, 1991). Hyperglycaemia also induces the enzymatic production of 02 
through activation of NAD(P)H oxidase in vascular cells (Inoguchi et al., 2000). In this 
study, fasting blood glucose was negatively associated with LH levels of which is 
puzzling because hyperglycaemia is a well-known oxidant (Keaney et al., 2003; Davi et 
al., 1999; Gopaul et al., 1995). However because the majority of subjects in this study 
had normal fasting glucose levels, it is possible that we lost the discriminatory value of 
fasting blood glucose as a correlate of oxidant stress. 
HDL levels was also found to be negatively associated with LH levels which may be a 
result of an underlying mechanism linking obesity to oxidant stress, itself in turn 
contributing to obesity-related disease. For example, it appears that the formation of 
oxidised cholesterol as a result of lipid peroxidation leads ultimately to a decrease in 
HDL production (Ozata et al., 2002). 
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Finally, it was surprising that no association was found between LH levels, dietary 
intake and physical activity. Lesgards et al (2002) concluded that regular physical 
activity and high fruit consumption was positively related to individual antioxidant 
capacity. It is speculated that no association was found because the study population 
across the normal-weight, overweight and obese groups did not record wide 
differences in physical activity and nutritional habits. This could be because the 7-day 
food diary and physical activity questionnaire did not reflect true eating and lifestyle 
habits of the subjects. 
To define the relationship further between LH and indices of physical and biochemical 
factors, a multiple regression analysis was performed. The results demonstrated that 
30.3% of the variance in LH could be explained by the following variables, namely 
weight (standardized beta, 0.250, P<0.05), fasting glucose (standardized beta, -0.276, 
P<0.01), triglycerides (standardized beta, 0.234, P<0.05) and vitamin A (standardized 
beta, 0.258, P<0.01). All these (weight, fasting glucose, triglycerides and vitamin A) 
have been discussed above in relation to their effects on LH levels. Further research 
should aim to examine other potential factors which could lead to enhanced lipid 
peroxidation in obesity. 
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4.4 CONCLUSION 
This study is the first to identify that LH levels are not enhanced in subjects who are 
overweight compared to normal-weight subjects. Similar to other research LH levels 
were markedly higher in the obese group compared to the normal-weight group. In 
addition, independent of BMI, LH levels were enhanced in subjects who had a waist 
circumference above the cut-off waist circumference guidelines for increased risk of 
CVD compared to below the cut-off waist circumference guidelines. The above 
changes could not be related to either TAS, SOD or GSH because these were reported 
to remain unchanged. Following multiple regression analysis, 30.3% of the variance in 
LH could be explained by a negative association with fasting plasma glucose, and 
positive associations with dietary vitamin A intake, weight and plasma triglycerides. 
Care should be taken when interpreting the associations between LH and vitamin A 
and LH and fasting blood glucose as other studies have shown a negative association 
between LH and vitamin A and a positive association between LH and fasting blood 
glucose. 
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Chapter FIVE 
Study 2 
Platelet responsiveness in healthy normal-weight, overweight 
and obese subjects: Association with lipid peroxidation and 
total antioxidant status. 
5.0 INTRODUCTION 
Central obesity is a risk factor for atherosclerotic CVD (Grundy et al., 2002; McGill et 
al., 2002), which interferes with a balance between blood coagulation and fibrinolysis, 
leading to increased thrombogenesis or platelet aggregation (Davi et al., 2002; Haszon 
et al., 2002; Juhan et al., 1980). For example Davi et al (2002) found that gynoid 
obesity (n=25) increased 11 -dehydrothromboxane B2 compared to non-obese control 
values (n=24) (P<0.001), which was even greater in android obesity (n=24) when 
compared to non-obese subjects (p<0.001) (gynoid: 610 (421-759) android: 948 (729- 
1296) and non-obese 215 (184-253) pg/mg of creatine). Furthermore, android obesity 
had significantly higher 11 -dehydrothromboxane B2 when compared to gynoid obesity 
(p<0.001). Haszon et al (2002) investigated platelet aggregation (measured using 
collagen as an agonist with a laser rheoaggregometer) in hypertensive non-obese and 
obese children and age-sex matched non-obese and obese children. Hypertensive 
children in the non-obese and obese group and the normotensive obese children 
showed increased platelet aggregation. A significant positive correlation was also 
observed between the BMI values and percentage platelet aggregation in overweight 
children with or without hypertension (r=0.501, n=35, P<0.01). Juhan et al (1980) 
studied platelet aggregation in 81 obese subjects in relation to fat mass and fat 
distribution. Results of this work showed that platelet activity was not related to body 
weight and displayed no correlation or a slightly negative one to fat mass excess. 
However, platelet activity was significantly increased in cases where obesity 
predominated in the upper body. Alternative measures of platelet activity such as 
mean platelet volume have been shown to be higher in obese subjects (Coban et al., 
1992), which may also be an indicator of platelet activation (Park et al., 2002). 
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Various risk factors for atherosclerosis and cardiovascular thrombosis such as diabetes 
mellitus, hypertension and hypercholesterolemia are associated with ROS-mediated 
platelet aggregation (Davi et al., 2003; Minuz et al., 2002; Davi et al., 1997) which 
suggests that increased oxidant stress in obesity may contribute to persistent platelet 
aggregation. In support of this, Davi et al (2002) noted a significant correlation 
between urinary excretion rate of 8-iso PGF2a and 11-dehydro-TxB2 in gynoid and 
android obesity (r=0.61, P<0.001). Furthermore following multiple regression analysis, 
CRP level was found to predict the highest rates of both lipid peroxidation and platelet 
activation. To characterise the cause and effect of obesity on 8-iso PGF2a and 11- 
dehydro-TxB2 further, Davi et al (2002) examined the effects of a short-term weight loss 
program on changes in urinary 8-iso PGF2a and 11 -dehydro-TxB2 in 20 android obese 
women. Following successful weight loss (15.3±10.5kg) the rates of 8-iso PGF2a and 
11-dehydro-TxB2 excretion were significantly reduced, by 32% and 54% respectively. 
Changes in urinary 11-dehydro-TxB2 excretion correlated with the amount of weight 
loss (r=0.67, P=0.02) and the values of thromboxane metabolite excretion fell within the 
reference range by the end of the study. Therefore, increased oxidant stress in obesity 
maybe a mechanism linking obesity-associated oxidant stress with platelet activity. 
Apart from Davi et al (2002), no other study has observed an association between 
oxidant stress and platelet aggregation in obesity. 
Limited evidence is available on the relationship between obesity, platelet aggregation 
and oxidant stress which may be due to the problems associated with measuring 
platelet aggregation. For example `the gold standard measure of platelet aggregation' 
is platelet aggregometry which is both labour intensive and expensive (Lau et al., 
2002). In addition the reproducibility of results is dependent on controlling many 
factors: temperature, pH, aggregometer stir speed, platelet count, sample volume and 
venepuncture technique (White and Jennings, 1999). In this study, a new direct 
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measure of platelet aggregation is used. PlateletWorks® is an adaptation of platelet 
aggregometry and measures platelet aggregation in whole blood, which is devoid of 
long laborious techniques. The PlateletWorks"' has been evaluated by Lau et al 
(2002) who found that this novel-bed-side assay of platelet function was extremely 
suitable for the clinical environment (acute care settings of percutaneous coronary 
intervention and cardiopulmonary bypass). In addition PlateletWorks® was evaluated 
against platelet aggregometry in a preliminary experiment as part of this thesis, which 
demonstrated that PlateletWorks" was a cost-effective, quick, valid and reproducible 
measure of platelet aggregation. 
This study aimed to identify the effect of BMI (normal-weight, overweight, obese) on 
platelet count and percentage ADP-induced platelet aggregation. In addition the study 
aimed to identify whether increased oxidant stress in obesity was a determinant of 
platelet aggregation levels in obesity. 
5.1 METHODOLOGY 
Subject Characteristics 
The study group consisted of 45 subjects who were sex-matched between groups [15 
normal-weight (BMI: 22.4±0.34kg/m2), 15 overweight (BMI: 25.5±0.20kg/m2) and 15 
obese (BMI: 31.8±1.22kg/m2) healthy male and females (n=18/27)] (see table 5.0 for 
subject characteristics). Volunteers were invited to take part in the study by local 
advertisement. An inclusion criterion was age between 18 and 50 years old and BMI 
between 20 and 40kg/m2. Subjects with a history of diabetes, cardiovascular or 
cerebrovascular disease, hepatic or renal disease, tobacco abuse, or those on hormone 
replacement therapy were excluded. In addition subjects were excluded if they were 
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hypertensive (with or without treatment), taking treatment for dyslipidaemia, taking any 
antioxidant supplementations or a smoker. Written informed consent was obtained 
from all the subjects after they had been given a full explanation of the study. The 
research was given ethical approval by Bedfordshire Local Research Ethics 
Committee. 
Table 5.0. Subject characteristics 
Characteristic 
Age, yr 
BMI, kg/m2 
Body mass, kg 
Body fat, kg 
Waist, cm 
Systolic BP, mmHg 
Diastolic BP, mmHg 
Fasting glucose, mmol/L 
Fructosamine, mmo/L 
Total cholesterol, mmo/L 
HDL-cholesterol, mmol/L 
LDL-cholesterol, mmol/L 
Triglycerides, mmol/L 
Normal-weight 
(NW) (n=15) 
(m/f; 6/9) 
33.20 ± 2.40 
22.38 ± 0.34 
62.2±1.60 
17.79 ± 1.39 
74.98 t 1.32 
111.93 ±2.27 
74.2 ± 2.10 
6.80 ± 0.41 
Overweight Obese NW 
(OW) (n=15) (0) (n=15) vs 
P Value 
NW OW 
vs vs 
(m/f; 6/9) (m/f; 6/9) OW 00 
36.47 t 2.34 35.53 t 2.05 . 
33 
. 
519 
. 
663 
25.48 ± 0.20 31.75 ± 1.22 <. 001 <. 001 <. 001 
73.7 ±2.14 91.8 ±4.09 <. 001 <. 001 <. 001 
20.88 t 1.76 33.58 t 3.15 . 213 <. 001 <. 01 
82.44 ± 2.31 99.11 ± 2.92 <. 02 <. 001 <. 001 
123.13 t 3.25 128.73 t 3.19 <. 01 <. 001 . 309 
79.93 t 2.41 83.67 t 1.51 . 177 <. 01 <. 05 
5.80±0.35 7.49±0.65 
. 110 . 709 <. 05 
226.34 ± 18.58 220.92 ± 11.79 202.38 ± 13.83 . 487 . 
251 
. 
457 
4.45±0.24 5.19±0.36 4.95±0.23 
. 146 . 178 . 950 
1.72±0.10 1.63±0.14 1.37 t 0.16 . 520 . 068 . 350 
2.41 ± 0.25 3.18 ± 0.33 3.05±0.26 . 120 . 110 . 950 
0.70±0.05 0.83±0.07 1.17±0.19 
. 130 <. 02 . 237 
Values are expressed as the mean±SEM. BMI, body mass index; BP, blood pressure; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein. Results were compared 
using a Mann Whitney U-Test and P values are given in the Table. P values < 0.05 
were considered significant. For further details see text. 
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Experimental design 
Subjects visited the Centre for Obesity Research on one occasion between 9-12am 
and were instructed to fast for 10-12 hours and refrain from exercise, caffeine and 
alcohol intake for 48 hours before the study visit. Subjects were also told to maintain 
their usual dietary regimen. 
Anthropometric and cardiovascular measurements and venous blood sampling. 
Height, weight and waist measurements are described in detail in the methodology 
chapter (section 3.2.1,3.2.2,3.2.3). Body composition was assessed using the 
BodPod which is outlined in the methodology chapter (section 3.2.3.1). Cardiovascular 
measurements and venous blood sampling are described in the methodology chapter 
(section 3.3,3.1.1 and 3.1.2). 
Biochemical measurements 
LH, TAS, SOD and GSH were performed as described in the methodology chapter 
(section 3.1.12 and 3.1.13). Other biochemical measures included, fasting plasma 
glucose, plasma fructosamine, plasma cholesterol, plasma LDL, plasma HDL and 
plasma triglycerides as described in the methodology chapter (section 3.1.6.1,3.1.7, 
3.1.8,3.1.9,3.1.10 and 3.1.11). ADP-induced percentage platelet aggregation was 
also measured using PlateletWorks"', which is outlined in the methodology chapter 
(section 3.1.14.2). Final concentrations of ADP used were 10 and 20pM. 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value). The Kolmogorov-Smirno test 
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confirmed that the data was not normally distributed so was analyzed by non- 
parametric methods to avoid assumptions about the distribution of the measured 
variables. The Kruskal Wallis analysis of variance test was used to compare groups 
and the Mann-Whitney U-Test was used to evaluate the differences between two 
independent groups. Associations between parameters were assessed by the 
Spearman rank correlation test. P-values < 0.05 were regarded as statistically 
significant. Analyzes of data was performed out using a computer software package 
(SPSS for Windows, Version 13.0). 
5.2 RESULTS 
Subject characteristics for the normal-weight, overweight and obese groups are shown 
in table 5.0. Body mass and waist circumference all progressively increased 
significantly (P<0.05) with higher BMI values. Body fat (kg) was significantly greater in 
the obese group when compared to both the normal-weight (P<0.001) and overweight 
(P<0.01) groups but no significant difference in body fat (kg) was found between the 
normal-weight and overweight group. Blood pressure increased incrementally with 
higher BMI values but significant differences were only identified in resting diastolic 
blood pressure between the normal-weight and obese, (P<0.01) and overweight and 
obese (P<0.05) group and in resting systolic blood pressure between the normal- 
weight and overweight, (P<0.01) and normal-weight and obese (P<0.001) group. 
Other significant differences between groups with increasing BMI values included 
increased triglycerides (normal-weight vs obese, P<0.02) and increased fasting blood 
glucose values (overweight vs obese, P<0.05). All subjects had similar fructosamine 
levels, total cholesterol, LDL and HDL levels. 
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Mean values for LH, TAS, SOD and GSH for the normal-weight, overweight and obese 
groups are shown in table 5.1. LH increased with higher BMI values with the obese 
group demonstrating an increased trend towards higher LH levels compared to the 
normal-weight group [obese vs normal-weight (0.97±0.12 vs 0.67±0.58pmol/L, 
P=0.078)] and overweight group [obese vs overweight (0.97±0.12 vs 0.68±0.49pmol/L, 
P<0.078)]. TAS levels were also increased with higher BMI values with the obese 
group demonstrating significantly higher TAS levels when compared to the normal- 
weight group [normal-weight vs obese (661.42±34.24 vs 817.67±57.93mmol/L, 
P<0.05)]. No other significant differences were noted between groups in TAS, SOD 
and GSH. 
Table 5.1. LH, TAS, SOD and GSH values observed in the normal-weight, overweight 
and obese groups. 
Variable Normal-Weight Overweight Obese NW NW OW 
(NW) (OW) (0) Vs Vs vs 
(n=15) (n=15) (n=15) OW 00 
LH, pmol/L 0.67 t 0.58 0.68 t 0.49 0.97 t 0.12 . 756 . 078 . 078 
TAS, mmol/L 661.42 f 34.24 699.67 t 48.29 817.67 t 57.93 . 604 <. 05 . 101 
SOD, U/g Hb 3427.22 t 259.35 3507.67 t 247.95 2890.86 t 175.77 . 738 . 206 . 105 
GSH, pmol/g Hb 15.33 t 1.72 16.55 t 2.25 16.67 t 1.58 . 648 . 868 . 967 
Values are expressed as the mean±SEM. LH, lipid hydroperoxide, TAS, total 
antioxidant status, SOD, superoxide dismutase, GSH, reduced glutathione. Results 
were compared using a Mann Whitney U-Test and P values are given in the Table. P 
values < 0.05 were considered significant. For further details see text. 
The mean values for platelet count and percentage ADP-induced platelet aggregation 
for the normal-weight, overweight and obese groups are given in table 5.2 and figure 
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5.0. No significant differences were noted between normal-weight, overweight and 
obese groups in platelet count. But the degree of percentage ADP-induced platelet 
aggregation decreased with increasing BMI values at both ADP final concentrations of 
10 and 20pM. ADP-induced platelet aggregation with 20pM ADP significantly 
decreased the degree of platelet aggregation in the obese group when compared to 
both the normal-weight and overweight group [obese vs normal-weight (80.07±2.18 vs 
89.33±0.89%, P<0.001) obese vs overweight: (80.07±2.18 vs 85.47±1.51%, P<0.05)]. 
ADP-induced platelet aggregation with 10pM ADP produced a significant decrease in 
the degree of platelet aggregation in the obese group when compared to the normal- 
weight group and a decreased non-significant trend when compared to the overweight 
group [obese vs normal-weight (65.27±2.66 vs 75.2±2.21%, P<0.05) obese vs 
overweight (65.27±2.66 vs 72.53±2.29%, P=0.064)]. 
Further analyses was also carried out to identify the impact of waist circumference on 
platelet count and percentage ADP-induced platelet aggregation (see table 5.3). 
Current guidelines suggest a cut-off greater than 102cm in men and 88cm in women on 
the basis of causing increased risk of many metabolic risk factors such as 
hyperinsulaemia and hyperlipidaemia (Han et al., 1995). ADP-induced platelet 
aggregation with 20pM ADP produced a significant decrease in the degree of platelet 
aggregation above the cut-off waist circumference guidelines compared to below the 
cut-off waist circumference guidelines (81.27±2.28 vs 86.80±1.02%, P<0.05). However 
no significant differences were found between the two groups for percentage ADP- 
induced platelet aggregation with 10pM ADP and platelet count. 
The Spearman rank correlation test found that both LH and TAS were not associated 
with either platelet count and ADP-induced platelet aggregation (final ADP 
concentration, 10NM and 20pM) (see table 5.4). 
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Table 5.2. Platelet count and percentage ADP-induced platelet aggregation (final ADP 
concentration, 10pM and 20pM) in the normal-weight, overweight and obese groups. 
Variable Normal-Weight Overweight Obese NW NW OW 
(NW) (OW) (0) S Vs vs 
(n=15) (n=15) (n=15) OW 00 
Platelet count 224.40 t 13.2 205.57 ± 12.47 230.00 ± 10.54 . 
455 . 819 . 
229 
10PM 75.27 t 2.21 72.53 ± 2.29 65.27 ± 2.66 . 454 <. 
05 
. 064 
20pM 89.33 t 0.89 85.47 ±. 1.51 80.07 ± 2.18 . 076 <. 001 <. 05 
Values are expressed as the mean±SEM. 10 and 20pM, Final concentrations of ADP- 
induced platelet aggregation. Results were compared using a Mann Whitney U-Test 
and P values are given in the Table. P values < 0.05 were considered significant. For 
further details see text. 
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Figure 5.0. Percentage ADP-induced platelet aggregation (10pM and 20pM) in the 
normal-weight, overweight and obese groups. Results (meantSEM) were compared 
using Mann-Whitney U Test. (*, P<0.05, **, P<0.01). For further details see text. 
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Table 5.3. Platelet count and percentage ADP-induced platelet aggregation according 
to waist circumference guidelines [cut-off points, reduced CVD risk (<88cm for women 
and <102cm for men) and increased CVD risk (>88cm for women and >102cm for 
men)]. 
Variable Reduced CVD risk waist Increased CVD risk waist NW 
circumference (n=30) circumference (n=15) Vs OW 
Platelet count 215.08 ± 9.3 229.80 ± 9.46 . 263 
10pM 73.10 t 1.66 66.87: t 2.79 . 162 
20NM 86.80: t 1.02 81.27. t 2.28 . 027 
Values are expressed as the mean±SEM. 10 and 20µM, Final concentrations of ADP- 
induced platelet aggregation. Results were compared using a Mann Whitney U-Test 
and P values are given in the Table. P values < 0.05 were considered significant. For 
further details see text. 
Table 5.4. Correlation coefficients for the relationship between LH and TAS with 
platelet count and ADP-induced platelet aggregation (final ADP concentration, 10pM 
and 20pM) 
Variable LH TAS 
Spearman rho P value Spearman rho P value 
Platelet Count 
. 077 . 617 -. 083 . 590 
10 PM -. 143 . 348 -. 197 . 195 
20 pM . 013 . 934 -. 139 . 361 
0 and 20µM, Final concentrations of ADP-induced platelet aggregation. Results were 
analyzed using the Spearman rank correlation test and P values are given in the Table. 
P values < 0.05 were considered significant. For further details see text. 
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5.3 DISCUSSION 
It is well established that the risk of CVD is increased with the degree of obesity and 
abdominal obesity (Coleman et al., 1992) and oxidant stress-mediated platelet 
aggregation is a mechanism through which obesity may affect CVD morbidity and 
mortality (Davi et al., 2002). This study examined the effect of BMI (normal-weight, 
overweight and obese) on platelet count and percentage ADP-induced platelet 
aggregation. In addition the study investigated whether increased oxidant stress in 
obesity is a determinant of percentage ADP-induced platelet aggregation. 
The study group consisted of 45 healthy subjects normal-weight, overweight and obese 
subjects. Although not significant, LH levels were higher in the obese group compared 
to the normal-weight group and overweight group. TAS levels were significantly higher 
in the obese group compared to the normal-weight group but no other significant 
differences were noted between groups in TAS, SOD and GSH. It was surprising that 
LH levels were not significantly higher in the obese group, but this could be attributed 
to variable LH levels as a result of sampling handling and/or storage duration 
(Södergren et al., 1998). For example Södergren et al (1998) found that the storage of 
plasma at -70°C was associated with a variable degree of loss of detectable plasma 
hydroperoxides. In this study, data was collected over a period of 6-months so the 
initial samples collected may have been affected by a loss of detectable 
hydroperoxides. Alternatively, the reduced LH levels in the obese group may be due to 
a reduced number of morbid obese subjects as their inclusion is more likely to increase 
mean LH levels (Yesilbursa at al., 2005; Keany et al., 2003; Ozata at al., 2002; Davi at 
al., 2002; Dandona et al., 2001; Präzny et al., 1999). 
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No differences in platelet count was identified between the normal-weight, overweight 
and obese groups. Percentage ADP-induced platelet aggregation decreased with 
increasing BMI values at both ADP final concentrations of 10 and 20pM with the obese 
group demonstrating significantly reduced ADP-induced platelet aggregation compared 
to the normal-weight group. These results suggest reduced platelet in vitro 
aggregability in obese subjects, perhaps due to reduced sensitivity of receptor sites to 
specific agonists. The decreased sensitivity to ADP in this study is an expression of 
enhanced in vivo platelet reactivity, consequent to a release of intraplatelet aggregating 
substances causing a state of platelet exhaustion (Tozzi-Ciancarelli et at, 1997). 
Further analyses also showed that percentage ADP-induced platelet aggregation with 
20pM ADP was significantly reduced in subjects with a greater waist circumference 
(above the cut-off waist circumference guidelines for increased risk of CVD, women, 
>88cm and men, >102cm) compared to subjects with a waist circumference below the 
cut-off waist circumference guidelines. No other significant relationships between 
waist-circumference and platelet count and percentage ADP-induced platelet 
aggregation with 10pM ADP were found. Correlation analysis found no significant 
association between LH and percentage ADP-induced platelet aggregation and TAS 
and percentage ADP-induced platelet aggregation, which suggests that both LH and 
TAS are not determinants of platelet aggregation. 
This is the first study to demonstrate the impact of a range of BMI groups and waist 
circumference (normal-weight, overweight obese) on percentage ADP-induced platelet 
aggregation. In particular the impact of being overweight on obesity has not been 
studied and it is reassuring that being overweight does not enhance in vivo platelet 
reactivity. The finding that obesity does enhance platelet aggregation is in agreement 
with several other studies (Juhan et at, 1980; Davi et al., 2002; Haszon et at, 2003). 
Juhan et al (1980) found that platelet activity was significantly related to android 
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obesity. Davi et al (2002) found that obesity increased 11 -dehydrothromboxane B2 
(a 
marker of in vivo platelet activation), which was further enhanced in subjects with 
android obesity [non-obese vs gynoid obesity vs android obesity (187 (140-225) vs 275 
(220-349) vs 523 (393-685)] (non-obese vs gynoid obesity (P<0.001), non-obese vs 
android obesity (P<0.001) and gynoid obesity vs android obesity (P<0.001). Haszon of 
al (2003) concluded that both normal-weight and obese hypertensive and obese 
nonotensive children demonstrated increased platelet aggregation (measured using 
collagen as an agonist with a laser rheoaggregometer) which contributed to the 
development of hypertension and to the promotion of vascular damage. Haszon of al 
(2003) also found a significant correlation between BMI vales and platelet aggregation 
in overweight children with and with out hypertension (r=0.51, n=35, P<0.01). 
The increased platelet aggregation in obesity may be explained by the reduced 
sensitivity towards antiaggregating agents (Trovati of at, 1994; Trovati of at, 1996; 
Vinik of at, 2001). For example insulin has been shown to reduce platelet responses 
to agonists by activating the NO/cyclic nucleotide pathway, but because insulin 
responses are often blunted in obese subjects (Trovati of al, 1995), platelet responses 
to agonists are increased. Obese subjects also demonstrate platelet resistance to the 
NO donor glyceryl trinitrate (GTN) (Anfossi of at, 1998a) and to adenosine (Anfossi et 
at, 1998b) and show an impaired platelet deposition to collagen when submitted to 
euglycaemic insulin infusion in vivo (Westerbacka et at, 2002). The resistance to the 
agents noted above act via the anti-aggregating cyclic nucleotides, cAMP and cGMP, 
the main mediators of platelet anti-aggregation (Geiger, 2001). They act via specific 
protein kinases (Waldman of al., 1987; Butt of at, 1994) to block several steps of the 
agonist-induced elevation of cytosolic Ca 2+ (Yamanishi of at, 1983; Kawahara et at, 
1984), which is a basic mechanism of platelet activation (Rink and Sage, 1990). It is 
known that plasma levels of ß-thromboglobulin, platelet factor-4, P-selectin, and the 
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surface expression of lysosomal or granule proteins also play a role in platelet 
activation (Haas et al., 1999) but the Interaction between these factors and obesity has 
not yet been extensively studied and elucidated. 
Despite observing increased in vivo platelet reactivity and LH levels in obesity, this 
study found no association between oxidant stress and percentage ADP-induced 
platelet aggregation suggesting that oxidant stress does not mediate platelet 
aggregation. This was surprising because other research studies support that oxidant 
stress participates in the regulation of platelet activation (Krotz et al., 2004). Oxidant 
stress-mediated platelet aggregation has been found in several settings of risk factors 
for atherosclerosis and cardiovascular thrombosis, including diabetes mellitus, 
hypertension and hypercholesterolemia (Davi et al., 2003; Minuz et al., 2002; Davi et 
al., 1997). Davi et al (2003) examined whether 8-iso-PGF2 formation (index of in vivo 
lipid peroxidation) correlates with the rate of urinary 11 -dehydro-TXB2 (index of in vivo 
platelet activation) excretion in newly diagnosed diabetic children and adolescents and 
children and adolescents with longerstanding disease. Newly diagnosed diabetic 
patients had significantly higher urinary 8-iso-PGF2 excretion and urinary 11-dehydro- 
TXB2 excretion than patients with longerstanding disease (P<0.05). In addition a 
statistically significant linear correlation was found between 8-iso-PGF2 and 11- 
dehydro-TXB2 excretion rates in both groups of diabetic patients (newly diagnosed and 
longerstanding disease groups) (r=0.73, P=0.0001 and r=0.70, P'=0.001, respectively). 
Davi et al (2003) concluded that the enhanced lipid peroxidation and platelet activation 
in newly diagnosed diabetic patients may be related to an acute imflammatory 
response. For example Davi et al (2003) found that patients with the shortest duration 
of disease and with the highest IL-6 had the highest rates of in vivo lipid peroxidation 
and platelet activation. However IL-6 variability is only likely to explain a small 
percentage of the variability in lipid peroxidation and platelet activation as other 
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inflammatory mediators are likely also to be triggers of enhanced lipid peroxidation and 
platelet activation such as including tumor necrosis factor-a (TNF- a), interleukin (IL)- 
1B (Davi et al., 2003). Minuz et al (2002) examined whether oxidant stress Is 
enhanced resulting in persistent platelet activation in patients with renovascular 
disease (RVD) which is a rare form of secondary hypertension. Lipid peroxidation as 
reflected by urinary 8-iso-PGF2 excretion and platelet activation as reflected by urinary 
11-dehydro-TX2 excretion, were both significantly enhanced in hypertensive patients 
with RVD compared to a control group and patients with essential hypertension. A 
relationship between 8-iso-PGF2 and 11-dehydro-TXB2 was also observed in 
hypertensive patients with RVD (rs=0.48; n=20; P=0.032). Minuz et al (2002) attributed 
the biochemical link between lipid peroixidation and platelet activation to activation of 
the renin-angiotensin system. Davi et al (1997) found a statistically significant 
correlation between the rates of excretion of 8-epi-PGF2a and 11-dehydro-TXB2 in 
hypercholesterolemic patients who demonstrated significantly enhanced levels of 8-epi- 
PGF2a and 11-dehydro-TXB2 compared to control subjects. Lastly, Davi et al (2002) 
noted a significant correlation between urinary excretion rate of 8-iso PGF2a and 11- 
dehydro-TxB2 in gynoid and android obesity (r=0.61, P<0.001). To characterise the 
cause and effect of obesity further on 8-iso PGF2a and 11 -dehydro-TxB2further, Davi et 
al (2002) examined the effects of a short-term weight loss program on changes in 
urinary 8-iso PGF2ai and 11-dehydro-TxB2 in 20 android obese women. Following 
successful weight loss (15.3t10.5kg) the rates of 8-iso PGF2a and 11-dehydro-TxB2 
excretion were significantly reduced, by 32% and 54% respectively. Changes in urinary 
11-dehydro-TxB2 excretion correlated with the amount of weight loss (r=0.67, P=0.02) 
and the values of thromboxane metabolite excretion fell within the reference range by 
the end of the study. Therefore, increased oxidant stress in obesity maybe a 
mechanism linking obesity-associated oxidant stress with platelet activity. In contrast, 
this study failed to demonstrate a potential biochemical link between platelet 
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aggregation and lipid peroxidation measured as ADP-induced platelet aggregation and 
lipid hydroperoxides, respectively. The conflicting findings may be attributed to 
methodological differences such as measurement of ADP-induced platelet aggregation 
which may measure different aspects of platelet activation and may 
differ in terms of 
sensitivity compared to the markers of platelet activation used in plasma 
in the above 
studies (Kamath et al., 2001). Possible variations in LH levels due to sampling 
handling and storage conditions (Södergren et al., 1998) may also have affected the 
identification of a biochemical link between lipid peroxidation and platelet aggregation. 
Several in vitro experimental approaches have been used to investigate the specific 
role for distinct ROS on platelets. Platelets exposed directly to H202 have caused 
divergent results. Inhibited ADP-dependent platelet activation (Ambrosio of al., 1994), 
enhanced collagen-dependent platelet activation and enhanced arachidonic acid (AA)- 
dependent platelet activation (Practio of al., 1992) have all been observed. The 
discrepancy in results may be caused by different antioxidant capacities of the buffers 
used in the studies (Krotz et al., 2004). Platelets exposed to 02 have shown a 
reduction in the threshold for platelet activation to thrombin, collagen, ADP or AA and 
induced spontaneous aggregation (Handin et al., 1977; Krotz of al., 2002; Salvemini et 
a/., 1989; De la Cruz et a/., 1992). 02'" also reacts with platelet or endothelium-derived 
NO to OONO'. The decreased bioavailability of NO is of particular importance for 
vascular thrombosis since NO is a potent inhibitor of platelet activation (Krotz et aL, 
2004). OONO" has also been shown to produce a dual effect on platelets. It activates 
platelets in normal buffer and inhibits them when in plasma (Moro of al., 1994; Brown of 
al., 1998). In addition to exogenously derived ROS affecting the regulation of platelet 
activation, recent data also suggests that the platelets themselves generate ROS. The 
release of 02 and other ROS by activated platelets was first observed by Marcus 
(1977). The platelet isoform of NAD(P)H-oxidase has been shown to produce 02'' and 
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enhance the recruitment of platelets by inactivating a platelet ectonicleotidase, thereby 
increasing the bioavailability of ADP (Krotz et al., 2002). A variety of other enzymes 
are capable of producing ROS in platelets such as NO synthase (Wolin et al., 2002) 
and phospholipase A2 (Caccese et al., 2000). 
5.4 CONCLUSION 
Percentage ADP-induced platelet aggregation progressively decreased with increasing 
BMI values but only obese subjects had significantly decreased ADP-induced platelet 
aggregation compared to normal-weight control subjects (expression of enhanced in 
vivo platelet reactivity). Waist circumference above the cut-off guidelines for increased 
CVD risk also showed a tendency for decreased percentage ADP-induced platelet 
aggregation levels when compared to a waist circumference below the cut-off 
guidelines for reduced CVD risk. The in vitro altered platelet behaviour observed in 
obesity, may be considered an expression of exhausted platelet reactivity to in vivo 
stimulation and maybe the underlying cause for increased risk of CVD (Davi et at, 
2002). Various risk factors for atherosclerosis and cardiovascular thrombosis such as 
hypercholesterolemia, diabetes mellitus and hypertension are associated with oxidant 
stress-mediated platelet aggregation (Davi et at, 2003; Minuz et at, 2002; Davi et al., 
1997), which suggests that increased oxidant stress in obesity may contribute to 
persistent platelet aggregation. However this study does not support the biochemical 
link between oxidant stress and platelet aggregation when measuring lipid 
hydroperoxide levels and percentage ADP-induced platelet aggregation. 
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Chapter SIX 
Study 3 
The effects of short-term dietary intervention for weight loss 
on lipid peroxidation and total antioxidant status. 
6.0 INTRODUCTION 
Obesity treatment typically promotes long-term adherence to a well-balanced weight 
loss promoting diet, which emphasises restriction of fat intake (British Nutrition 
Foundation, 2003). However these diets are often associated with modest weight loss 
(Brehm et aL, 2003), poor compliance (Westerterp et aL, 1996), and weight regain in 
the long term (Toubro and Astrup, 1997) and there has been a concomitant increased 
trend in the use of short term bouts of 'crash' dieting and carbohydrate restriction e. g. 
the Atkins Diet (Atkins, 1992) which typically promotes rapid weight loss in the first few 
days or weeks (Atkins, 1992). Possible mechanisms accounting for the increased 
weight loss on the LowCD include the simplicity of the diet (restricting food choices) 
(Foster et al., 2003), alterations in central satiety factors (Foster et al., 2003), dietary 
adherence (Foster et al., 2003), glycogen depletion (Astrup et al., 2004) and 
associated water loss (Astrup et al., 2004). 
The LowCD derives large proportions of calories from fat and protein (Atkins, 1992), 
which may potentially have a detrimental impact on the risk of CVD (Blackburn et aL, 
2001). Increased consumption of saturated fat has been linked to an adverse lipid 
profile (Law, 2000), glucose intolerance (Marshall et al., 1997) and obesity (Bray and 
Popkin, 1998). However improvements in conventional CVD risk factors have been 
found on the LowCD such as triglyceride and HDL-cholesterol concentration and 
insulin sensitivity (Astrup et al., 2004) which may be attributed to weight loss. The 
effects of a LowCD on more novel CVD risk factors such as oxidant stress as yet is 
unknown (Hayden and Reaven, 2000) but it is important to explore these as 
conventional CVD risk factors do not fully explain the observed rates of coronary heart 
disease (Reaven, 1997). 
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Since the early 1990's, it has been accepted that oxidant stress plays a critical role in 
the pathogenesis of endothelial dysfunction (Loscalzo, 2003). Systemic processes 
that invoke endothelial dysfunction include stress-induced activation of intracellular 
oxidative signalling (Cai and Harrison, 2000), with secondary oxidative modulation of 
low density lipoprotein oxidation (LDLOx) (Witztum, 1994) and NO bioavailability 
(Williams et al., 2002). These processes may be modulated by factors such as 
obesity (Williams et al., 2002), weight loss (Higashi et al., 2003) and dietary 
composition (macronutrient and micronutrient intake) (Roberts et al., 2002). 
Several research studies have reported that obesity was associated with increased 
oxidant stress in humans (Yesilbursa et al., 2005; Mohn et aL, 2005; Keaney et al., 
2003; Ozata et al., 2002; Davi et al., 2002; Dandona et al., 2001; Präzny et al., 1999) 
i. e. increased free-radical production and/or depleted cellular antioxidant defence 
systems (Powers et aL, 2004). The proposed mechanisms that may underlie the 
obesity-related oxidant stress include, increased 02 consumption (i. e. mechanical 
overload) and subsequent radical production via mitochondrial respiration, diminished 
antioxidant capacity, increased fat deposition and cell injury causing increased rates 
of radical formation such as 02 and OH" (Vincent et al., 2001). In addition, 
hyperglycaemia, hypertension and hyperleptinemia are also possible sources of 
increased oxidant stress in obesity (Vincent and Taylor, 2006). These abnormalities 
have been shown to be reversible with weight loss (Davi et al., 2002; Vincent et al., 
2001). The macronutrient composition of diets may also influence the oxidant- 
antioxidant balance For example, high-fat (Slim et aL, 1996) and high-sugar diets 
(Faure et aL, 1997) have been shown to induce oxidant stress, whilst a reduced fat 
and reduced sugar intake reduces oxidant stress (Roberts et al., 2002). The quantity 
and composition of dietary fat may also affect fat-soluble anti-oxidative vitamin intake 
and/or anti-oxidative capacity and lipid peroxidation status (Velthuis-te Wierik et al., 
1996). Fat in food serves as a carrier for fat-soluble vitamins, so reduced-fat foods 
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may adversely affect the availability of fat-soluble vitamins and potentially reduce anti- 
oxidative capacity (Velthuis-te Wierik et al., 1996). In addition to the long-term effects 
of dietary intervention, it has been shown that following an acute high fat meal or 
glucose load, free-radical production is enhanced (Vogel et al., 1997; Dandona et aL, 
2001). The independent contributions of changes in dietary macro-nutrient 
composition, energy restriction and weight loss on reducing oxidant stress, to date 
remain unclear (Fenster et aL, 2002). 
The present studies aimed to investigate the effects of two commercially available diet 
plans for weight loss i. e. LowCD and ConvD (Slimming World) versus a control diet 
(CtrID) on LH, TAS, SOD and GSH in healthy overweight women. 
6.1 METHODOLOGY 
Subject Characteristics: 
Thirty (n=30) overweight women participated in the study (see table 6.0 for subject 
characteristics). Inclusion criteria were: age between 18 and 50 years and BMI 
between 25 and 33kg/m2. Exclusion criteria included recent compliance (minimum 2 
weeks) to a dietary regimen for weight loss within the last 3-months, clinically 
significant physician-diagnosed illnesses such as diabetes or hypertension, physician 
prescribed hypotensive or lipid-lowering medications, taking medications affecting 
body weight such as Orlistat and Sibutramine, or any form of antioxidant therapy, and 
pregnancy or lactation. Written informed consent was obtained from all the subjects 
after they had been given a full explanation of the study. The research was approved 
by De Montfort University Ethics Committee. 
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Table 6.0. Subject characteristics. 
Characteristic LowCD ConvD CtrID LowCD LowCD ConvD 
(N = 12) (N = 12) (N = 6) vs vs vs 
ConvD CtrID Ctrld 
Age, jr 39.8 t 2.75 41.5 ± 1.86 36.8 ± 3.29 . 882 . 
763 . 525 
Body mass, kg 84.4 ± 2.91 84.1 ± 2.96 75.6 ± 2.68 . 940 . 
088 . 112 
BMI, kg/m 30.2 ± 0.84 31.2 ± 0.80 28.7 ± 1.26 . 412 . 
481 . 192 
Body fat, kg 32.3 ± 2.16 32.6 ± 2.14 26.1 ± 2.01 . 923 <. 
05 . 075 
Waist circumference, cm 95.6 ± 3.58 96.6 ± 3.31 89.3 ± 5.60 . 984 . 558 . 475 
Systolic BP, mmHg 125.2 ± 3.87 123.6 ± 3.95 114.7 ± 3.70 . 847 . 
104 . 236 
Diastolic BP, mmHg 84.6 ± 3.16 84.2 ± 2.96 76.8 ± 2.90 . 869 . 170 . 
344 
Total cholesterol, mmoVL 5.7 ± 0.53 5.3 ± 0.50 5.1 t 0.59 . 789 . 209 . 542 
LDL cholesterol, mmoVL 3.60 t 0.42 3.59: t 0.41 3.14t 0.45 . 916 . 116 . 068 
HDL cholesterol, mmoVL 1.68±0.24 1.16 t 0.22 1.54: t 0.26 . 173 . 604 . 586 
Triglycerides, mmoVL 0.8 ± 0.11 0.9 ± 0.10 1.0 ± 0.11 . 362 . 282 . 847 
Fasting Glucose, 4.71 t 0.19 4.76 t 0.18 4.64 t 0.21 . 121 . 264 . 300 
mmoVL 
Values expressed as the mean±SEM. BMI, body mass index; BP, blood pressure; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein. Results were compared using a 
Scheffe multiple comparison test and P values are given in the Table. P values < 0.05 
were considered significant. For further details see text. 
Experimental design 
The volunteers were randomly assigned to follow either the LowCD (Atkins Diet), 
ConvD (Slimming World Diet) or CtrlD (Control). On the LowCD, volunteers were 
instructed to follow an ad libitum diet with a maximum intake of 20g carbohydrate/day, 
which induced ketosis (as shown in all volunteers on the LowCD by using a urinary 
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ketone kit). After 2 weeks of dieting, volunteers increased their intake of carbohydrate 
to 40-60g/d if self-testing of urinary ketones continued to indicate ketosis. Volunteers 
following the LowCD were also instructed to take a daily multivitamin (Holland & Barrett 
Multivitamin, ABC Plus) as recommended in the Atkins Diet. On the ConvD, volunteers 
followed the Slimming World Diet, which meets the guidelines of the Balance of Good 
Health (British Nutrition Foundation, 2003) i. e. high carbohydrate (60% of total kcal 
intake) / low fat (<30% of total kcal intake) and moderate protein (12% of total kcal 
intake) content. Volunteers following the CtrlD were instructed to continue their usual 
dietary regime. 
The study was conducted over a 7-week period. All subjects completed a 2-week 
baseline period, 4-week weight loss programme and a 1-week post-diet follow-up. The 
subjects attended the research laboratory weekly on the same day until the study was 
completed. During each visit, volunteers had blood samples taken, underwent 
anthropometric assessments and volunteers following the LowCD and ConvD received 
additional dietary advice. 
Anthropometric and cardiovascular measurements and venous blood sampling 
Height, weight and waist measurements are described in detail in the methodology 
chapter (section 3.2.1,3.2.2,3.2.3). Body composition was analyzed using the BIA 
(BodyStat® Quadscan 4000) which is outlined in the methodology chapter (section 
3.2.4.1). Cardiovascular measurements and venous blood sampling are described in 
the methodology chapter (section 3.3,3.1.1 and 3.1.2). 
159 
Food diary 
Dietary intake was monitored using a 3-day weighed food diary, which was 
subsequently analyzed for macro-micronutrient content using dietary analysis software, 
Compeat (methodology chapter, section 3.8). 
Biochemical measurements 
LH, TAS, SOD and GSH were performed as described in the methodology chapter 
(section 3.1.12 and 3.1.13). Other biochemical measures included, fasting plasma 
glucose, plasma fructosamine, plasma cholesterol, plasma LDL, plasma HDL and 
plasma triglycerides as described in the methodology chapter (section 3.1.6.1,3.1.7, 
3.1.8,3.1.9,3.1.10 and 3.1.11). 
Statistics 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value or the mean change or improvement). 
The Kolmogorov-Smirno test confirmed that the data was normally distributed. Data 
was analyzed using ANOVA with repeated measures which is an appropriate method 
for detecting differences between groups, time effects and interactions. A two way 
(AxB) mixed analysis of variance (ANOVA) was used which incorporated one between 
group (groups: LowCD vs ConvD cs CtrlD) and one within (time: baseline vs Wk 1 vs 
Wk 2 vs Wk 4) subjects factor. When significant F values were noted, post hoc 
analyzes were performed with a Scheffe multiple comparison test. Paired t-tests were 
used to detect specific differences within groups at certain time points during the study. 
Relationships between dietary intake and biochemical parameters were examined 
using Pearson's test of linear correlation. P-values < 0.05 were regarded as 
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statistically significant. Analyzes of data were carried out using a computer software 
package (SPSS for Windows, Version 13.0). 
6.2 RESULTS 
Subject characteristics for the LowCD, ConvD and CtrlD group are shown in table 6.0. 
The majority of parameters were similar between the three groups at the beginning of 
the study; age, BMI, waist circumference, blood pressure, fasting lipid profile and 
fasting glucose, except for body fat levels. Body fat was significantly higher in the 
LowCD group when compared to the CtrID group (32.3±2.16 vs 26.1±2.01 kg, P<0.05), 
however there was no significant difference in body fat between the ConvD and CtrID 
group (32.6±2.14 vs 26.1±2.01 kg). 
Weight loss and Changes in Body Composition 
Following the 4-week dietary intervention both the LowCD and ConvD groups 
demonstrated significant weight loss [LowCD vs ConvD (mean, -4.88t1.28kg, P<0.001 
vs. -3.14t1.76kg, P<0.001, respectively)] with the LowCD achieving a greater weight 
loss when compared to the ConvD (P=0.01). Despite advice to maintain their habitual 
dietary regimen and physical activity, the CtrID group did lose weight over the 4-weeks 
but this was not statistically significant (-1.2±0.82kg, P>0.05). In terms of body 
composition, following the 4-week dietary intervention both the LowCD and ConvD 
groups demonstrated significant mean fat loss [LowCD vs ConvD (-2.34±0.47kg, 
P<0.001 vs -3.6±0.58kg, P<0.001)]. Although the ConvD resulted in the greatest fat 
loss over 4-weeks, this was not significantly different when compared to fat loss in the 
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LowCD group (P>0.05). The CtrID group demonstrated no significant change 
in fat 
mass (-0.89±0.96kg, p>0.05) (see table 6.1). 
Table 6.1. Body weight and body fat during the study period (baseline and week 1,2 
and 4 of the dietary intervention period) on the LowCD, ConvD and CtrID. 
Group Baseline Week 1 Week 2 Week 4PPP 
group time interact 
Weight (kg) 
LowCD 84.4±2.78 81.6±2.86****'* *t 81.4±2.93* "l 79.5±2.89*** "m *t 
ConvD 84.0±2.96 82.6±2.90* 82.0±2.87'Nl 80.9±2.7411" 0.001 0.000 0.000 
CtrID 75.6±3.99 75.5±4.20 74.7±4.14* 74.4±4.23 
Group Baseline Week 1 Week 2 Week 4PPP 
group time interact 
Total Body Fat (kg) 
LowCD 32.2±1.74 31.0±1.82" 30.3±1.88'g* 30.0±1.784" 
ConvD 32.6±2.14 31.3±2.15" 30.1±2.021" 29.0±1.93* "0 0.135 0.000 0.032 
CtrID 26.1±2.20 25.5±2.62 25.3±3.00* 25.2±2.76 
Values expressed as the mean±SEM. LowCD, low carbohydrate diet, ConvD, 
Conventional diet, CtrlD, control diet. Results were analyzed using ANOVA with 
repeated measures. P values < 0.05 were considered significant. For further details 
see text. 
* P<0.05, "** P<0.001 denotes values compared to CtrlD group 
P<0.05, P<0.01, ana P<0.001 denotes values compared to baseline levels. 
It P<0.01 denotes difference between LowCD group and ConvD group. 
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Food Intake 
Food intake data is summarized in table 6.2. Mean total daily calorie Intake was 
significantly reduced on both the ConvD and LowCD by approximately one-third versus 
baseline values [baseline vs 4-week diet (ConvD (1848±127 vs 1229±69kcal), LowCD 
(1438±89 vs 1032±7Okcal), P<0.01)], but did not change significantly on the CtrID 
[baseline vs 4-week diet (1491±366 vs 1612±203kcal, P>0.05)]. Mean fat intake 
(percentage of total calorie intake) was significantly lower (-24%) on the ConvD 
[baseline vs 4-week diet (38.5±1.7 vs 29.1±1.2%, P<0.001)] and % fat intake higher 
(+55.2%) on the LowCD [baseline vs 4-week diet (37.1±2.1 vs 57.6±2.1%, P<0.001)]. 
Fat intake was unchanged in the CtrID. When expressed in grams, mean fat intake 
was significantly lower on the ConvD [baseline vs 4-week diet (80.5±7.59 vs 
40.4±3.25g, P<0.001) but did not show any significant changes in both the LowCD and 
CtrID. Mean carbohydrate intake (percentage of total calorie intake) was significantly 
higher (+13.6%) on the ConvD [baseline vs 4-week diet (43.8±1.5 vs 49.8±1.2%, 
P<0.01)] and was significantly reduced (-77%) on the LowCD [baseline vs 4-week diet 
(41.4±2.8 vs 9.2±1.5%, P<0.01)], but unchanged on the CtrlD. When expressed in 
grams, carbohydrate intake was significantly reduced following the LowCD [baseline vs 
4-week diet (160.2±16.14 vs 24.3±3.56g, P<0.001)] and the ConvD [baseline vs 4- 
week diet (213.9±14.15 vs 162.6±9.75g, P<0.05)] but the degree of reduction was 
greater following the LowCD compared to the ConvD (-85% vs -24%). No changes in 
carbohydrate intake expressed in grams was found on the CtrID. Mean protein intake 
(percentage of total calorie intake) increased on the ConvD (+23%) [baseline vs 4- 
week diet (15.3±0.50 vs 18.9±0.71%, P<0.01)] and on the LowCD (+78%) [baseline vs 
4-week diet (18.4±1.2 vs 32.8±1.8%, P<0.01)]. Mean protein intake (percentage of 
total calorie intake) was unchanged on the CtrID. When expressed in grams, mean 
protein intake decreased on the ConvD [baseline vs 4-week diet (69.8±4.14 vs 
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57.2±2.43g, P<0.05)], increased on the LowCD [baseline vs 4-week diet (66.0±5.51 vs 
81.1±6.26g, P<0.05)] and was unchanged on the CtrlD. Over the course of the four- 
week dietary intervention, the main between group differences in dietary intake 
expressed in grams were significantly greater fat intake on the LowCD compared to the 
ConvD (P<0.001), significantly lower carbohydrate intake on the LowCD compared to 
the ConvD (P<0.001) and CtrID (P<0.001) and significantly greater protein intake on 
the LowCD when compared to the ConvD (P<0.001). No significant differences in fat 
intake and protein intake was found between the LowCD and CtrlD. 
Table 6.2. Dietary composition at baseline and mean values for the four-week dietary 
intervention periods on the LowCD, ConvD and CtrlD. 
P 
Group Baseline Diet period P group P time interact 
KCAL LowCD 1438.1 t 88.53" 1031.6. t 70.38" 
ConvD 1847.8±126.581 1229.2 t 69.21 *" P<0.011 0.002 P<0.012 
CtrID 1490.6 ± 366.19 1611.8 ± 203.20 
FAT (%) LowCD 37.1 t 2.08 57.6: t 2.06118"' 
ConvD 38.5: t 1.68 29.1 t 1.24"o 
CtrID 36.6: t 1.70 34.0: L 1.94 
FAT (g) LowCD 58.3 ± 3.93 66.7 ± 5.85t' 
ConvD 80.5: t 7.59 40.4 t 3.25'01x 
CtrID 69.6 ± 9.13 62.6 ± 10.33 
CARBOHYD 
RATE (%) LowCD 41.4 ± 2.75 9.2: t 1.45"****ttt 
P<0.001 0.035 P<0.001 
0.806 P<0.01 P<0.001 
ConvD 43.8 ± 1.51 49.8 ± 1.12" P<0.001 P<0.001 P<0.001 
CtrID 50.1 t 2.07 48.0: t 2.05 
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CARBOHYD 
RATE (g) LowCD 160.2: t 16.14 24.3. t 3.56***###ttt 
ConvD 213.9: t 14.15 162.6: t 9.75*1 P<0.001 P<0.001 P<0.001 
CtrID 220.9 t 29.22 202.5 ± 20.99 
PROTEIN 
(%) LowCD 18.4: t 1.21 32.8: t 1.76"Ns***trt 
ConvD 15.3 ± 0.50 18.9 ± 0.71 "m P<0.001 P<0.001 P<0.001 
CtrID 15.1 ± 0.82 15.8 t 0.88 
PROTEIN 
(g) LowCD 66.0: t 5.51 81.1 t 6.26"tt 
ConvD 69.8 ± 4.14 57.2 ± 2.43" . 284 0.918 
P<0.01 
CtrID 66.1 ± 11.24 63.3 t 8.31 
Values expressed as the mean±SEM. LowCD, low carbohydrate diet, ConvD, 
Conventional diet, CtrID, control diet. Results were analyzed using ANOVA with 
repeated measures. P values < 0.05 were considered significant. For further details 
see text. 
* P<0.05, ** P<0.01, *** P<0.001 denotes values compared to CtrlD group 
P<0.05, P<0.01, ### P<0.001 denotes values compared to baseline levels. 
P<0.05, tt P<0.05, ttt P<0.001 denotes difference between LowCD group and ConvD 
group. 
Figures 6.0,6.1,6.2 and 6.3 show the results for lipid peroxidation and antioxidant 
status measures as LH, TAS, the intracellular antioxidant defence GSH and the free- 
radical scavenging enzyme SOD. 
In comparison to baseline levels, subjects following LowCD demonstrated variable LH 
levels. An initial non-significant trend for increased levels at week 1 was apparent 
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(P=0.08), followed by a significant increase at week 2 (P<0.05), which returned to near 
baseline levels at week 4 (P>0.05). LH levels did not change significantly on the 
ConvD (P>0.05) but on the CtrID there were slight fluctuations e. g. LH levels 
increased at week 1 (P<0.05) but this returned to baseline level at week 2 (P>0.05). 
Baseline 
I 
Wk1 Wk2 
i 
i 
Wk4 
Q ConvD 
Q LowCD 
  CtrID 
Week 
Figure 6.0. LH levels (pmol/L) at baseline and during the four-week dietary intervention 
on ConvD, LowCD and CtrlD. 
ConvD, conventional diet, LowCD, low carbohydrate diet, CtrID, control diet. Results 
(mean±SEM) were analyzed using ANOVA with repeated measures. (*, P<0.05). For 
further details see text. 
In comparison to baseline levels, subjects following LowCD demonstrated increased 
TAS during the four-week intervention period (week 1, P<0.05; week 2, P<0.05 and 
week 4, P<0.001). No changes in TAS were found during the four-week intervention 
period in the ConvD. In the CtrID, TAS significantly increased compared to baseline 
level at week 2 of the four week intervention period (P<0.05), but returned to near 
baseline levels at week 4. 
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Figure 6.1. TAS levels (pmol/L) at baseline and during the four-week dietary 
intervention on ConvD, LowCD and CtrlD. 
ConvD, conventional diet, LowCD, low carbohydrate diet, CtrID, control diet. Results 
(mean±SEM) were analyzed using ANOVA with repeated measures. (`, P<0.05, 
p<0.001). For further details see text. 
No significant changes were noted in GSH levels and SOD activity following 4-weeks of 
dietary intervention in all diet groups. However there were non-significant trends for 
higher GSH and SOD levels in the LowCD group following the 4-week dietary 
intervention when compared to baseline level (P = 0.066 and P=0.075 respectively). 
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Figure 6.2. GSH levels (pmol/g Hb) at baseline post four-week dietary intervention on 
ConvD, LowCD and CtrlD. 
ConvD, conventional diet, LowCD, low carbohydrate diet, CtrlD, control diet. Results 
(mean±SEM) were analyzed using ANOVA with repeated measures. (*, P=0.06). For 
further details see text. 
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Figure 6.3. SOD levels (U/g Hb) at baseline post four-week dietary intervention on 
ConvD, LowCD and CtrID. 
ConvD, conventional diet, LowCD, low carbohydrate diet, CtrID, control diet. Results 
(mean±SEM) were analyzed using ANOVA with repeated measures. (', P=0.08). For 
further details see text. 
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6.3 DISCUSSION 
This study investigated the short-term effects of either a LowCD or 
ConvD, versus a 
control group, on LH, TAS, SOD and GSH in overweight healthy women. 
Increased consumption of saturated fat has been linked to an increased risk of CVD 
because of associations with increased plasma concentrations of lipids (Law, 2000), 
glucose intolerance (Marshall et al., 1997) and obesity (Bray and Popkin, 1998). The 
LowCD typically has a high proportion of saturated fat consumption (Atkins, 1992). 
Despite this, a recent study indicated that both the LowCD and ConvD may have 
favourable effects on lipoprotein subfractions and inflammatory processes over a 6- 
month period, so the effects of dietary intervention on cardiovascular risk factors may 
be more complex (Astrup et al., 2004). However such improvements may be in 
response to decreased calorie consumption (Roberts et al., 2002; Velthuis-te Wierik et 
al., 1996). In light of these conflicting findings, this study investigated whether the 
LowCD adversely affected related factors relating to cardiovascular health such as 
oxidant stress parameters, which to date have not been widely studied. 
Evidence suggests that high-fat (Slim et al., 1996) and high-sugar diets (Faure et al., 
1997), can induce oxidant stress, by producing radical-producing substances 
(polyunsaturated fatty acids) (Vogel et al., 1997) and/or reduced antioxidant 
substances such as vitamin E and C (Vogel et al., 1997). In addition to long-term 
dietary effects, it has been shown that following an acute high fat meal or glucose load, 
free-radical production is enhanced (Vogel et al., 1997; Dandona et al., 2001, 
respectively). This can make studying the effect of macro-nutrients on oxidant stress 
difficult as it is unknown whether observed increases in ROS were due to excess 
calorie consumption or metabolic alterations associated with obesity (Fenster et al., 
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2002). Evidence suggests that reduced energy Intake (reduced fat products) 
contributes to a reduction In MDA level (Velthuis-to Wierik et aL, 1996), and energy 
restriction (without malnutrition) retards the development of atherosclerosis, due to a 
reduction in 02 molecules within the mitochondria, thereby lowering ROS (Ramsey et 
aL, 2000). The independent contributions of changes in dietary Intake (macro and 
micro-nutrient composition), energy restriction and weight loss on reducing oxidant 
stress, still remains unclear (Fenster of al., 2002). 
At the beginning of the study all thirty overweight women had similar baseline subject 
characteristics. For example age, BMI, waist circumference, blood pressure, fasting 
lipid profile and fasting glucose were not significantly different between each diet group 
when randomised. However body fat was significantly higher in the LowCD when 
compared to the CtrID group (32.3±2.16 vs 26.1±2.01kg, P<0.05). Surprisingly, there 
were no significant differences in body fat between ConvD and CtrOD (32.6±2.14 vs 
26.1±2.01 kg), despite the mean and standard deviation of the ConvD being similar to 
the LowCD. Following the 4-week dietary intervention both the LowCD and ConvD 
groups demonstrated significant weight loss (-4.88±1.28kg, P<0.001 vs. -3.14±1.76kg, 
P<0.001, respectively) with the LowCD achieving a greater weight loss when compared 
to the ConvD (P=0.01). In terms of body composition, following the 4-week dietary 
intervention both the LowCD and ConvD groups demonstrated significant fat loss 
(-2.34±0.47kg, P<0.001 vs -3.6±0.58kg, P<0.001, respectively). Although the ConvD 
resulted in the greatest fat loss over 4 weeks, this was not significantly different when 
compared to fat loss on the LowCD (P>0.05). It is possible that the greater weight loss 
on the LowCD is a result of greater glycogen depletion (Astrup of al., 2004) and 
associated water loss (Astrup of al., 2004). 
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Following the four week dietary intervention In the LowCD, TAS Increased significantly 
at week 4, LH significantly increased at week 1 and 2 and decreased at week 4 and 
both SOD and GSH showed a non-significant Increased trend at week 4. These 
changes could reflect initial increased susceptibility to free-radical production, Induced 
perhaps by the change in macronutrient content (Slim of al., 1996; Velthuis-te Wierik of 
a/., 1996) [e. g. increased fat and/or protein content], followed by compensatory 
elevations in antioxidant enzyme levels, to help protect tissue against potential oxidant 
damage. However antioxidant concentration changes should be interpreted with 
caution, as this might not indicate tissue damage (Packer, 1997). For example 
according to Cooper et al (2002) a rise in plasma antioxidant levels might enhance the 
antioxidant defences in blood, but could possibly impair defences at the sites from 
which they are mobilized. It is worth noting that the above changes in oxidant stress 
markers may have been further enhanced if subjects were not taking a daily 
multivitamin. A daily multivitamin may have reduced the oxidant stress response seen 
on the LowCD (Anderson et al., 1999). 
The observed adverse effects of the LowCD on oxidant stress and lipid peroxidation 
indicates that further investigation is required (both short-term and long-term). It would 
not seem prudent to recommend a diet for inducing weight loss to improve 
cardiovascular health if the diet has an adverse effect on oxidant stress and the 
subsequent development of atherosclerosis. The present data does not support the 
notion that calorie restriction may be the major modulator of the pro-oxidant/antioxidant 
balance as increased oxidant stress susceptibility in the LowCD group was observed 
despite achieving the greatest weight loss in comparison to both ConvD and CtrID 
groups. However, despite not finding a correlation between dietary fatty acid intake 
and oxidant stress in this study, the quantity and composition of dietary fat intake could 
influence fat-soluble anti-oxidative vitamin intake and also modulate anti-oxidative 
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capacity and lipid peroxidation status. For example, SFAs have been shown to 
adversely affect plasma lipids, lipoproteins and haemostatic factors (Mitropoulos of al., 
1994) as well as susceptibility to oxidation (Mata of al., 1996). Berry of al (1991) and 
Reaven of al (1991) support the notion that subjects who consume diets rich in MUFAs 
demonstrate lower LDL oxidation than subjects who consume diets rich in PUFAs. But 
according to Schwab of al (1998) replacing SFAs with either MUFAs or PUFAs in diets 
that provide less total fat did not appreciably affect LDL oxidative susceptibility. In 
addition, Velthuis-te Wierik et al (1996) found that In healthy normal-weight subjects, 
neither the difference in energy intake, or change in dietary fat composition affect MDA 
and antioxidant status levels. Research findings therefore suggest that relating lipid 
content and oxidant stress is not entirely straight forward (Wolff and Nourooz-Zadeh, 
1996). Although it has been shown that diets high in PUFAs and MUFAs and low in 
SFAs decrease atherosclerosis risk (Watts of al., 1992), lipoproteins isolated from 
individuals consuming diets rich in PUFA and MUFA also demonstrate greater pre- 
disposition to peroxidation than lipoproteins from individuals given SFAs (Kleinveld et 
al., 1993). Wolff and Nourooz-Zadeh (1996) suggested that lipid hydroperoxide intake 
is influenced by the consumption of lard and compound cooking fat (such as baking 
and frying margarines) which contain high levels of pre-formed hydroperoxides. 
Therefore individual hydroperoxide intake is expected to vary widely amongst 
individuals and will be largely dependent upon the intake of food containing 
hydroperoxides generated by pyrolysis such as fatty fried foods (Wolff and Nourooz- 
Zadeh, 1996). This information was unrecorded in the diet diaries in this study so the 
above can only be suggested as a cause for changes in LH and TAS status in the 
LowCD. 
Changes in protein intake could modulate anti-oxidative capacity and lipid peroxidation 
status. According to Fang et al (2002) high protein diets lead to increased oxidant 
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stress. High protein diets, Increase homocysteine levels, which Is an Independent risk 
factor for CVD, (Boushey et al., 1995). Homocysteine Increases endothelial 02' 
production and induces oxidant stress in the vasculature (Wu and Meininger, 2002). 
Increasing protein intake has also been shown to stimulate generation of ROS and lipid 
peroxidation in human polymorphonuclear leukocytes and mononuclear cells (Mohanty 
et al., 2002) and increase whole-body NO production by constitutive and inducible NOS 
in rats (Wu et aL, 1999). 
The overall glycaemic index and glycaemic load (product of glycaemic index of a 
specific food and its carbohydrate content) of diets has also been found to be 
independent risk factors for cardiovascular events (Liu et al., 2000), so may be 
important contributors modulating anti-oxidative capacity and lipid peroxidation status. 
Direct evidence from studies in both normal subjects and those with diabetes show that 
induced hyperglycaemia (Ceriello et al., 1998a) or meal intake and its attendant 
increase in glucose (Ceriello et al., 1998b; Ursini et al., 1998) can increase oxidant 
stress and reduce antioxidant defences. The increase in oxidant stress was 
significantly greater after meals that produced a greater degree of hyperglycaemia 
(Ceriello et a/., 1999). Hu et al (2006) supported a direct relation between dietary 
glycaemic index and markers of oxidant stress, MDA and 8-iso PGF2a by assessing 
dietary glycaemic index and glycaemic load in the form of a food-frequency 
questionnaire and measuring plasma MDA and 8-iso PGF2q in 292 healthy adults. The 
observed rise in plasma MDA and 8-iso PGF2a from the lowest to the highest quartile of 
glycaemic index was comparable to the differences in those concentrations found 
between normal-weight and overweight subjects (Block et al., 2002). This data 
suggests that chronic consumption of high-glycaemic index foods may lead to 
chronically elevated oxidant stress. Therefore increasing dietary intakes of low- 
glycaemic index foods, such as most fruit and vegetables, dairy products and whole 
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gains may be beneficial in terms of reduced oxidant stress. Although the consumption 
of high- and low-glycaemic index foods was not measured In this study, It can be 
speculated that it is unlikely that the changes In LH and TAS on the LowCD Is related 
to the consumption of chronic consumption of high-glycaemic index carbohydrates 
because the total carbohydrate intake on this diet was only about 9.1% of energy 
intake, which is very low. Further research Is needed to Investigate the effects of low- 
and high-glycaemic index on oxidant stress, particularly In relation to commercial diets. 
This study was designed to focus on short term effects of dietary factors on oxidant 
stress but there is a need to study both lipid peroxidation and TAS status following a 
LowCD of a longer duration. Since the study was conducted in a realistic context as 
opposed to a strict but perhaps 'artificial' laboratory environment, it was not possible to 
isolate the independent effects of altered calorie intake and changes in dietary 
composition on the pro-oxidant/antioxidant balance. Consequently future research 
should also be undertaken to examine the effect of diet composition variation, whilst 
controlling for total calorie intake, on the pro-oxidant/antioxidant balance. 
6.4 CONCLUSION 
In conclusion, the above study demonstrated that short-term consumption of a high fat / 
high protein / low carbohydrate diet can predispose individuals to increased oxidant 
stress. Short-term adherence to a ConvD did not demonstrate such potential 
deleterious effects. A greater understanding is needed of the individual contributions of 
body weight and composition, energy restriction and diet composition to lipid 
peroxidation and TAS. Further research should concentrate therefore on the influence 
of longer-term dietary intervention on the integrity of the pro-oxidant/antioxidant 
balance. 
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Chapter SEVEN 
Part (1) 
Preliminary experiment (3) 
Changes in lipid peroxidation and total antioxidant status In response to 
an acute session of low-intensity and high-Intensity exercise 
Part (2) 
Study 4 
The effects of acute high-intensity exercise between normal-weight and 
overweight subjects on lipid peroxidation, total antioxidant status and 
platelet responsiveness 
The intention of the preliminary study was to identify an exercise intensity which 
predisposes healthy individuals to enhanced oxidant stress levels. This could then be 
applied to future research studies to assess the impact of obesity on exercise-induced 
oxidant stress and the effect of antioxidant therapy on reducing exercise-induced 
oxidant stress. Although other researchers have examined the effect of various 
exercise intensities on oxidant stress markers, this study was carried to ensure an 
exercise intensity was selected which elicited the oxidant stress makers used in this 
thesis such as lipid hydroperoxide and total antioxidant status. 
PART ONE - Preliminary Experiment 
7.0 INTRODUCTION 
Physical exercise is associated with a significant increase in V02 both at the whole- 
body level and at skeletal muscle (Ji, 1996). Maximal V02 is increased 10-15 fold 
during exercise in relation to a resting period and a small fraction of 02 is converted 
into intermediate oxidative products (Ji, 1996; Alessio, 1993) causing biochemical 
changes and tissue damage (Ji, 1992; Ji, 1995a). The increased oxidative state 
observed during exercise could be produced by increased free-radical formation or 
reduced activity of antioxidant enzymes (Ji, 1995a). 
During exercise primary sources of radical production in skeletal muscle are the 
mitochondria, xanthine oxidase, NAD(P)H oxidase and the production of NO by NO 
synthase (Davies et al., 1982; Jackson et al., 1985; Reid of al., 1992a, b; Borzone et 
a/., 1994; O'Neil of a/., 1996; Jackson, 1998). Secondary sources of free-radical 
production during exercise include autoxidation of catecholamines, radical generation 
by phagocytic white cells and radical formation due to the disruption of iron-containing 
proteins (Jackson, 1998; Halliwell and Gutteridge, 1999). However the mitochondria is 
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the primary source of free-radical production in skeletal muscle. While 95-98% of 02 
consumption by skeletal muscle results in the formation of ATP and H2O, the remaining 
2-5% of the 02 undergoes one electron reduction to produce 02 (Jackson, 1998; 
Halliwell and Gutteridge, 1999). If the increased production of radicals is not balanced 
by the antioxidant capacity, subsequent reactions may give rise to other ROS such as 
H202 and OR. 
Since physical activity protects against the development of CVD and modifies CVD risk 
(Wannamethee and Shaper, 1998), a regular exercise programme is desirable 
(National Institute of Health, 1996). However this presents a biochemical paradox as 
regular exercise is necessary to obtain good cardio-respiratory fitness, but at the same 
time an acute exercise session may be theoretically harmful (Cutler, 1984; Hooper, 
1989). 
Ajmani et al (2003) found that in healthy individuals (n=14), a maximal graded exercise 
test (modified Balke test) caused significant increases in plasma LH levels [pre vs post- 
exercise (6.5±2.0 to 7.9±1.9pM, P<0.0001)]. Similarly, Lawson at al (1997) studied 5 
subjects and found an increase in MDA levels by 60% from a baseline of 3.28±1.74 to 
peak levels of 5.18±1.91nmol/mL (P<0.01) following the modified Bruce exercise 
treadmill protocol. In addition, SOD activity increased significantly by 256% from a 
baseline value of 2.37±1.27 to 8.47±319U/mL (P<0.01). Some investigators have 
failed to observe any signs of exercise-induced oxidant stress (Margaritis et al., 1997; 
Witt et aL, 1992), which could be due to a number of reasons. The use of different test 
subjects (training status, disease state, age and gender) might influence the findings of 
different studies. A range of different exercise protocols (high- and low-intensity 
aerobic exercise) have also been used to study exercise-induced oxidant stress. Only 
high-intensity exercise regimes appear to increase free-radical production enough to 
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overwhelm antioxidant defences. For example, Lovlin of al (1987) demonstrated that 
maximal exercise, eliciting 100% VO2max resulted in a 26% Increase In plasma MDA 
(P<0.005), exercise eliciting 70% VO2max resulted in a non-significant reduction In 
plasma MDA (P>0.05) and exercising at 40% VO2max resulted In a 10.3% decrease in 
plasma MDA (P<0.05). Tozzi-Ciancarelli of al (2002) demonstrated that strenuous 
exercise (maximal exercise test on a cycle ergometer), but not moderate exercise (30 
minutes at 60% VO2max on a cycle ergometer) resulted in increased levels of TBARS 
[rest vs post-exercise (TBARS: moderate (1.5±0.2 vs 1.4±0.1 pmol/L, P>0.05) and 
strenuous (1.6±0.2 vs 3.9±0.3pmol/L, P<0.05) and decreased TAS levels [rest vs post- 
exercise (TAS: moderate (1.35±0.04 vs 1.47±0.05U/mL, P>0.05) and strenuous 
(1.45±0.03 vs 1.05±0.03U/mL, P<0.05)]. 
This study investigated the effects of an acute session of low- and high-intensity 
exercise on LH and TAS responses in healthy subjects. 
7.1 METHODOLOGY 
Subject Characteristics 
The study group consisted of eleven (n=11) apparently healthy male and females 
(n=9/2) who were recruited from De Montfort University, Department of Sport Sciences 
(see table 7.0 for subject characteristics). Subjects with a history of diabetes, 
cardiovascular or cerebrovascular disease, hepatic or renal disease, tobacco abuse, or 
those on hormone replacement therapy were excluded. In addition subjects were 
excluded if they were hypertensive (with or without treatment), taking treatment for 
dyslipidaemia, taking any antioxidant supplementations or a smoker. Written informed 
consent was obtained from all the subjects after they had been given a full explanation 
of the study. The research was given ethical approval by Bedfordshire Local Research 
Ethics Committee. 
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Table 7.0. Subject characteristics 
Characteristic Mean ± SEM 
Age, yr 21.3 t 0.30 
BMI, kg/m2 25.3: t 1.25 
Body mass, kg 77.1 t 4.42 
Body fat, kg 16.3: t 1.89 
Values expressed as the mean±SEM. BMI, body mass index. 
Experimental design 
Subjects visited the exercise physiology laboratories at Do Montfort University, Bedford 
on two separate occasions between 9-11 am over a 2-week period. For each visit, 
subjects were instructed to fast for 10-12 hours and refrain from exercise, caffeine and 
alcohol for 48 h before the study visit. Subjects were also asked to maintain their usual 
dietary pattern. 
During week 1 anthropometric measures were taken which was followed by an 
exercise session. During week 2 an alternative exercise session was carried out. In 
both weeks, prior to and immediately post each exercise session a venous blood 
sample was obtained from a forearm antecubital vein and arterialised capillary blood 
from a finger-tip. 
Exercise session 
The exercise testing protocol utilised a motorised treadmill (see methodology section 
3.5). For each subject, two exercise sessions were completed (30 minutes walking at 
40% or 70% heart rate reserve). The order of the two exercise sessions were 
randomised and separated by 14 days. The Karvonen method was used to estimate 
heart rate reserve: % heart rate reserve = [(hr max (220-age) - resting heart rate) x (% 
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heart rate reserve intensity/100) + resting heart rate. Heart rate was monitored 
throughout the exercise session. 
Anthropometric and cardiovascular measurements and venous blood sampling 
Height, weight and waist measurements are described in detail in the methodology 
chapter (section 3.2.1,3.2.2,3.2.3). Body composition was analyzed using the BIA 
(BodyStat® Quadscan 4000) which is outlined in the methodology chapter (section 
3.2.4.1). Cardiovascular measurements are described in the methodology chapter 
(section 3.3). Venous blood sampling (blood only collected in plain serum tube) and 
arterialized blood samples for assessment of plasma volume were collected which are 
described in the methodology chapter (section 3.1.1,3.1.2,3.1.3,3.1.4 and 3.1.5). 
Biochemical measurements 
LH and TAS were performed as described in the methodology chapter (section 
3.1.12.1 and 3.1.13.1). Haematocrit was measured using a Hawksley Micro Hct 
Reader and Haemoglobin using a HemoCue B-Haemoglobin photometer which are 
described in the methodology chapter (section 3.14 and 3.1.5). Haematocrit and 
Haemoglobin were measured to calculate the change in plasma volume (Dill and 
Costill, 1974). 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value or the mean change or improvement). 
The Shapiro-Wilk test confirmed that the data was not normally distributed so was 
analyzed by non-parametric methods to avoid assumptions about the distribution of the 
measured variables. The Wilcoxon signed-rank test for paired data was used to 
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determine the significance of differences of LH and TAS between pre- versus post- 
exercise among both the low- and high-intensity exercise sessions. Differences were 
considered statistically significant at P<0.05. Statistical analysis was performed using 
a computer software package (SPSS for Windows, Version 13.0). 
7.2 RESULTS 
LH levels only increased significantly following high-intensity exercise [rest vs post- 
exercise (0.73±0.04 vs 0.88±0.04pmol/L, P<0.02)] which was also shown to be 
significantly higher than the LH level post-exercise in the low-intensity group [high- 
intensity vs low-intensity (post-exercise, 0.88±0.04 vs 0.75±0.03pmol/L, P<0.05)] 
(figure 7.0). TAS increased significantly following low-intensity exercise [rest vs post- 
exercise (1046.6±64.87 vs 1128.54±70.84mmol/L, P<0.05)] (figure 7.1) and decreased 
slightly following high-intensity exercise but this was not significant [rest vs post- 
exercise (1120.2±80.22 vs 1088.8±64.82mmol/L, P>0.05)]. 
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Figure 7.0. LH levels (pmol/L) pre and post acute aerobic exercise (low- and high- 
intensity). Results (mean±SEM) were analyzed using the Wilcoxon signed-rank test. 
(*, P<0.05, '*, P<0.02). For further details see text. 
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Figure 7.1. TAS levels (mmol/L) pre and post acute aerobic exercise (low- and high- 
intensity). Results (mean±SEM) were analyzed using the Wilcoxon signed-rank test. 
(', P<0.05). For further details see text. 
7.3 DISCUSSION 
This study examined the effects of acute high- (70% heart rate reserve) and low- 
intensity (40% heart rate reserve) aerobic exercise on LH and TAS in eleven healthy 
subjects. Prior to both high- and low-intensity aerobic exercise, LH levels were both 
similar. LH levels only increased significantly following high-intensity exercise which 
was also shown to be significantly higher than the LH levels post-exercise following 
low-intensity exercise. TAS levels increased significantly following low-intensity 
exercise and decreased slightly following high-intensity exercise but this was not 
significant. 
In comparison to other research studies investigating exercise-induced oxidant stress, 
this study found similar findings. For example both Ajamini et al (2003) and Lawson et 
al (1997) observed a significant increase of 22% (P<0.0001) and 60% (P<0.01) in LH 
and MDA respectively, following a maximal graded exercise stress test. This study 
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found a 21% increase in LH levels post high-intensity exercise which is similar to 
Ajamini et al (2003). Lovlin et al (1987) demonstrated that exercise eliciting 100% V02 
max resulted in a 26% increase in plasma MDA, whilst exercise eliciting 70% of V02 
max resulted in a non-significant reduction in plasma MDA (P>0.05) and exercising at 
40% V02 max resulted in a 10.3% decrease in plasma MDA (P<0.05). Similar to 
findings in this study, Tozzi-Ciancarelli et al (2002) demonstrated that strenuous 
exercise (maximal exercise test on a cycle ergometer), but not moderate exercise (30 
minutes at 60% V02max on a cycle) resulted in increased levels of TBARS [rest vs post- 
exercise (TBARS: moderate, 1.5±0.2 vs 1.4±0.1 pmoVL, P>0.05 and strenuous, 1.6±0.2 
vs 3.9±0.3pmol/L, P<0.05)]. The findings in this study at low-intensity exercise and 
those of Tozzi-Cianarelli et al (2002) at moderate-intensity exercise did not observe a 
reduction in LH levels which was found by Lovlin et al (1987). The difference in 
exercise-induced oxidant stress findings between studies may be explained by 
methodological differences. For example factors such as training status, age and 
gender of subjects and different exercise protocols could all play a role (Cooper et al., 
2002). High-intensity exercise appears to be most consistent factor in provoking 
increases in free-radical production that overwhelms antioxidant defences (Poulsen et 
al., 1996). However if oxidative reactions are not elevated directly after exercise, the 
absence of signs of oxidative stress does not necessarily imply that oxidative damage 
has not occurred because oxidative reactions may occur hours (Koyama et al., 1999) 
or even days (Hartmann et al., 1998) after the end of exercise. 
In this study, mean TAS values increased significantly following low-intensity exercise 
(P<0.05) and also decreased slightly following high-intensity exercise but this did not 
achieve significance. This suggests that a greater oxidant production and antioxidant 
usage occurred during high-intensity exercise, as the high-intensity exercise group had 
lower TAS levels post-exercise compared with the low-intensity exercise group 
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(P>0.05). Similarly Tozzi-Ciancarelli et al (2002) also demonstrated that strenuous 
exercise (maximal exercise test on a cycle ergometer), but not moderate exercise (30 
minutes at 60% VO2max on a cycle) resulted in decreased levels of TAS [rest vs post- 
exercise (TAS: moderate, 1.35±0.04 vs 1.47±0.05U/mL, P>0.05 and strenuous, 
1.45±0.03 vs 1.05±0.03U/mL, P<0.05)]. However, Ashton et al (1998) found that an 
exhaustive cycling test increased TAS levels post-exercise (P>0.05) which were similar 
to the findings of Maxwell et al (1993), who showed an increase in plasma TAS levels 
following 60-minutes of box-stepping exercise. This highlights that the significance of 
exercise-induced changes in levels of antioxidants post-exercise in relation to oxidant 
stress is difficult to determine. Oxidant stress could cause a primary decrease in 
antioxidants, whilst mobilization from secondary sources elsewhere in the body might 
result in an apparent increase in TAS (Cooper et al., 2002). It has been shown fairly 
consistently that the GSH: GSSG ratio in the blood decreases with exercise (Dufaux et 
a/., 1997; Viguie et al., 1993), whereas plasma levels of vitamins C and E tend to 
increase (Gleeson et al., 1987; Duthie et al., 1990; Pincemail et al., 1988). Mobilization 
of vitamin E has been suggested as a mechanism to explain the changes in vitamin E 
secondary to oxidative stress; for example, Elsayed et al (1990) suggested that vitamin 
E is mobilized from other tissues to the lungs in response to ozone exposure. In 
addition, exercise-associated oxidant stress (Ji, 1995b) has shown changes in the 
distribution of vitamin E, which suggests that some tissues deliver vitamin E. Therefore 
although changes in oxidation state or concentration of antioxidants can point to 
impaired antioxidant defences, they do not necessarily indicate tissue damage (Packer, 
1997) and it is unclear to what extent they influence oxidant stress. A rise in 
antioxidant levels might enhance the antioxidant defences in blood, but could possibly 
impair defences at the sites from which they are mobilized (Cooper at al., 2002). 
High-intensity exercise could increase LH in several ways, but the primary source is the 
mitochondria. As 02 consumption increases with exercise intensity, the rate of ROS 
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production increases (Jackson, 1998; Halliwell and Gutteridge, 1999), particularly if the 
increased production of radicals is not balanced by the antioxidant capacity. 
Secondary sources of free-radical production include autoxidation of catecholamines, 
radical generation by phagocytic white cells and radical formation due to the disruption 
of iron-containing proteins (Jackson, 1998; Halliwell and Gutteridge, 1999). Exercise- 
induced neutrophilia is another possible source of oxidant stress post aerobic exercise. 
Neutrophils generate 02 reduced plasma vitamin C and uric acid and create oxidant 
stress (Quindry et al., 2003). Elevations in inflammatory cytokines such as tumor- 
necrosis factor-a also occur after aerobic exercise (Sen, 1999), which initiate a rapid 
rise in endogenous oxidants as an essential step in postreceptor signal transduction 
(Reid and Li, 2001). An alternative mechanism by which exercise may promote free- 
radical production involves ischaemia-reperfusion. Strenuous exercise is associated 
with transient tissue hypoxia in several organs as blood is shunted away to cover the 
increased blood supply required in active skeletal muscles and the skin (Cooper et al., 
2002). Strenuous exercise can also cause muscle fibres to undergo relative hypoxia 
as oxygen supply cannot match the energy requirements (Koyama et al., 1999). Re- 
oxygenation post-exercise, can also be associated with the production of ROS (Packer, 
1997; Koyama et al., 1999). 
7.4 CONCLUSION 
This study found that thirty-minutes of high-intensity exercise and not low-intensity 
exercise produced a significant increase in LH levels in healthy subjects. With regards 
to total antioxidant status, levels increased following thirty-minutes low-intensity 
exercise, but decreased following thirty-minutes high-intensity exercise. This suggests 
that a greater oxidation production and antioxidant usage during high-intensity aerobic 
exercise predisposes subjects to increased oxidant stress. 
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PART TWO - Study 4 
7.5 INTRODUCTION 
Obese subjects are prone to increased oxidant stress levels at rest (Yesilbursa at al., 
2005; Mohn at al., 2005; Keany at al., 2003; Ozata at al., 2002; Davi at al., 2002; 
Dandona at al., 2001; Präznjr at aL, 1999) and four reports of exercise-induced oxidant 
stress in obesity suggest increase susceptibility to oxidant damage following high- 
intensity exercise (Saiki at aL, 2001; Vincent et al., 2004; Vincent at al., 2005a; Vincent 
et aL, 2005b). Possible mechanisms for the increased exercise-induced oxidant stress 
include enhanced oxygen metabolism, anoxia-reoxygenation, mechanical damage to 
tissues and increased inhalation of environmental pollutants (NO2, ozone etc) (Vincent 
et al., 2004). This could have long-term implications as increased oxidant stress is 
associated with reduced contractile function, arrhythmias and muscle fatigue (Kukreja 
and Hess, 1992; Vincent et al., 1999; Yu, 1994) and is implicated in pathologies such 
as diabetes, atherosclerosis and obesity (Bouloumie at al., 1999; Gackowksi et al., 
2001; Johnson, 2002; Kennedy and Lyons, 1997; Vincent et al., 1999). 
Following an acute exercise session, platelet aggregation may also be increased, 
which potentially increases the risk of developing atherothrombotic vascular disease 
(Grundy et al., 2002; McGill et al., 2002). Previous studies have shown that a single 
bout of moderate-intensity exercise does not cause platelet activation (Chicarro et al., 
1994) or tends to desensitize platelets (Wang et al., 1994) and that strenuous-intensity 
exercise may favour (Kestin et al., 1993) platelet aggregation. Although it has been 
shown that obesity increases platelet aggregation (Davi et al., 2002), it is unknown if 
obesity also increases exercise-induced platelet aggregation. It could be speculated 
that platelet aggregation during exercise should be enhanced in obesity when 
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compared to normal-weight subjects. Furthermore, exercise-induced oxidant stress 
in 
obesity may be a pivotal cause for increased exercise-induced platelet aggregation. 
For example, evidence suggests that not only does exogenously derived ROS affect 
the regulation of platelet activation, but platelets themselves also generate ROS (Krotz 
et al., 2004). 
This study investigated the effect of acute high-intensity aerobic exercise on LH, TAS, 
SOD, GSH and percentage ADP-induced platelet aggregation in normal-weight and 
overweight subjects. The association between LH, TAS and ADP-induced platelet 
aggregation during acute high-intensity aerobic exercise was also studied. 
7.6 METHODOLOGY 
Subject Characteristics 
The study group consisted of 20 subjects who were sex-matched between groups [10 
normal-weight (BMI: 23.6±0.53kg/m2) and 10 overweight (BMI: 28.4±0.71 kg/m2) 
healthy male and females (n=10/10)] (see table 7.1 for subject characteristics). 
Volunteers were invited to take part in the study by local advertisement. An inclusion 
criterion was age between 18 and 50 years old and BMI between 20 and 35kg/m2. 
Subjects with a history of diabetes, cardiovascular or cerebrovascular disease, hepatic 
or renal disease, tobacco abuse, or those on hormone replacement therapy were 
excluded. In addition subjects were excluded if they were hypertensive (with or without 
treatment), taking treatment for dyslipidaemia, taking any antioxidant supplementations 
or a smoker. Written informed consent was obtained from all the subjects after they 
had been given a full explanation of the study. The research was given ethical 
approval by Bedfordshire Local Research Ethics Committee. 
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Table 7.1. Subject characteristics 
Characteristic 
P-Value 
Normal Weight Overweight NW 
NW (n=10) OW (n=10) vs 
(m/f; 5/5) (m/f; 5/5) OW 
Age, yr 27.90 t 2.19 31.40t 1.98 . 251 
Body mass, kg 67.78: t 3.03 82.50 t 3.86 <. 01 
BMI, kg/m 23.55t 0.53 28.40: t 0.71 <. 001 
Body fat, kg 17.93: t 1.33 28.50: t 3.08 <. 01 
Waist, cm 77.89 ± 1.99 93.50 ± 2.94 <. 001 
Systolic BP, mmHg 117.70: L 3.06 126.70: L 3.94 . 088 
Diastolic BP, mmHg 73.10 t 1.43 82.80 ± 1.28 <. 001 
Fasting glucose, mmol/L 6.51 t 0.45 5.87: t 0.44 . 327 
Fructosamine, mmo/L 182 ± 8.25 195 ± 7.52 . 28 
Total cholesterol, mmo/L 4.60: t 0.54 4.24: t 0.28 . 856 
HDL-cholesterol, mmol/L 1.40 ± 0.13 1.23 ± 0.10 . 322 
LDL-cholesterol, mmoVL 2.09 ± 0.19 2.28 ± 0.21 <. 05 
Triglycerides, mmoVL 2.10 : t. 0.83 2.39: t 0.56 . 466 
Values expressed as the mean±SEM. BMI, body mass index; BP, blood pressure; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein. Results were compared using a 
One-way ANOVA and P values are given in the Table. P values < 0.05 were 
considered significant. For further details see text. 
Experimental design 
Subjects visited the Centre for Obesity Research on two separate occasions between 
9-11 am over a 2-week period and were instructed to fast for 10-12 hours and refrain 
from exercise, caffeine and alcohol for 48 hours before the study visits. Subjects were 
also asked to maintain their usual dietary pattern. 
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During week 1 anthropometric measures, a venous blood sample and V02max test were 
completed. 
During week 2, following a 15-minute supine rest a venous blood sample was taken. 
Subjects were then asked to exercise on a motorised treadmill. The exercise session 
adopted the following protocol 
  5-minutes warm up (40% VO2max) 
  The subject was then required to perform a constant workload 
corresponding to 70% VO2max for 30-minutes. 
Heart rate was monitored throughout the exercise sessions. A venous blood sample 
was taken, immediately post and 30-minutes post-exercise. 
Anthropometric and cardiovascular measurements and venous blood sampling 
Height, weight and waist measurements are described in detail in the methodology 
chapter (section 3.2.1,3.2.2,3.2.3). Body composition was assessed using the 
BodPod, which is outlined in the methodology chapter (section 3.2.4.2). 
Cardiovascular measurements are described in the methodology chapter (section 3.3). 
Venous blood samples were collected as described in the methodology chapter 
(section 3.1.1 and 3.2.2). 
Maximal aerobic exercise test 
The maximal exercise test incorporated the Bruce Protocol (Bruce, 1972). 02 uptake 
was assessed using the MetaMax 3B®. Maximal aerobic capacity was determined 
when the subject met two of the following criteria: 
  Within 10 beats of maximal age predicted heart rate (220 -age) 
  Respiratory quotient greater than 1.1 
  Rating of perceived exertion >17 
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Biochemical measurements 
LH, TAS, SOD and GSH were performed as described in the methodology chapter 
(section 3.1.12.1,3.1.14.1,3.1.14.2 and 3.1.14.3). Other biochemical measures 
included, fasting plasma glucose, plasma fructosamine, plasma cholesterol, plasma 
LDL, plasma HDL and plasma triglycerides as described in methodology chapter 
(section 3.1.6,3.1.7,3.1.8,3.1.9,3.1.10 and 3.1.11). Percentage ADP-induced platelet 
aggregation was measured using PlateletWorks®, which is outlined in the methodology 
chapter (section 3.1.14.2). Final concentrations of ADP used for platelet aggregation 
were 10 and 20 NM. Haematocrit and haemoglobin was also measured using 
PlateletWorks® which is also outlined in the methodology chapter (section 3.1.4.1 and 
3.1.5.1). Haematocrit and haemoglobin were measured to calculate the change in 
plasma volume (Dill and Costill, 1974). 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value or the mean change or improvement). 
The Kolmogorov-Smirno test confirmed that the data was normally distributed. The 
data was analyzed using analysis of variance (ANOVA) with repeated measures, which 
is appropriate for detecting differences between groups, time effects and interactions. 
A two-way (AxB) mixed ANOVA was used which incorporated one between (exercise 
intensity: low intensity vs high intensity) and one within (time: rest vs post-exercise) 
subjects factor. When significant F values were noted paired t-tests were used to 
detect specific differences within groups at certain time points during the study. To 
detect differences between groups, one-way ANOVA was incorporated with one within 
(time: rest vs post-exercise) subject factor. Associations between parameters were 
assessed using the Pearson correlation test. Differences were considered statistically 
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significant at P<0.05. Statistical analysis was carried out using a computer software 
package (SPSS for Windows, Version 13.0). 
7.7 RESULTS 
Subject characteristics for the normal-weight and overweight groups are shown in table 
7.1. Body mass, BMI, body fat and waist circumference, DBP and LDL concentration 
were all significantly higher in the overweight group compared to the normal-weight 
group (P<0.001, P<O. 01, P<O. 001, P<O. 001, P<0.05, respectively). All subjects had 
similar SBP, fasting glucose, fructosamine, cholesterol, HDL and fasting triglycerides. 
Figures 7.2 and 7.3 demonstrate LH and TAS levels pre- and post-exercise in the 
normal-weight and overweight groups, respectively. At rest there was no difference in 
LH between the groups [normal-weight vs overweight (0.64±0.06 vs 0.77±0.09pmol/L, 
P>0.05). However following high-intensity aerobic exercise, LH levels increased 
significantly in the overweight group (P<0.05) compared to the normal-weight group 
(P>0.05) (percentage increase in LH levels post high-intensity exercise, overweight vs 
normal-weight, +24.6% vs +12.5%). Thus the LH level in the overweight group was 
significantly higher than the normal-weight group post-exercise [overweight vs normal- 
weight (0.96±0.09 vs 0.72±0.06pmol/L, P<0.05)]. Although thirty-minutes post-exercise 
LH levels had declined, they were not as significantly different from both pre and post 
LH levels. No significant differences in TAS levels were noted between the normal- 
weight and overweight group pre- and post-exercise, and pre- and post-exercise within 
each group. 
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Figure 7.2. LH levels (pmol/L) pre and post high-intensity exercise in normal-weight 
and overweight subjects. Results (mean±SEM) were analyzed using one-way ANOVA 
and paired t-tests (', P<0.05). For further details see text. 
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Figure 7.3. TAS levels (mmol/L) pre and post high-intensity exercise in normal-weight 
and overweight subjects. Results (meantSEM) were analyzed using one-way ANOVA. 
For further details see text. 
SOD and GSH levels pre- and post-high-intensity aerobic exercise in normal-weight 
and overweight subjects are given in table 7.2. SOD and GSH levels were not 
significantly different in the normal-weight and overweight group at rest or post- 
exercise. In addition, no interaction effect was identified between the normal-weight 
and overweight group and pre- and post-high-intensity aerobic exercise. 
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Table 7.2. SOD and GSH levels pre and post high-intensity exercise in normal-weight 
and overweight subjects. 
Variable Pre-exercise Post-exercise 30 minutes post-exercise 
SOD U/g Hb 
Normal-weight 3965.90±306.23 3967.47±336.23 4013.28±325.31 
Overweight 4076±453.37 5018.71±621.52 3912.39±422.46 
GSH umol/g Hb 
Normal-weight 20.86±3.00 12.85±2.43 18.15±3.15 
Overweight 16.62±1.78 16.74±5.14 27.6±8.98 
Values expressed as the mean±SEM. SOD, superoxide dismutase; GSH, reduced 
glutathione. Results were analyzed using a one-way ANOVA. For further details see text. 
Percentage ADP-induced platelet aggregation pre- and post-high-intensity exercise in 
normal-weight and overweight subjects are given in figure 7.4. No significant 
differences in percentage ADP-induced platelet aggregation levels were identified in 
the normal-weight and overweight group at rest or post-exercise. In addition no 
interaction effect was identified between the normal-weight and overweight group and 
pre- and post-high-intensity aerobic exercise. 
The association between LH and percentage ADP-induced platelet aggregation pre- 
and post-exercise is shown in figure 7.5. For both ADP-induced platelet aggregation 
concentrations (10 and 20pM) an increase in LH level was associated with decreased 
percentage platelet aggregation, indicating enhanced in vivo platelet reactivity. 
Pearson correlation found that at 20pM, percentage ADP-induced platelet aggregation 
with LH was r=-0.329, P<0.01 and at 10pM, the percentage ADP-induced platelet 
aggregation with LH was r=-0.240, P=0.065. 
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7.8 DISCUSSION 
This study investigated the effect of acute high-intensity aerobic exercise on LH, TAS, 
SOD, GSH and percentage ADP-induced platelet aggregation in normal-weight and 
overweight subjects. The association between LH and ADP-induced platelet 
aggregation pre- and post-high-intensity acute aerobic exercise was also studied. 
Overweight subjects were used in this study to exclude high-risk exercising patients 
and to exclude many con-founding factors associated with obesity such as diabetes, 
hypertriglyceridaemia and hyperlipidaemia. Acute high-intensity exercise significantly 
increased LH levels in the overweight group, which returned to pre-exercise levels 
thirty-minutes post-exercise. No significant changes in LH were identified following 
high-intensity exercise in the normal-weight group. Interestingly, although no 
significant difference was identified in LH levels pre-exercise between the normal- 
weight and overweight group, post-exercise there was a significant difference in LH 
levels between the two groups. No other significant changes were identified in TAS, 
SOD, GSH and percentage ADP-induced platelet aggregation in and between the 
normal-weight and overweight group, pre- and immediately post-exercise. 
In support of the above findings, several other studies found increased susceptibility to 
oxidant damage following exercise in obese subjects (Saiki at al., 2001; Vincent et al., 
2004; Vincent et al., 2005a; Vincent at al., 2005b). Saiki et a/ (2001) studied 7 obese 
and 16 normal-weight subjects and observed changes in serum hypoxanthine following 
aerobic exercise on a treadmill (15 minutes at 70% heart rate reserve). Baseline 
hypoxanthine levels were significantly higher in the obese group compared to the 
normal-weight group [obese vs normal-weight (3.4613.70 vs 1.23t1.16mmoVL, 
P<0.05)]. Exercise-induced a pronounced increase in serum hypoxanthine level in the 
obese group compared with the normal-weight group [obese vs normal-weight 
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(43.86±4.56 vs 10.65±6.81 mmol/L, P<0.01)]. Vincent et al (2004) assessed LH levels 
in normal-weight (n=14) and obese (n=14) subjects, pre and post aerobic exercise. 
At 
rest LH levels were not significantly different between the normal-weight and obese 
group, but post-exercise LH levels increased by 70% and 62% in the obese and 
normal-weight, respectively, which was significantly different to pre-exercise LH 
levels 
and significantly different between the normal-weight and obese group. Vincent at al 
(2005a) also found significantly increased post-exercise LH levels following a maximal 
graded exercise stress test on a treadmill in obese women compared to normal-weight 
women [obese vs normal-weight (0.13 vs 0.02 (nmol/mL) (O2/kg/min)]. This occurred 
despite a 20% shorter exercise time for the obese women than for the normal-weight 
women. After controlling for body fat percentage and baseline LH, the major 
contributors of the change in LH levels during exercise were age, peak heart rate and 
exercise duration. However, when exercise loads were matched by relative intensity, 
LH responses still remained higher in obese than normal-weight persons [obese vs 
normal-weight (0.289 vs 0.054 (nmoVmL) (02/kg min)] (Vincent et a/., 2005b). All 
studies have shown that compared to normal-weight, obese subjects have a 300-600% 
greater increase in LH lipid peroxidation markers, post high-intensity exercise. In this 
study the overweight group had a 133% greater increase in LH post high-intensity 
exercise when compared to the normal-weight group. The lower increase in LH values 
may be due to using subjects with lower BMI values compared to the above studies. 
For example, in this study the mean BMI of the overweight group was 28.40kg/m2 
compared to 33.3kg/m2 and 30.6kg/m2 in the obese group of Vincent at als (2005) and 
Saiki et als study. In addition other factors which affect differences in LH responses 
post high-intensity exercise include exercise intensity and exercise duration (Poulsen et 
al., 1996). 
Despite matching for oxygen uptake during exercise in the normal-weight and 
overweight groups, LH levels post-exercise were still greater in the overweight group. 
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The exacerbated exercise-induced lipid peroxidation in the overweight group may be 
due to several factors including an insufficient antioxidant defence. Several studies 
suggest that obesity is associated with lower plasma antioxidant concentration 
(Reitman et al., 2002; Strauss et al., 1999; Decsi et al., 1997; Kuno et aL, 1998; Moor 
De Burgos et aL, 1992) and decreased activities of erythrocyte cytoprotective enzymes 
(Olusi, 2002; Ozata et al., 2002; Beltowski et aL, 2000). A lowered antioxidant defence 
leaves the tissues susceptible to free-radical attack during exercise (Ashton et al., 
1998). Higher tissue lipid levels in the obese may also provide a larger target for 
oxidative damage by free-radicals (Vincent et al., 2001). In the obesity exercise- 
induced study by Vincent et al 2004, elevated dietary fat intakes and plasma 
triglycerides were present in the obese group compared to the non-obese group, which 
was shown to be positively correlated with exercise-induced change in LH levels. 
Despite the increase in consumption of dietary fats in the obese group compared to the 
non-obese group, this did not enhance consumption of antioxidants, which suggests 
that the obese group may not have taken in antioxidant amounts necessary to prevent 
oxidant stress. High cell respiration and 02 consumption may also have been 
exacerbated in muscle tissue during physical activity in the overweight group due to the 
additive mechanical load of carrying excessive body weight (Vincent et al., 2004) and 
mechanical inefficiency (Vincent and Taylor, 2006). For example during the same 
absolute load-bearing walking activity, obese persons have 38% higher VO2 (oxygen 
consumption) values than non-obese persons and these values are correlated with 
post-exercise LH values (Vincent et al., 2004). Lastly, increased body weight, may 
cause oxidant stress via endothelial enzymatic sources within tissues (i. e. increased 
NADH oxidase activity and H202) (Rajagopalan et al., 1996; Kaminski et al., 2002) or 
by pro-oxidant complications of increased body weight such as hypertension that 
increase vascular 02 and LH levels (Frisbee et al., 2002). 
In addition to this study, other research has also found no change in TAS levels pre- 
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and post-aerobic exercise in and between normal-weight and obese subjects (Vincent 
et a12004). SOD and GSH also showed no significant difference in and between the 
normal-weight and obese group, pre- and post-high intensity exercise. Likewise, 
Vincent et al (2005b) observed no difference in antioxidant thiol profiles (total thiols, 
protein thiols, and nonprotein thiols (glutathione) before and after exercise between 
normal-weight and obese groups. It was anticipated that in this study the overweight 
group would have lower antioxidant enzymes pre- and post-exercise compared to their 
normal-weight counterparts, because of the evidence for reduced antioxidant status at 
rest in obesity (Vincent et al., 2001). It is possible that the lack of reduction in TAS post 
high-intensity exercise may be a result of mobilization of secondary sources of 
antioxidants (Cooper et al., 2002). For example mobilization of vitamin E has been 
suggested as a mechanism to explain the changes in increased vitamin E, levels 
secondary to oxidative stress (Elsayed et al., 1990). However mobilization of 
secondary sources of antioxidants might rise antioxidant defences in the blood, but 
impair defences at the site from which the antioxidants were mobilized (Cooper et al., 
2002). 
This study aimed to identify the link between oxidant stress and percentage ADP- 
induced platelet aggregation during acute aerobic high-intensity exercise. Results from 
chapter five concluded that at rest oxidant stress in obesity was not a source of 
increased platelet aggregation in obesity. However Davi et a/ (2002) demonstrated a 
linear relationship between 8-iso PGF2a and 11-dehydro-TxB2 (r=0.61, P<0.001) 
concluding that the association between lipid peroxidation and platelet activation may 
be a novel mechanism, through which obesity may affect cardiovascular morbidity and 
mortality (Grundy et al., 2002; McGill at al., 2002). Furthermore oxidant stress- 
mediated platelet aggregation has also been found in several settings of risk factors for 
atherosclerosis and cardiovascular thrombosis, including diabetes mellitus, 
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hypertension and hypercholesterolemia (Davi et al., 2003; Minuz et al., 2002; Davi et 
al., 1997). This study is the first to identify whether there is a possibility of 'oxidant 
stress-mediated platelet aggregation' during and post acute aerobic high-intensity 
exercise in normal-weight and overweight subjects. Tozzi-Ciancarelli et al (2002) 
demonstrated that oxidant stress induced by strenuous exercise interfered with platelet 
responsiveness. This was evident by adding LDL-Ox to PRP obtained from blood 
samples collected from 6 subjects immediately after strenuous exercise as ADP- 
induced platelet aggregation increased and intra-platelet NO content decreased. 
However the speculation by Tozzi-Ciancarelli et al (2002) that strenuous exercise 
interfered with platelet responsiveness by promoting LDL-Ox mediated platelet 
activation did not necessarily prove that the exercise-associated increase in platelet 
aggregation was mediated by LDL-Ox formation. In this study, following correlation 
coefficient analysis for platelet aggregation and LH responses, pre and post acute 
aerobic high-intensity exercise in normal-weight and overweight subjects, it was found 
that LH demonstrated a significant negative association with platelet aggregation at 
high ADP-induced platelet aggregation (20pM: r=-0.0.329, P<0.01) and a negative 
trend towards being associated with platelet aggregation at low ADP-induced platelet 
aggregation (10pM: r=-0.240, P=0.065). This confirms the suggestion that increased 
LH may decrease percentage ADP-induced platelet aggregation (which is an 
expression of enhanced in vivo platelet reactivity). However this finding, despite 
increased LH post-exercise did not cause decreases in ADP-induced platelet 
aggregation in both normal-weight and overweight subjects following high-intensity 
acute aerobic exercise. It is proposed that high-intensity exercise was not strenuous 
enough to induce platelet aggregation because both Tozzi-Ciancarelli et al (2002) and 
Wang et al (1994) demonstrated increased platelet aggregation following strenuous 
exercise. 
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7.9 CONCLUSION 
In conclusion, exercise-induced oxidant stress is enhanced in overweight subjects, 
compared to normal-weight subjects, despite controlling and matching V02 usage 
during high-intensity exercise. A combination of obesity related factors including 
elevated body fat and triglyceride levels, decreased antioxidant status, and increased 
V02 during exercise have been implicated in this process. During high-intensity 
aerobic exercise, LH levels may be associated with decreased platelet aggregation 
(expression of enhanced in vivo platelet reactivity) but decreased platelet aggregation 
(expression of enhanced in vivo platelet reactivity) was not observed in either the 
normal-weight group and overweight group. 
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Chapter EIGHT 
Study 5 
The effect of selenium supplementation on lipid peroxidation, 
total antioxidant status and platelet responsiveness at rest and 
post high-intensity acute exercise in normal-weight and 
overweight subjects 
8.0 INTRODUCTION 
Given that both obesity and acute high-intensity exercise induces oxidant stress, it is 
crucial that therapies are developed to reduce this exacerbated response. Oxidant 
stress is associated with reduced contractile function, arrhythmias and muscle fatigue 
during acute exercise (Kukreja and Hess, 1992; Vincent et aL, 1999; Yu, 1994) and is 
implicated in pathologies such as diabetes, atherosclerosis and obesity (Bouloumie et 
aL, 1999; Gackowksi et al., 2001; Johnson, 2002; Kennedy and Lyons, 1997; Vincent 
et al., 1999). Potential treatment therapies to reduce oxidant stress include calorie 
restriction (Velthuis-te Wierik et al., 1996), increased antioxidant intake (diet 
composition) (Armstrong and Doll, 1975; Rimm et al., 1996), exercise training (Fukai et 
al., 2000) and antioxidant supplementation (Skrha of al., 1999; Manning of al., 2004; 
Anderson et al., 1999). 
Several researchers have demonstrated that antioxidant therapy may reduce oxidant 
stress levels at rest in obesity. For example both Skrha et al (1999) and Manning et al 
(2004) observed decreased MDA levels at 3-months and reduced LH levels at 3- 
months and 6-months following vitamin E supplementation in obese subjects, 
respectively. In addition, Anderson et al (1999) indicated protection against formation 
of oxidative biomarkers with an 8-week antioxidant treatment [ß-carotene (24mg), 
vitamin C (1000mg) and vitamin E (8001U)]. Antioxidant therapy has also been 
investigated as a therapy to reduce the exercise-induced oxidant stress during high- 
intensity exercise. For example, Sumida et al (1989) demonstrated that 4-weeks of 
vitamin E supplementation prevented a rise in plasma MDA levels following maximal- 
intensity cycle exercise. Ashton et al (1999) demonstrated that acute ascorbic acid 
supplementation prevented exercise-induced oxidant stress in healthy subjects. In 
contrast to these findings, daily supplementation with an antioxidant mixture (30 mg ß- 
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carotene, 592 mg vitamin E and 1000 mg vitamin C) did not prevent the exercise- 
induced rise in plasma MDA after moderate- to high-intensity treadmill running (Kanter 
et al., 1993). The effects of antioxidant supplementation on oxidant stress levels in 
overweight and obese subjects has not been studied following acute exercise. 
Alternatively, selenium (Se) supplementation may be a suitable candidate to reduce the 
obesity-associated oxidant stress and exercise-induced oxidant stress. Se is an 
essential component of the GSH-Px system (Ladenstein et al., 1979), which functions 
as part of an antioxidant system to protect PUFAs and proteins from the damaging 
effects of peroxides and LH (Richter, 1987; Del Maestro et al., 1980). In humans, Se 
deficiency has been implicated in the etiology of CVD and other conditions in which 
oxidant stress and inflammation are prominent features, but there is still only limited 
evidence from epidemiological studies for this and the therapeutic benefit of Se 
administration in the prevention and treatment of CVD remains insufficiently 
documented (Alissa at al., 2003). 
Epidemiological studies have indicated an association between a low Se status and an 
increased risk for ischaemic heart disease (Huttunen, 1986). However these results 
are not consistent with the findings of Miettinen et a/ (1983) and Kok et a/ (1987) who 
found no association between blood Se levels and the risk of CVD. In addition, no 
differences in tissue Se were apparent in patients who died, with or without myocardial 
infarction (Ringdal et aL, 1986). However Kiem and Feinendegen (1984) did observe 
diminished activities of GSH-Px and decreased Se levels in platelets from patients with 
acute myocardial infarction exhibiting a greater tendency to aggregation. Neve (1996) 
supported the proposed protective effect of Se against CVD by the ability of GSH-Px to 
combat the oxidative modification of lipids and to reduce platelet aggregation. The 
prevention of LH build-up promotes the production of vasodilatory prostacylin by the 
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endothelium which in turn reduces the production of thromboxane, thus reducing 
vasoconstriction and platelet aggregation (Neve, 1996). 
Considering potential consequences of low Se intake, it is no surprise that current UK 
Se intake is a cause for concern (Rayman, 2002). UK daily intakes of So have reduced 
from 60-63 ug/d to the current level of 34-39pg/d (Barclay et a/., 1995; Ministry of 
Agriculture Fisheries and Food, 1997,1999) which does not meet the reference 
nutrient intake for males and females (75 and 60pg/d respectively) (Department of 
Health, 1991). In addition, current plasma or serum Se concentrations may not allow 
maximal expression of plasma GSH-Px (Duffield et al., 1999). Consequently Se 
supplementation in all individuals may be of benefit but specific population groups may 
need to be targeted first. For example obese subjects are prone to both enhanced 
oxidant stress (Yesilbursa et aL, 2005; Mohn et al., 2005; Keany et al., 2003; Ozata et 
aL, 2002; Davi et aL, 2002; Dandona et al., 2001; Präzny et al., 1999) and platelet 
hyperactivity (Anfossi et aL, 2004) and furthermore have been shown to have reduced 
GSH-Px levels (Olusi et al., 2002). 
Although the effect of Se supplementation in overweight or obese subjects on oxidant 
stress levels at rest or following exercise is unknown, it can be speculated that Se 
supplementation will reduce both the obesity-associated oxidant stress and exercise- 
induced oxidant stress. Several studies support that Se supplementation has the 
potential to reduce oxidant stress. For example Sarada et al (2002) noted that Se 
supplementation reduced lipid peroxidation in male albino rats during exposure to 
hypoxia-induced oxidant stress. Bortoli et al (1991) and Wilke et al (1992) observed 
reduced MDA levels following Se supplementation in elderly women and 
phenylketonuric (PKU) children (at risk of Se deficiencies), respectively. However a 
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double-blind, cross-over study demonstrated no beneficial effect of Se supplementation 
on reducing organic hydroperoxide levels in cystic fibrosis children (Portal et al., 1995). 
This study investigated the effect of Se supplementation on LH, TAS, GSH, SOD and 
ADP-induced platelet aggregation in healthy normal-weight and overweight subjects at 
rest and following acute aerobic high-intensity exercise. The study aimed to evaluate 
the potential Se supplementation may have on reducing both obesity-associated 
oxidant stress and exercise-induced oxidant stress and associated impact on platelet 
aggregation, which may determine whether Se supplementation is a potential 
therapeutic tool for reducing the risk of CVD. 
8.1 METHODOLOGY 
Subject Characteristics 
The study group included 20 subjects [10 normal-weight (BMI: 23.4±0.46kg/m2) and 10 
overweight (26.6±0.36kg/m2) healthy males and females (normal-weight (n=4/6), 
overweight (n=4/6)] (see table 8.0 for subject characteristics). Volunteers were invited 
to take part in the study by local advertisement. An inclusion criterion was age 
between 18 and 50 years old and BMI between 20 and 35kg/m2. Subjects with a 
history of diabetes, cardiovascular or cerebrovascular disease, hepatic or renal 
disease, tobacco abuse, or those on hormone replacement therapy were excluded. In 
addition subjects were excluded if they were hypertensive (with or without treatment), 
taking treatment for dyslipidaemia, taking any antioxidant supplementations or a 
smoker. Written informed consent was obtained from all the subjects after they had 
been given a full explanation of the study. The research was given ethical approval by 
Bedfordshire Local Research Ethics Committee. 
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Table 8.0. Subject characteristics 
P Value 
Characteristic Normal-weight Overweight NW 
NW (n=10) OW (n=10) vs 
m/f (5/5) m/f (5/5) OW 
Age, yr 27.9 ±2.19 31.4±1.98 . 251 
Body mass, kg 67.72: t 2.98 82.82 t 3.73 <. 01 
Body mass index, kg/m 23.55 t 0.53 28.4210.73 <. 001 
Body fat, kg 16.64±1.53 28.01±3.17 <. 01 
Waist, cm 77.95±1.94 92.58±3.02 <. 001 
Systolic BP, mmHg 116.3013.19 128.3013.37 . 08 
Diastolic BP, mmHg 73.60±2.00 83.10±1.49 <. 001 
Fasting glucose, mmoVL 6.5110.45 5.8710.44 . 327 
Fructosamine, mmol/L 188±8.34 201.33±7.30 . 38 
Total cholesterol, mmo/L 4.60±0.53 4.77±0.18 . 856 
HDL-cholesterol, mmol/L 1.66±0.11 1.52±0.13 . 32 
LDL-cholesterol, mmol/L 2.58±0.45 2.72±0.22 <. 05 
Triglycerides, mmoUL 0.79t0.07 1.14t0.27 . 47 
Values expressed as the mean±SEM. BMI, body mass index; BP, blood pressure; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein. Results were compared using a 
one-way ANOVA and P values are given in the Table. P values < 0.05 were 
considered significant. For further details see text. 
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Experimental design 
Subjects visited the Centre for Obesity Research, Luton and Dunstable Hospital on four 
separate occasions between 9-11 am over a 14-week period and were instructed to fast 
for 10-12 hours and refrain from exercise, caffeine and alcohol for 48 hours before the 
study visits. Subjects were also asked to maintain their usual dietary pattern. 
A placebo-controlled, double-blind, cross-over study was performed, with a wash-out 
period before crossing over. Each subject received 200µg Se (sodium selenite) for 3- 
weeks and placebo during another 3-week period. Ten subjects underwent the 
treatment in the following order: Se/placebo and the other 10 subjects in the reverse 
order: placebo/Se. The wash-out period was observed for 2-months after the first 
treatment period. A general scheme of the intervention is presented in figure 8.0. 
Selenium/Placebo Supplementation (3 weeks) 
Week 
Anthropometric measures, blood sample 
and cardiorespiratory fitness test. 
Week 3 
'jr 
Selenium/Placebo Supplementation (3 weeks) 
I 
Week 11 
Anthropometric measures, blood sample 
and cardiorespiratory fitness test. 
Week 14 
I I resting blood sample t bout of aerobic physical activity (30 minutes at 70% VO2max) Blood sample immediately post-exercise and thirty minutes post-exercise 
Figure 8.0. General schema of the selenium supplementation intervention 
At visit 1 and 3, prior to each treatment, all subjects underwent anthropometric 
measures, a venous blood sample and an incremental exercise test to exhaustion for 
assessment of cardio-respiratory fitness. 
Wash-out 
period (8 
weeks) 
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Following each 3 week treatment, subjects completed an exercise session which 
adopted the following protocol (visit 2 and 4): 
 5 min warm up (40% VO2max) 
  The subject was then required to perform a constant workload 
corresponding to 70% VO2max for 30 minutes. 
Heart rate was monitored throughout the exercise sessions. Prior to, immediately post- 
exercise and 30 minutes post exercise, a venous blood sample was collected. 
Anthropometric and cardiovascular measurements and venous blood sampling 
Height, weight and waist measurements are described in detail in the methodology 
chapter (section 3.2.1,3.2.2,3.2.3). Body composition was assessed using the 
BodPod, which is outlined in the methodology chapter (section 3.2.4.2). 
Cardiovascular measurements are described in the methodology chapter (section 3.3). 
Venous blood samples were collected as described in the methodology chapter 
(section 3.1.1 and 3.2.2). 
Maximal aerobic exercise test 
The maximal exercise test incorporated the Bruce Protocol (Bruce, 1972). 02 uptake 
was assessed using the MetaMax 3B®. Maximal aerobic capacity was determined 
when the subject met two of the following criteria: 
  Within 10 beats of maximal age predicted heart rate (220 - age) 
  Respiratory quotient greater than 1.1 
" Rating of perceived exertion >17 
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Biochemical measurements 
LH, TAS, SOD, GSH and Se were performed as described in methodology chapter 
(section 3.1.12.1,3.1.14.1,3.1.14.2,3.1.14.3 and 3.1.14.4). Other biochemical 
measures included, fasting plasma glucose, plasma fructosamine, plasma cholesterol, 
plasma LDL, plasma HDL and plasma triglycerides as described in methodology 
chapter (section 3.1.6,3.1.7,3.1.8,3.1.9,3.1.10 and 3.1.11). ADP-induced percentage 
platelet aggregation was measured using PlateletWorks®, which is outlined in the 
methodology chapter (section 3.1.14.2). Final concentrations of ADP used for platelet 
aggregation were 10 and 20pM. Haematocrit and Haemoglobin was also measured 
using PlateletWorks® which is also outlined in the methodology chapter (section 3.1.4.1 
and 3.1.5.1). Haematocrit and Haemoglobin were measured to calculate the change in 
plasma volume (Dill and Costill, 1974). 
Statistical Analysis 
Values reported as mean±SEM. SEM was appropriate because it demonstrates how 
liable to error the mean is (e. g. the mean value or the mean change or improvement). 
The Kolmogorov-Smirno test confirmed that the data was normally distributed. The 
data was analyzed using analysis of variance (ANOVA) with repeated measures, which 
is appropriate for detecting differences between groups, time effects and interactions. 
A three-way (AxBxC) mixed ANOVA was used which incorporated two between 
(groups: normal-weight vs overweight and placebo vs selenium supplementation) and 
one within (time: rest vs post-exercise vs thirty minutes post-exercise) subject factor. 
When significant F values were noted paired t-tests were used to detect specific 
differences within groups at certain time points during the study. To detect differences 
between groups, one-way ANOVA was incorporated with one within (time: rest vs post- 
exercise) subject factor. Differences were considered statistically significant at P<0.05. 
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Statistical analysis was carried out using a computer software package (SPSS for 
Windows, Version 13.0). 
8.2 RESULTS 
Subject characteristics at week 1 for the normal-weight and overweight groups are 
shown in table 8.0. Body mass, BMI, body fat and waist circumference, DBP and LDL 
cholesterol were all significantly higher in the overweight group compared to the 
normal-weight group (P<0.01, P<0.001, P<0.01, P<0.001, P<0.001 and P<0.05, 
respectively). All subjects demonstrated similar systolic blood pressure, cholesterol, 
HDL, triglycerides, fasting glucose and fructosamine levels. At week 12, following the 
wash-out period, the subject characteristic differences between the normal-weight and 
overweight group remained the same, indicating there was no change in physiological 
and biochemical measurements over the duration of the study. 
LH, TAS, SOD and GSH values in the normal-weight and overweight groups at week 0 
and 12 (following wash-out period) are given in table 8.1. No significant differences 
were found in LH, TAS, SOD and GSH between week 0 and 12 in the normal-weight 
and overweight group. However when comparing between the normal-weight and 
overweight group, at weeks 0 and 12, several differences were noted. For example, at 
week 0, LH levels in the overweight group were significantly higher than the normal- 
weight group [overweight vs normal-weight (0.61±0.06 vs 0.74±0.06pmoVL, P<0.05)] 
and at week 12, LH levels demonstrated a non-significant increased trend in the 
overweight group compared to the normal-weight group [overweight vs normal-weight 
(0.60±0.06 vs 0.73±0.06pmol/L, P=0.06)]. No significant differences in TAS, SOD and 
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GSH levels were observed between the normal-weight and overweight group at week 0 
and 12. 
Table 8.1. LH, TAS, SOD and GSH values in the normal-weight and overweight group 
at week 0 and 12 (following wash-out period). 
Normal-weight (n=10) Overweight (n=10) 
Wk O Wk 12 Wk 0 Wk 12 
LH, pmol/L 0.61±0.06 0.60±0.06 0.74±0.06 " 0.73±0.06 
TAS, mmol/L 686.10±32.16 755.07±66.61 831.20±46.35 797.60±64.83 
SOD, U/g Hb 3735.14±264.16 3947.29±291.86 3265.75±3565.44 3565.44±222.97 
GSH, pmol/g Hb 18.03±1.41 18.47±2.31 16.33±1.55 17.69±2.31 
Values expressed as the mean±SEM. LH, lipid hydroperoxide; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione. Results were analyzed 
using repeated measures, a one-way ANOVA and paired t-test. (*, P<0.05, compared 
to normal-weight group). P values < 0.05 were considered significant. For further 
details see text. 
Plasma Se levels in the normal-weight and overweight group at week 0,12 (following 
wash-out period) and immediately following 3 weeks placebo and Se treatment are 
shown in table 8.2. Plasma Se levels in both the normal-weight and overweight group 
remained similar at week 0, week 12 and following placebo treatment. However, 
compared to week 0, plasma Se levels significantly increased following 3-weeks Se 
supplementation in both the normal-weight and overweight group [wk 0 vs post Se 
treatment (normal weight, 68.44±6.91 vs 97.38±6.08pg/L, P=0.028 and overweight, 
46.40±1.55 vs 81.72±6.71pg/L, P=0.003). Interestingly, plasma Se levels were 
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significantly lower in the overweight group when compared to the normal-weight group 
at wk 0,12 and following placebo treatment [overweight vs normal-weight (wk 0, 
68.44±6.91 vs 46.40±1.55pg/L, P=0.014, Wk 12,65.46±5.45 vs 46.46±1.68pg/L, 
P=0.010, post placebo treatment, 71.46±7.06 vs 45.20±2.28pg/L, P=0.008)], but 
following Se supplementation this significant difference disappeared as plasma Se 
levels in the overweight group increased to a level similar to the normal-weight group 
[normal-weight vs overweight (97.38±6.08 vs 81.72±6.71 pg/L, P=0.122) 
Table 8.2. Plasma Se levels in the normal-weight and overweight group at wk 0, wk 
12 (following wash-out period), following 3 weeks placebo treatment and following 3 
weeks Se treatment. 
Selenium (pg/L) WkO Wk 12 
(post wash-out) 
Post placebo 
treatment 
Post selenium 
treatment 
Normal-weight 68.44±6.91A 65.46±5.45^^ 71.46±7.06^^ 97.38±6.08 0° 
Overweight 46.40±1.55 46.46±1.68 45.20±2.28 81.72±6.71" 00 00 
Values expressed as the mean±SEM. WkO, baseline visit; Wk 12, visit after wash-out 
period. Results were analyzed using repeated measures, one-way ANOVA and paired 
t-test (^, P<0.05, compared to overweight, ", P<0.01, compared to overweight, *, 
P<0.05, compared to wk 0, **, P<0.01, compared to wk 0,0, P<0.02, compared to 
wk12,00, P<0.01, compared to wk12, °, P<0.05, compared to placebo, °°, P<0.01, 
compared to placebo. P values < 0.05 were considered significant. For further details 
see text. 
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Table 8.3 and 8.4 and figure 8.1 and 8.2 show LH levels in the normal-weight and 
overweight groups, pre- and post-acute aerobic high-intensity exercise following 
placebo and Se supplementation. During placebo treatment in the normal-weight 
group, an acute high-intensity exercise session did not significantly increase LH levels 
post-exercise [rest vs post exercise (0.64±0.06 vs 0.72±0.06pmol/L, P>0.05)]. Se 
supplementation in the normal-weight group also did not have any beneficial effect on 
LH levels at rest, post-exercise and 30-minutes post-exercise when compared to the 
placebo supplementation [Se vs placebo, pre vs post vs 30-minutes post (0.60±0.07 vs 
0.64±0.06pmol/L, P>0.05; 0.70±0.05 vs 0.72±0.06pmol/L, P>0.05 and 66±0.05 vs 
0.65±0.06pmol/L, P>0.05)]. During placebo treatment in the overweight group, LH 
levels increased significantly following the high-intensity acute exercise session [rest vs 
post (0.77±0.09 vs 0.96±0.09pmol/L, P<0.02)] and following 30-minutes recovery LH 
levels returned to near resting levels (0.78±0.12pmoVL, P<0.05). Following Se 
supplementation in the overweight group, LH was reduced immediately post acute 
exercise when compared to the placebo supplementation [Se vs placebo (0.71±0.08 vs 
0.96±0.09pmol/L, P<0.02)] and LH levels did not significantly increase following high- 
intensity acute exercise (as seen following placebo treatment). When comparing the 
normal-weight and overweight group, LH levels were significantly higher in the 
overweight group immediately post-exercise and 30-minutes post-exercise in the 
placebo group [normal-weight vs overweight, post vs 30-minutes post-exercise 
(0.72±0.06 vs 0.96±0.09pmoVL, P<0.05 and 0.65±0.06 vs 0.78±0.12pmol/L, P<0.05)] 
but this significance disappeared post-exercise and 30-minutes post-exercise following 
Se supplementation in the overweight group [normal-weight vs overweight, post vs 30- 
minutes post-exercise (0.70±0.05 vs 0.71±0.08pmoVL, P>0.05 and 0.66±0.05 vs 
0.69±0.07pmol/L, P>0.05)]. 
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Table 8.3. LH, TAS, SOD and GSH values in the normal-weight group, pre and post 
high-intensity acute exercise, following placebo and Se supplementation. 
Placebo 
Pre Post 30mins post 
LH, pmol/L 0.64±0.06 0.72±0.06 0.65±0.06 
TAS, mmol/L 748.84±46.81 724.20±29.68 770.13±31.73 
SOD, U/g Hb 3965.90±306.02 4005.28±347.22 3770.49±279.54 
GSH, pmoVg Hb 20.86±3.00 15.16±3.10 17.45±3.00 
Se supplementation 
Pre Post 30mins post 
LH, pmol/L 0.60±0.07 0.70±0.05 0.66±0.05 
TAS, mmol/L 646.04±10.800 779.17±53.61 * 778.32±39.36** 
SOD, U/g Hb 3473.80±430.77 3727.88±370.77 2931.48±232.12# 
GSH, pmol/g Hb 20.43±3.76 21.65±4.97 19.32±5.03 
Values expressed as the mean±SEM. LH, lipid hydroperoxide; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione. Results were analyzed 
using repeated measures, a one-way ANOVA and paired t-test. (*, P<0.05, compared 
to pre-values, **, P<0.02, compared to pre-values, 0, P<0.05, compared to placebo 
values). P values < 0.05 were considered significant. For further details see text. 
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Table 8.4. LH, TAS, SOD and GSH values in the overweight group, pre and post high- 
intensity acute exercise, following placebo and Se supplementation. 
Placebo 
Pre Post 30mins post 
LH, pmoVL 0.77±0.09 0.96±0.09** ° 0.78±0.12 * 
TAS, mmol/L 853.88±52.33 836.08±70.27 851.10±50.0 
SOD, U/g Hb 4212.07±422.36 3908.85±262.58 3237.41±259.73*^ 
GSH, pmol/g Hb 16.39±2.39 17.36±2.72 19.12±3.41 
Se supplementation 
Pre Post 30mins post 
LH, pmol/L 0.67±0.08 0.71±0.08$$ 0.69±0.07 
TAS, mmoVL 902.95±77.72 
00 931.51±72.83 895.10±57.99 
SOD, U/g Hb 3298.30±236.32# 3674.96±315.66 3644.49±321.59 
GSH, pmol/g Hb 14.61±2.57 13.55±3.00 12.05±3.02 
Values expressed as the meantSEM. LH, lipid hydroperoxide; TAS, total antioxidant 
status; SOD, superoxide dismutase; GSH, reduced glutathione. Results were analyzed 
using repeated measures, a one-way ANOVA and paired t-test. (*, P<0.05, compared 
to pre-values, **, P<0.02, compared to pre-values, ^, P<0.02, compared to post-values, 
0, P<0.05, compared to placebo values, 00, P<0.02, compared to placebo values, °, 
P<0.05, compared to normal-weight group, °°, P<0.02, compared to normal-weight 
group. P values < 0.05 were considered significant. For further details see text. 
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Figure 8.1. LH values (pmol/L) in the normal-weight group, pre and post high-intensity 
acute exercise, following placebo and Se supplementation. Results (mean±SEM) were 
analyzed using repeated measures, one-way ANOVA and paired t-tests. For further 
details see text. 
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Figure 8.2. LH values (pmol/L) in the overweight group, pre and post high-intensity 
acute exercise, following placebo and Se supplementation. Results (mean±SEM) were 
analyzed using repeated measures, one-way ANOVA and paired t-tests (", P<0.02, °, 
P<0.05 compared to normal-weight group). P values < 0.05 were considered 
significant. For further details see text. 
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No consistent changes in TAS, SOD and GSH levels (see table 8.2 and 8.3) were 
observed in the normal-weight and overweight group following placebo or Se 
supplementation, pre-, post- or 30-minutes-post acute exercise. No changes in ADP- 
induced platelet aggregation (ADP dose 10 and 20pM) were noted following placebo or 
Se supplementation in or between the normal-weight or overweight group, pre-, post- 
and 30-minutes-post-acute exercise (see figure 8.3 and 8.4) 
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Figure 8.3. Percentage ADP-induced platelet aggregation (10pM) in the normal-weight 
and overweight group, pre and post high-intensity acute exercise, following placebo 
and Se supplementation. Results (mean±SEM) were analyzed using repeated 
measures and one-way ANOVA. For further details see text. 
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Figure 8.4. Percentage ADP-induced platelet aggregation (20pM) in the normal-weight 
and overweight group, pre and post high-intensity acute exercise, following placebo 
and Se supplementation. Results (meantSEM) were analyzed using repeated 
measures and one-way ANOVA. For further details see text. 
8.3 Discussion 
In a double-blind cross-over study, the short term effects of Se supplementation were 
investigated on LH, TAS, SOD, GSH and ADP-induced platelet aggregation at rest and 
following an acute high-intensity aerobic exercise in both normal-weight (n=10) and 
overweight (n=10) subjects. This is the first study to assess the impact of Se 
supplementation on the obesity-associated oxidant stress at rest, the exercise-induced 
oxidant stress response and ADP-induced platelet aggregation. 
Very few studies have assessed the independent role of Se supplementation on 
reducing both LH, TAS, SOD, GSH levels and platelet aggregation, but the general 
consensus is that Se supplementation may reduce oxidant stress levels (Wilke et al., 
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1992; Bortoli et al., 1991; Sarada et al., 2002). However, the effects of Se 
supplementation on platelet aggregation are conflicting, indicating a possible beneficial 
effect (Kiem and Feinendegen., 1984) or no effect (Van Dokkum et aL, 1992). 
Research suggests that Se supplementation provides a more efficient antioxidant 
system by enhancing GSH-Px activity (Bortoli et al., 1991; Wilke et aL, 1992) which 
catalyses the decomposition of H202 and organic peroxides (Halliwell and Gutteridge, 
1999). Neve (1996) proposed that GSH-Px has the ability to combat the oxidative 
modification of lipids and reduce platelet aggregation. The prevention of LH build-up 
promotes the production of vasodilatory prostacyclin by the endothelium which in turn 
reduces the production of thromboxane, thus reducing vasoconstriction and platelet 
aggregation (Neve, 1996). Alternatively, reduced oxidant stress levels as a result of Se 
supplementation may indirectly affect platelet aggregation as research suggests that 
oxidant stress participates in the regulation of platelet activation (Krotz at al., 2004) (as 
discussed in chapter 5 and 7). The impact of GSH-Px on reducing both oxidant stress 
and platelet aggregation is of particular relevance to obese subjects as Olusi et al 
(2002) demonstrated reduced GSH-Px levels in this subject group compared to a non- 
obese group (84.3±6.7 vs 98.4±3.3U/g Hb, P<0.001). Since Se is an essential metal 
cofactor for the activity of GSH-Px (Rotruck et al., 1973), Se supplementation in the 
obese group may increase GSH-Px activity (Bortoli at aL, 1991; Wilke et al., 1992). 
To date few researchers have investigated the effect of Se supplementation on oxidant 
stress levels and platelet aggregation which are discussed below. Wilke et a/ (1992) 
noted improvements in oxidant stress status in PKU children (n=15) (at risk of Se 
deficiencies) who were given a daily sodium selenite (0.13pmol Se/kg/day) supply for 6 
months. Compared to control values, PKU children had significantly lower plasma and 
erythrocyte Se, significantly lower plasma and erythrocyte GSH-Px activity and 
significantly higher plasma MDA. Following Se supplementation, compared to control 
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levels, plasma Se, and GSH-Px values normalised after 1 month, erythrocyte Se after 2 
months, and erythrocyte GSH-Px and plasma MDA after 4 months. Bortoli et al (1991) 
studied the effects of 30 days Se supplementation (4 x 16.5pg inorganic Se and 5.0mg 
Vitamin E) in twenty elderly women. MDA levels showed insignificant changes during 
the Se supplementation period but 30-days post-Se supplementation, MDA decreased 
to a level lower than pre-Se supplementation [baseline vs 30-days post Se 
supplementation (4.3±0.6 vs 3.3±0.3pmol/L, P<0.05)]. Sarada et al (2002) found a 
reduction in hypoxia-induced oxidant stress in male Sprague-Dawley rats. Compared 
to the hypoxia only group, hypoxia plus Se supplementation demonstrated a significant 
decrease in MDA [hypoxia vs hypoxia + Se (4.0±0.4 vs 1.7±0.7nmol/mL, P<0.05)] and 
subsequent increase in plasma GSH levels [hypoxia vs hypoxia + Se (11.9±1.0 vs 
25.8±9.7nmoVmL, P<0.05)]. Similarly, blood GSH-Px, plasma protein and plasma Se 
content also increased (P<0.05, P<0.05, P<0.05, respectively) in the Se supplemented 
hypoxia group compared with hypoxia alone. However, no beneficial effect of Se 
supplementation was found by Portal et al (1995) who performed a double-blind cross- 
over Se supplementation study on lipid peroxidation markers in cystic fibrosis patients. 
Similar to obese patients, cystic fibrosis patients have been shown to have increased 
lipid peroxidation markers (Wilke et al., 1990), as a result of increased production of 
ROS mediated by infections or a defect in antioxidant defences (Portal et al., 1995). 
Portal et al (1995) assessed twenty seven cystic fibrosis children who were given 2.8pg 
of sodium selenite per kg per day for 5-months and 5-months with a placebo control 
and inversion of treatment periods. Simultaneously, 17 healthy children were also 
investigated as control subjects. Although Se status was similar in both the control 
(n=17) and cystic fibrosis children (n=27), cystic fibrosis children had significantly 
higher lipid peroxidation markers (organic hydroperoxides) (122.6±23.3 vs 
171.5±54.4pmol/L, P<0.05). However organic hydroperoxides were normalized at 12- 
months on either Se or placebo treatment. After the initial treatment, Se 
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supplementation increased plasma Se concentration and increased GSH-Px- activity 
whilst the placebo group demonstrated a reduction in plasma Se concentration and no 
significant changes in GSH-Px activity [baseline vs first treatment: Se concentration 
(Se group, 0.83±0.17 vs 1.11±0.18pmol/L, P<0.05 and placebo group, 0.78±0.14 vs 
0.67±0.13pmoVL, P<0.05), GSH-Px concentration (Se group, 269.8±40 vs 
340.4±77pmol/L, P<0.05 and placebo group, 260±45 vs 291.4±67pmo1/L, P>0.05)]. 
However compared to month 5, following the second treatment period, Se 
supplementation increased plasma Se concentration (P<0.05) but decreased GSH-Px 
activity (P>0.05) whilst in the placebo group plasma Se concentration decreased 
(P<0.05) and GSH-Px activity decreased (P>0.05). These results indicated that 
improvement of lipid peroxidation markers in cystic fibrosis was not related to the Se 
supplementation. The decrease in organic hydroperoxide levels observed following Se 
treatment may be linked to the improvement of the biological indices of Se status as 
reported in studies by Bortoli et al (1991) and Wilke et al (1990). However this 
relationship is inconsistent with data observed in the placebo group since organic 
hydroperoxide levels normalized in spite of a reduced plasma selenium concentration. 
It may be possible that the variable organic hydroperoxide levels in healthy subjects 
was a result of seasonal variations or the interpretation of the data may have been 
limited as a result of inferences in the organic hydroperoxide marker, despite complying 
with the criteria of good analytical practice. Alternatively, the reduced organic 
hydroperoxide levels in the placebo group may be a placebo effect which may have 
been influenced by change in patient behaviour due to inclusion in the clinical protocol 
(Portal et al., 1995). 
With regards to the effect of Se supplementation on platelet aggregation, research is 
limited but Kiem and Feinendegen (1984) did observe diminished activities of GSH-Px 
and decreased Se levels in platelets from patients with acute myocardial infarction 
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exhibiting a greater tendency to aggregation. But Van Dokkum et al (1992) concluded 
that dietary Se supplementation (200pg Se as Se-rich bread for six weeks (Se-wheat)) 
did not improve platelet aggregation in healthy young men (n=6) despite showing 
significantly increased GSH-Px activity. However in a pilot study (Van der Torre et at, 
1989), platelet aggregation was monitored in four subjects after supplementation with 
Se-rich yeast tablets which observed an increased platelet GSH-Px activity and 
decreased platelet aggregation. Levander et al (1983) suggested that the Se 
compounds in yeast differed from those in wheat so Van Dokkum at al (1992) 
confirmed that it may be conceivable that another Se compound in yeast could be of 
importance to platelet aggregation. 
In this study the effects of 3 weeks Se supplementation (200µg sodium selenite) versus 
placebo in a double blind manner (with wash-out period) was investigated on LH. TAS, 
SOD and GSH and ADP-induced platelet aggregation at rest and following acute high- 
intensity aerobic exercise in both normal-weight (n=10) and overweight (n=10) 
subjects. For the duration of the study, no changes in physiological and biochemical 
measurements were observed which could have had an impact on oxidant stress 
levels. The effect of Se supplementation in plasma was clearly identified in both the 
normal-weight and overweight groups. Compared to week 0, Se levels significantly 
increased following 3-weeks Se supplementation in both the normal-weight and 
overweight groups [wk 0 vs post Se treatment (normal weight, 6.84±0.69 vs 
9.7410.61 pg/L, P=0.028 and overweight, 4.64±0.15 vs 8.17±0.67pg/L, P=0.003)]. 
Interestingly, plasma Se levels were significantly lower in the overweight group when 
compared to the normal-weight group at wk 0,12 and following placebo treatment 
[overweight vs normal-weight (wk 0,6.84±0.69 vs 4.64±0.15pg/L, P=0.014, Wk 12, 
6.54±0.54 vs 4.64±0.17pg/L, P=0.010, post placebo treatment, 7.15±0.71 vs 
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4.52±0.23pg/L, P=0.008)], but following Se supplementation this significant difference 
disappeared as Se levels in the overweight group increased to a level similar to the 
normal-weight group [normal-weight vs overweight (9.74±0.61 vs 8.17±0.67pg/L, 
P=0.122). At time-points other than following Se supplementation, such as Wk 0, Wk 
12 (following wash-out period) and following placebo treatment, plasma Se levels were 
all similar in both the normal-weight and overweight groups which highlights that the 
wash-out period was effective at clearing the body of Se as a result of Se 
supplementation. 
LH levels at rest in week 0,12 and following placebo treatment demonstrated either a 
significant or a non-significant increased level in the overweight group compared to the 
normal-weight group. Following Se supplementation, LH levels decreased in both the 
normal-weight and overweight groups but this was not significant. In addition, following 
Se supplementation LH levels were not significantly different between the normal- 
weight and overweight groups. TAS levels significantly decreased in the normal-weight 
group and SOD levels significantly decreased in the overweight group compared to 
placebo treatment. Both of these changes cannot be explained. Se supplementation 
demonstrated no affect on GSH and percentage ADP-induced platelet aggregation 
levels compared to placebo treatment in both the normal-weight and overweight 
groups. 
LH responses immediately post and 30 minutes post high-intensity exercise in the 
normal-weight group following placebo treatment did not demonstrate any significant 
changes but in the overweight group LH levels significantly increased immediately 
post-exercise, which returned to resting levels 30-minutes post exercise. This confirms 
an exercise-induced oxidant stress response following high-intensity exercise in the 
overweight group. Furthermore compared to the normal-weight group, LH levels were 
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significantly higher in the overweight group at both immediately post and 30-minutes 
post high-intensity exercise time-points. Se supplementation in the normal-weight 
group demonstrated no positive effect on LH levels immediately post-exercise and 30 
minutes post-exercise. However in the overweight group, Se supplementation 
prevented a significant increase in LH levels immediately post-exercise. As a result, 
following Se supplementation, LH levels between the normal-weight and overweight 
groups were not significantly different immediately post and 30-minutes post exercise. 
No significant changes in TAS, SOD, GSH and platelet aggregation levels were 
observed in the normal-weight and overweight groups following placebo or Se 
supplementation, immediately post or 30 minutes post high-intensity exercise. 
This study found that 3 weeks Se supplementation (200pg/d sodium selnite) was 
affective at increasing plasma Se levels in both the normal-weight and overweight 
groups. Furthermore Se supplementation in the overweight group reduced the 
exercise induced oxidant stress response observed following placebo treatment. This 
is particularly important for overweight or obese individuals who exercise sporadically 
because they may be at greater risk of exercise-induced oxidant stress since the lack 
of regular training would not permit an enhancement of the defence mechanisms. This 
is perhaps even more relevant in the overweight / obese patient because obese people 
have been shown to have lower antioxidant concentration (Reitman et al., 2002; 
Strauss et al., 1999; Decsi et al., 1997; Kuno et al., 1998; Moor De Burgos et al., 1992) 
and decreased activities of erythrocyte cytoprotective enzymes (Olusi, 2002; Ozata et 
al., 2002; Beltowski et al., 2000). Furthermore in this study, overweight subjects were 
shown to have lower plasma Se levels [normal-weight vs overweight (6.84±0.69 vs 
4.64±0.15pg/L, P<0.05) which may lead to a more ineffective antioxidant system by 
reducing GSH-Px activity (Bortoli et al., 1991; Wilke et al., 1992). 
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The findings of this study have been compared to other antioxidant therapy studies in 
obesity aimed at reducing oxidant stress levels. It is difficult to make comparable 
conclusions between this study and others with regards to the effectiveness of Se 
supplementation on reducing oxidant stress levels because studies have all used 
various oxidant stress markers. At rest, this study demonstrated a reduction in LH 
levels of 13% in the overweight group and a 6.25% reduction in the normal-weight 
group following 3-weeks Se supplementation [placebo vs Se (overweight, 0.77±0.09 vs 
0.67±0.08pmoVL, P>0.05, normal-weight, 0.64±0.06 vs 0.60±0.07pmol/L, P>0.05)]. In 
comparison, Skrha et al (1999) found that vitamin E (600mg daily) administration in 
obese diabetic patients for 3 months decreased plasma MDA from 3.13±0.68 to 
2.87±0.97pmoVL which is an 8% reduction in MDA levels. Similarly Manning et al 
(2004) found reduced LH levels in obese subjects following 6-months of vitamin E 
supplementation (3 months 8001U vitamin E/day, 3 months 1200lU vitamin E/day). LH 
was decreased by 27% at 3-months and by 29% at 6-months following vitamin E 
supplementation and the decrease in LH was positively correlated with plasma vitamin 
E concentrations at the 6-month time point (r = 0.40, P=0.01, n=39). Another study 
also indicated protection against formation of oxidative biomarkers with antioxidant 
treatment, for example in overweight type II diabetic versus non diabetic contols 
(Anderson et al., 1999). Twenty diabetics completed an 8-week control period, 8 week 
treatment period (ß-carotene (24mg), vitamin C (1000mg) and vitamin E (8001U) 
followed by an 8-week control period (subjects were on a weight maintaining diet). 
Following the treatment period in the diabetic group, TBARS formation decreased by 
30% (pre vs post: 101.5±10.70 vs 70.6±9.75nmoVmg, P<0.001). 
The effect of antioxidant therapy on reducing exercise-induced oxidant stress has not 
been undertaken in the obese setting but research has been completed in normal- 
weight subjects. In this study, compared to placebo, Se supplementation reduced LH 
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production immediately post high intensity exercise by 2.7% in the normal-weight group 
[placebo vs Se (0.72±0.06 vs 0.70t0.05pmol/L, P>0.05)] and by 26% in the overweight 
group [placebo vs Se (0.96±0.09 vs 0.71±0.08pmol/L, P<0.02)]. In comparison, 
Sumida et al (1989) demonstrated that 4-weeks of vitamin E supplementation 
prevented a rise in plasma MDA levels following maximal-intensity cycle exercise. 
Ashton et al (1999) demonstrated that acute ascorbic acid supplementation prevented 
exercise-induced oxidant stress in healthy subjects. For example in the control phase, 
strenuous exercise caused a significant increase in LH levels [pre-exercise vs post- 
exercise (1.14±0.06 vs 1.62±0.19pmol/L, P=0.005)] and after acute ascorbic acid 
supplementation no change in LH levels were found post strenuous exercise [pre- 
exercise vs post-exercise (1.12±0.21 vs 1.12±0.08pmol/L)]. In contrast to these 
findings, daily supplementation with an antioxidant mixture (30 mg B-carotene, 592 mg 
vitamin E and 1000 mg vitamin C) did not prevent the exercise-induced rise in plasma 
MDA after moderate- to high-intensity treadmill running (Kanter et al., 1993). This 
study found that the normal-weight group did not benefit from reduced LH levels 
following high-intensity exercise, which might be because the normal-weight subjects 
did not have reduced GSH-Px activity (Olusi et al., 2002) suggesting that Se levels 
prior to Se supplementation may have been at a level which allowed for maximal 
expression of GSH-Px activity (Pearson et al., 1990). Alternatively, in all Se 
supplementation studies, variability in results may be associated with differences in 
study protocol. For example, the form of Se ingested affects the response of the 
selenoenzymes (Brown et aL, 2000), the concentration of some selenoenzymes is 
affected more than others by scarce selenium supply owing to the hierarchy of 
selenoprotein expression (Behne et al., 2000). In addition there is considerable 
variation between individuals in the extent of the response of the selenoenzymes to Se 
supplementation so Se requirements between individuals in the same population may 
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differ (Institute of Medicine, 2000) and adaptation to low Se intake can occur by sparing 
excretion (Thomson et al., 1993). 
This study attempted to elucidate if oxidant stress mediates platelet aggregation by 
examining the effect of reduced oxidant stress following So supplementation on platelet 
aggregation levels. Several research studies suggest that oxidant stress participates in 
the regulation of platelet activation (Krotz et al., 2004) and oxidant stress-mediated 
platelet aggregation has been found in several settings of risk factors for 
atherosclerosis and cardiovascular thrombosis, including diabetes mellitus, 
hypertension and hypercholesterolemia (Davi et al., 2003; Minuz of al., 2002; Davi et 
al., 1997). Similarly, Tozzi-Ciancarelli et al (2002) demonstrated that oxidant stress 
induced by strenuous exercise interfered with platelet responsiveness. This was 
evident by adding LDL-Ox to PRP obtained from blood samples collected from 6 
individuals immediately after strenuous exercise as ADP-induced platelet aggregation 
increased and intra-platelet NO content decreased. Several in vitro experimental 
approaches have also been used to investigate the specific role for distinct ROS on 
platelets. Briefly, platelets exposed directly to H202 have enhanced collagen- 
dependent platelet activation and enhanced arachidonic acid (AA)-dependent platelet 
activation (Practio of al., 1992). Platelets exposed to 02 have shown a reduction in 
the threshold for platelet activation to thrombin, collagen, ADP or AA and induced 
spontaneous aggregation (Handin et al., 1977; Krotz et al., 2002; Salvemini of al., 
1989; De la Cruz of al., 1992). 02 - also degrades NO which is a potent inhibitor of 
platelet activation. In addition to exogenously derived ROS affecting the regulation of 
platelet activation, recent data also suggests that the platelets themselves generate 
ROS (Marcus, 1977). 
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This study does not support the association that oxidant stress mediates platelet 
aggregation. At rest and post-high intensity exercise, compared to placebo treatment, 
Se supplementation had no affect on reducing in vivo platelet reactivity In both the 
normal-weight and overweight groups. These findings are similar to that of Van 
Dokkum et al (1992) who concluded that dietary Se supplementation did not improve 
platelet aggregation in healthy young men despite showing significantly increased 
GSH-Px activity. However Kiem and Feinendegen (1984) found that platelets that 
aggregated have significantly lower concentrations of Se (P=0.02) and that platelets 
with higher Se concentrations were less prone to aggregate. The lack of an 
association between Se supplementation and reduced platelet aggregation in this study 
may be because sodium selenite is not important in the role of platelet aggregation. 
For example Levander et al (1983) suggested that the increased platelet GSH-Px 
activity and decreased platelet aggregation in a pilot study following Se-rich yeast 
tablets suggests that particular Se compounds may be importance to platelet 
aggregation because Van Dokkum et al (1992) observed no beneficial effect of wheat 
Se supplementation on platelet aggregation levels. However the increased platelet 
aggregation and TxB2 levels in diabetic rates was shown to reverse following sodium 
selenite supplementation (Ersöz et at, 2003). Another possibility for the lack of 
association between Se supplementation and reduced platelet aggregation may be 
because 3 weeks sodium selenite supplementation is too short a term to establish lipid 
peroxidation-mediated changes in platelet function (Salonen et at, 1991). Stampfer et 
al (1988) observed no significant effects on either in vitro platelet aggregation ability or 
serum thromboxane B2 concentration in 20 healthy university staff member who were 
supplemented with 727mg vitamin E/d for 5 weeks. Salonen et al (1991) attributed the 
lack of changes to the short term supplementation period. Salonen et al (1991) found 
that antioxidant supplementation daily for 5 months (600mg ascorbic acid, 300mg a- 
tocpherol, 27mg B-carotene, and 75pg selenium in yeast) in men (39 controls and 39 
226 
supplemented) with low antioxidant status and high fat intake, reduced 
lipid 
peroxidation, the capacity of platelets to aggregate and to produce thromboxane A2 and 
in vivo platelet activation. Furthermore, Salonen et al (1991) found that the presence of 
the associations between antioxidant changes and change in lipid peroxides was in 
accordance with the hypothesis that antioxidants reduce platelet activity through the 
elimination of circulating lipid peroxides. The discrepancy in the different findings 
between Stampfer et al (1988) and Salonen et al (1991) may also be attributed to the 
difference in baseline antioxidant status and dietary fat intake between the two study 
populations. 
This study provided an insight into the potential role Se could play as an antioxidant 
therapy to reduce oxidant stress at rest and following high-intensity exercise in 'high 
risk' population groups. Although the study benefits from being a double-blind cross- 
over study, questions still remain unanswered regarding the use of Se supplementation 
in everyday practice. For example, the type of supplement, dosage and length of 
consumption must be investigated. It is important to be aware of the reduced Se intake 
in the UK (Rayman et al., 20002) and a Se type and dosage should be selected on the 
basis of normalizing plasma selenium levels in individuals. Normalization of plasma Se 
levels may in turn optimize GSH-Px activity (Duffield et al., 1999), and reduce oxidant 
stress levels. 
8.4 CONCLUSION 
Three-weeks Se supplementation in overweight subjects has the potential to decrease 
LH levels at rest and normalize LH levels immediately post high-intensity exercise. 
However the improvements in LH levels did not extend to reducing in vivo platelet 
reactivity, suggesting that oxidant stress may not be a pivotal determinant of platelet 
aggregation. 
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Chapter NINE 
General discussion 
9.0 Integration and summary of research findings 
Oxidant stress is an imbalance between the formation of reactive oxygen / nitrogen 
species and antioxidants (Powers et al., 2004). The level of redox signalling is 
elevated in conditions such as hypertension, hyperinsulinemia, hyperlipidaemia and 
obesity (Vincent and Taylor, 2006). In addition, high fat (Slim et al., 1996) and high 
sugar diets (Faure at al., 1997) and moderate unaccustomed exercise all pose an 
acute oxidant stress (Alessio et al., 2000). Paradoxically though, regular endurance 
exercise is associated with increased intracellular antioxidants and antioxidant 
enzymes and decreased ROS production during exercise (Fukai et aL, 2000). 
Similarly alternative strategies such as dietary modifications (Velthuis-te Wierik et al., 
1996), weight loss (Davi et al., 2002) and antioxidant therapy (Skrha et al., 1999; 
Manning et al., 2004) may improve oxidant stress levels, leading to long-term 
vascular protection, or protection against several diseases associated with oxidant 
stress such as premature aging, diabetes mellitus, arthritis and cancer (Niki, 2001). 
The present research was conducted to investigate whether (1) both overweight and 
obese individuals are susceptible to increased oxidant stress (2) a short-term low 
carbohydrate diet in overweight subjects may generate oxidant stress (3) overweight 
individuals are more susceptible to exercise-induced oxidant stress (4) selenium 
supplementation may attenuate oxidant stress in overweight subjects at rest and 
following aerobic exercise (5) oxidant stress may play a pivotal role in platelet 
aggregation. 
Figure 9.0 integrates and summarises the research findings of all the studies 
conducted as part of this thesis. Where a question mark is presented, this indicates 
that the finding or mechanism is open to discussion since it was not sufficiently 
elucidated in this work. 
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Figure 9.0. Chain of events for oxidant stress and platelet aggregation in 
overweight/obese individuals, following acute high-intensity exercise 
and short-term low carbohydrate diets and the effect of selenium 
supplementation. 
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9.1 BMI and oxidant stress 
Study 1 demonstrated significantly elevated levels of oxidant stress levels in obese 
individuals when compared to normal-weight and overweight individuals as 
evidenced by increases in LH levels. This may be associated with an increase in 
oxygen consumption, implicating the mitochondria as a potential source of primary 
oxygen-centred free radical species. Other possibilities include reduced antioxidant 
status, cell injury/inflammation and increased fat deposition (Vincent et al., 2001), 
hyperglycaemia, hypertension and hyperleptinaemia (Vincent and Taylor, 2006). 
Although this study did not set out to identify potential causes of increased oxidant 
stress in obesity, lowered antioxidant status, hypertension and hyperglycamia were 
found not to be factors contributing to increased oxidant stress in obesity because (1) 
antioxidant status was not shown to be lower in obesity and (2) obese individuals 
with either hypertension or hyperglycaemia were excluded from the study. 
Despite overweight individuals not being predisposed to enhanced oxidant stress, 
studies 3 and 4 found that lifestyle habits such as short-term low carbohydrate diets 
and/or acute exercise can increase oxidant stress levels in overweight individuals. It 
can therefore be speculated that obese individuals would also respond to the above 
strategies with increased oxidant stress levels. It was appropriate to study the effect 
of these strategies in overweight subjects because overweight/obese individuals 
often attempt to lose with weight by exercising and changing dietary habits 
(Goldbeter, 2006). 
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9.2 Short-term low carbohydrate diets and oxidant stress 
Study 3 investigated the impact of commercial diets for weight loss in a real-life 
setting on oxidant stress parameters. Compared to a conventional and control diet, a 
low carbohydrate diet caused an increase in LH levels during the first two weeks 
which decreased at week 4 whilst total antioxidant status levels increased gradually 
to week 4. This occurred despite the low carbohydrate diet achieving the greatest 
weight loss compared to the conventional and control diet (which can be a potential 
mechanism to reduce oxidant stress). The change in oxidant stress levels are likely 
to reflect initial increased susceptibility to oxidants possibly caused by changes in 
macro-nutrient intake (Slim et aL, 1996; Velthuis-te Wierik et al., 1996) versus 
baseline [e. g. increased fat (total or saturated fat content) and or protein intake], 
followed by compensatory elevations in antioxidant enzyme levels to help protect 
tissues against further tissue damage. For example SFAs have been shown to be 
susceptible to oxidation (Mata et al., 1996) and MUFAs lower LDL oxidation (Berry et 
al., 1991; Reaven et al., 1991) whilst lipoproteins isolated from individuals consuming 
diets rich in PUFAs and MUFAs demonstrate greater pre-disposition to peroxidation 
than lipoproteins from individuals given SFAs (Kleinveld et al., 1993). Changes in the 
consumption of lard and compound cooking fat (such as baking and frying 
margarines) which contain high levels of pre-formed hydroperoxides (Wolff and 
Nourooz-Zadeh, 1996) may explain changes in LH levels on the LowCD or explain 
the diverse results in lipid peroxidation responses in studies investigating the impact 
of composition of dietary fat on oxidant stress levels (largely dependent upon the 
intake of food containing hydroperoxides generated by pyrolysis such as fatty fried 
foods). Increased protein intake on the LowCD may also promote oxidant stress 
(Fang et al., 2002). High protein diets increase homocysteine levels, which can 
increase endothelial 02' production and induce oxidant stress in the vasculature (Wu 
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and Meininger, 2002). In addition, increased protein intake has also been shown to 
stimulate generation of ROS and lipid peroxidation in human polymorphonuclear 
leukocytes and mononuclear cells (Mohanty et al., 2002) and increase whole-body 
NO production by constitutive and inducible NOS in rats (Wu et al., 1999). It is 
important to note that the above changes in oxidant stress may have increased 
further if subjects adhering to the low carbohydrate diet were not taking a daily multi- 
vitamin. It would be interesting to determine the number of individuals in the public 
who consume low carbohydrate diets without a daily multivitamin. The conventional 
diet and control diet had no significant effect on oxidant stress levels in overweight 
women over a 4-week period, which demonstrates that a diet promoting low-fat 
consumption (consisting of MUFAs and PUFAs) and low-glycaemic index foods are 
favourable for lower oxidant stress levels. It is important to highlight that although the 
low-carbohydrate diet achieved the greatest weight loss compared to the 
conventional and control diet, oxidant stress levels still increased on the low- 
carbohydrate diet. 
9.3 Acute exercise and oxidant stress 
In study 4, despite matching oxygen consumption during exercise between the 
normal-weight and overweight groups, it was shown that overweight individuals are 
still predisposed to a greater increase in oxidant stress levels post high-intensity 
exercise compared to normal-weight individuals. Post-high intensity exercise, LH 
levels significantly increased in the overweight group (+19.8 %) but not in the normal- 
weight group (+10.3 %). Although differences in resting LH levels between the 
normal-weight and overweight were not significantly different, they were immediately 
post-exercise. At 30-minutes post-exercise these levels reduced to pre-exercise 
levels. No consistent changes were identified within or between the normal-weight 
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and overweight groups for TAS, GSH and SOD pre-exercise, post-exercise and 
thirty-minutes post-exercise. The exacerbated exercise-induced oxidant stress in the 
overweight group is likely to be due to the factors which are associated with the 
obesity-associated oxidant stress e. g. reduced antioxidant status, cell 
injury/inflammation and increased fat deposition (Vincent of al., 2001), 
hyperglycaemia, hypertension and hyperleptinaemia (Vincent and Taylor, 2006). As 
a result of exercise-induced oxidant stress, overweight/obese individuals who are 
repeatedly undertaking infrequent bouts of exercise (high-intensity) to lose weight 
may be frequently enhancing oxidant stress and placing themselves at greater risk of 
physiological complications such as cardiac arrthymias, fibrinolysis and angina 
(Alessio, 1994). However this risk may be lessened by exercising at moderate 
exercise intensities (Tozzi-Ciancarelli et al., 2002). In addition continuous exercise 
training (Fukai of al., 2000) and antioxidant therapy (Skrha et al., 1999; Manning et 
a/., 2004; Anderson et al., 1999) may be useful strategies to reduce oxidant stress in 
obesity at rest and during exercise. 
Due to obesity and lifestyle habits such as short-term low carbohydrate diets and 
acute high-intensity exercise increasing oxidant stress, study 5 was designed to 
determine the effect of antioxidant supplementation on oxidant stress in overweight 
individuals at rest and following high-intensity exercise. It was speculated that any 
significant benefits found may extend into the obese population. Selenium 
supplementation was chosen as the antioxidant of choice because it is an essential 
component of the GSH-PX system (Ladenstein et al., 1979), which functions as part 
of an antioxidant system to protect PUFAs and proteins from the damaging effects of 
peroxides and LH (Richter, 1987; Del Maestro et al., 1980). Also given that current 
UK daily intakes of Se are so low (Department of Health, 1991) that they do not allow 
maximal expression of plasma GSH-PX (Duffield et al., 1999) and evidence that 
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obese individuals have reduced GSH-PX levels (Olusi et al., 2002) selenium 
supplementation seemed a good antioxidant choice. 
9.4 Selenium supplementation and oxidant stress 
The results of study 5 provided an insight into the potential role Se could play as an 
antioxidant therapy to reduce oxidant stress at rest and following high-intensity 
exercise in normal-weight and overweight individuals. At rest, although not 
significant, Se supplementation produced a trend for decreased LH levels in both the 
normal-weight and overweight group but the greatest effect was observed in the 
overweight group. Immediately following and 30 minutes post-exercise, compared to 
placebo, Se supplementation also reduced LH levels in the overweight weight but 
this did not occur in the normal-weight group. Interestingly, although LH levels 
between the normal-weight and overweight groups were significantly different post 
and 30 minutes post exercise on placebo, this was not the case following Se 
supplementation. These results suggest that Se supplementation in overweight 
individuals has the potential to reduce LH levels at rest and normalize LH levels 
during acute aerobic high-intensity exercise. The minimal changes in TAS, SOD and 
GSH do not explain why Se supplementation may have reduced LH levels in 
overweight subjects. However, it can be speculated that the improvements in LH in 
the overweight group may be due to a significant increase in plasma selenium levels 
which in turn maximised GSH-PX activity (since it was shown that overweight 
individuals compared to normal-weight individuals in the placebo group had 
significantly lower plasma selenium levels). 
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9.5 Oxidant stress-mediated platelet aggregation 
Since platelets play a central role in the process of thrombus formation (Hoak, 1988), 
as well as playing an important role in atherogenesis (Rabbani and Loscalzo, 1994) 
and the progression of atherosclerotic lesions (Kamath et al., 2001) it seemed 
significant to investigate whether increased oxidant stress (due to obesity or 
unhealthy lifestyles) contributes to persistent platelet aggregation. It has already 
been shown that oxidant stress mediates platelet aggregation in several settings 
such as diabetes mellitus, hypertension and hypercholesterolemia (Davi et al., 2003; 
Minuz et al., 2002; Davi at al., 1997) which suggests that increased oxidant stress in 
obesity may contribute to persistent platelet aggregation. Several in vitro 
experimental studies have identified specific effects of ROS on platelet activity. For 
example (1) H202 has been shown to enhance collagen-dependent platelet activation 
and enhance arachidonic acid (AA)-dependent platelet activation (Practio at al., 
1992) (2) O2 have been shown to reduce the threshold for platelet activation to 
thrombin, collagen, ADP or AA and induced spontaneous aggregation (Handin at al., 
1977; Krotz at al., 2002; Salvemini et al., 1989; De la Cruz at al., 1992) and also 
reacts with NO to form OONO which decreases bioavailability of NO, a potent 
inhibitor of platelet activation (Krotz et al., 2004). In addition to exogenously derived 
ROS affecting the regulation of platelet activation, recent data also suggests that the 
platelets themselves generate ROS (Krotz et al., 2002). 
In this study, oxidant stress-mediated platelet aggregation was investigated using 
correlation analysis between oxidant stress parameters measured as LH and platelet 
aggregation measured as ADP-induced platelet aggregation using PlateletWorks. 
Although percentage ADP-induced platelet aggregation levels progressively 
decreased (expression of enhanced in vivo platelet reactivity) and LH levels 
progressively increased with increasing BMI levels, no association was found 
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between LH and ADP-induced platelet aggregation in healthy individuals (including a 
range of BMIs). In addition no association was found between TAS and ADP- 
induced platelet aggregation. However correlation coefficient analysis from data 
obtained prior to and post high-intensity acute exercise demonstrated that LH has a 
significant negative association with platelet aggregation at high ADP-induced 
platelet aggregation (20pM) (r=-. 0.329, P<0.01) and a negative trend towards being 
associated with platelet aggregation at low ADP-induced platelet aggregation (10pM) 
(r=-. 240, P=0.065). This suggests that increased LH could decrease the sensitivity of 
platelet activity to ADP (which is an expression of enhanced in vivo platelet 
reactivity). However this association is not entirely clear because this study failed to 
observe reduced platelet aggregation post high-intensity exercise despite observing 
significantly increased LH levels. 
To gain a clearer picture of the potential oxidant stress may have on mediating 
platelet aggregation, the impact of Se supplementation on platelet aggregation (since 
Se supplementation reduces LH levels) was examined in both normal-weight and 
overweight individuals, pre and post high-intensity acute exercise. At rest and post- 
high intensity exercise, compared to placebo treatment, Se supplementation had no 
effect on reducing in vivo platelet reactivity in both the normal-weight and overweight 
groups. The lack of an association between Se supplementation and reduced 
platelet aggregation in this study may be because sodium selenite is not important in 
the role of platelet aggregation. For example Levander et a/ (1983) suggested that 
the increased platelet GSH-Px activity and decreased platelet aggregation in a pilot 
study following Se-rich yeast tablets suggests that particular Se compounds may be 
importance to platelet aggregation because Van Dokkum et a/ (1992) observed no 
beneficial effect of wheat Se supplementation on platelet aggregation levels. 
However the increased platelet aggregation and TxB2 levels in diabetic rats was 
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shown to reverse following sodium selenite supplementation (Ersöz et aL, 2003). 
Another possibility for the lack of association between Se supplementation and 
reduced platelet aggregation may be because 3 weeks sodium selenite 
supplementation is too short a term to establish lipid peroxidation-mediated changes 
in platelet function (Salonen et al., 1991). 
9.5 Conclusion 
It is well established that obesity enhances oxidant stress but whether this is a cause 
and effect relationship or a result of obesity-related diseases or a combination of the 
two remains unclear. Overweight individuals were not predisposed to enhanced 
oxidant stress but lifestyle habits such as short-term low carbohydrate diets and/or 
acute exercise were shown to increase oxidant stress levels in overweight 
individuals. Interestingly this exacerbated exercise induced response in overweight 
individuals was ameliorated by three-weeks selenium supplementation which is 
particularly important for overweight or obese individuals who exercise sporadically 
because they may be at greater risk of exercise-induced oxidant stress since the lack 
of regular training would not permit an enhancement of the defence mechanisms. In 
addition to oxidant stress, it seemed significant to identify if increased oxidant stress 
(due to obesity or unhealthy lifestyles) contributes to persistent platelet aggregation 
(since platelets play a central role in the process of thrombus formation, 
atherogenesis and atherosclerotic lesions). Overall, it appeared that oxidant stress 
does not mediate platelet responsiveness. Although a possible association between 
oxidant stress and platelet responsiveness pre- and post-high-intensity exercise in 
both normal-weight and overweight subjects was found, the nature of the association 
between oxidant stress and platelet aggregation remained unresolved as no 
association was found between lipid hydroperoxide levels and percentage ADP- 
induced platelet aggregation at rest across normal-weight, overweight and obese 
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groups and selenium supplementation did not improve platelet responsiveness in 
overweight individuals, despite ameliorating oxidant stress levels. 
As evident from the following section, much work is still required in the domain of 
obesity, exercise, diet and oxidant stress in both health and disease. It is therefore 
hoped that the work contained in this thesis provides an induction into the area of 
free radical research and platelet aggregation in overweight/obesity, exercise, diet 
and pathology, and helps to generate future research ideas. 
9.6 Future Work 
The present study provided evidence that obesity may mediate oxidant stress as 
shown by elevated lipid hydroperoxide levels. It was also shown that oxidant stress 
is exacerbated in overweight individuals who were undertaking short-term LowCD, 
and high-intensity acute exercise. However caution should be taken when employing 
biomarkers for oxidant stress to examine these concepts as their measurement and 
interpretation are hampered by several factors. For example, oxidant stress assays 
(such as TBARS, MDA and LH) lack specificity, sensitivity and definition (in defining 
commonly accepted normal reference intervals). Precise analytical methods for 
oxidant stress need to be introduced for application in routing clinical laboratories 
which allow more precise interpretations of laboratory results to be made. Similarly, 
the impact of oxidant stress on platelet aggregation should be analysed using a wide 
range of biomarkers which reflect different aspects of platelet activation and may 
differ in terms of sensitivity. 
To investigate further the effects of obesity and obesity-related diseases on oxidant 
stress, it would be useful to compare various groups of body mass index and 
existence of co-morbidities on oxidant stress levels. Future obesity studies into 
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oxidant stress should also include an assessment of GSH-Px which was not included 
in the present studies. Olusi et a! (2002) observed that GSH-Px was lower in obese 
compared to a non-obese individuals, so it would be interesting to further define its 
role in the pro-oxidant/antioxidant balance. 
Having shown that short-term adherence to LowCD in overweight individuals 
increased susceptibility to oxidant stress, an investigation is needed of longer 
duration. In addition, assessment of the effect of the LowCD on oxidant stress in 
obese individuals is needed. Future research should also be performed to identify 
the independent effects of dietary consumption and calorie restriction on the pro- 
oxidant / antioxidant balance. 
The present studies have clearly demonstrated that exercise-induced oxidant stress 
was increased in overweight individuals compared to normal-weight individuals, 
following high-intensity exercise. Therefore exercise-induced oxidant stress 
response in obesity could also be examined following both moderate- and high- 
intensity exercise to identify an exercise intensity which is of lowest risk to the obese 
individual. Future research could study the effects of an incremental graded exercise 
stress on oxidant stress to identify if there is a 'oxidant stress threshold' (point at 
which LH levels significantly increase) during exercise. Exercising below the 
`threshold' may potentially put individuals at less risk of the exercise-induced oxidant 
stress. 
Short term Se supplementation may be advantageously used in overweight subjects 
completing a high intensity aerobic exercise session. However long-term intervention 
studies are needed to evaluate the efficacy of this new therapeutic approach to the 
prevention and treatment of exercise-induced oxidant stress following high-intensity 
exercise in overweight individuals. In addition, the type of Se supplement, dosage 
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and length of consumption should also be investigated. The application of Se 
supplementation at rest, pre and post exercise should also be studied in the obese 
population. 
Further research should also examine the effects of long term adherence to weight 
management (including dietary changes and exercise training) on the pro- 
oxidant/antioxidant balance, which may provide greater insight into the importance of 
weight loss or cardio-respiratory fitness. 
Finally, the impact of obesity-related oxidant stress should be examined in relation to 
its impact on clinical outcomes measures and physiological complications such as 
cardiac arrthymias, fibrinolysis and angina in the short-time and premature aging, 
inflammation, diabetes, CVD and cancer in the long-term (Alessio, 1994). This could 
further highlight the importance of oxidant stress measures in health and disease. 
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